<PAGE>
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
_______________
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
June 22, 1999
Date of Report (Date of earliest event reported)
ALZA Corporation
(Exact Name of Registrant as Specified in its Charter)
_____________________________________________________
<TABLE>
<S> <C> <C>
Delaware 1-6247 77-0142070
(State or other (Commission File Number) (I.R.S. Employer
Jurisdiction of Identification No.)
Incorporation)
</TABLE>
________________________________________
950 Page Mill Road
P.O. Box 10950
Palo Alto, CA 94303-0802
(Address of Principal Executive Offices)(Zip Code)
Registrant's telephone number, including area code: (650) 494-5000
_____________________________________________________
<PAGE>
Item 5. Other Events.
On June 21, 1999, ALZA Corporation, a Delaware corporation ("ALZA"),
entered into an Agreement and Plan of Merger (the "Merger Agreement") with
Abbott Laboratories, an Illinois corporation ("Abbott"), and AC Merger Sub Inc.,
a Delaware corporation and a wholly-owned subsidiary of Abbott (the "Merger
Sub"). Pursuant to the terms of the Merger Agreement, and subject to the
conditions set forth therein (including approval of the transaction by the
stockholders of ALZA), the Merger Sub will be merged with and into ALZA (the
"Merger"). At the effective time of the Merger, the separate existence of the
Merger Sub will cease, ALZA will become a wholly-owned subsidiary of Abbott and
each outstanding share of ALZA common stock will be exchanged for 1.2 shares of
Abbott common stock. The Merger is intended to be a tax-free reorganization
pursuant to Section 368(a) of the Internal Revenue Code of 1986, as amended, and
is intended to be treated as a pooling of interests for financial reporting
purposes. A copy of the Agreement is attached hereto as Exhibit 2.1 and
incorporated herein by reference.
In addition, Abbott and ALZA entered into two Co-Promotion Agreements with
respect to certain products of ALZA, which agreements are attached hereto as
Exhibits 99.2 and 99.3 and incorporated herein by reference.
Item 7. Financial Statements, Pro Forma Financial Information and Exhibits.
(c) Exhibits.
Exhibit No. Description
- ----------- -----------
Exhibit 2.1 Agreement and Plan of Merger by and among ALZA Corporation, a
Delaware corporation, Abbott Laboratories, an Illinois
corporation, and AC Merger Sub Inc., a Delaware corporation, dated
as of June 21, 1999, including exhibits thereto.
Exhibit 99.1 Press Release dated June 21, 1999.
Exhibit 99.2 Co-Promotion Agreement between ALZA Corporation and Abbott
Laboratories, dated as of June 21, 1999.
Exhibit 99.3 Co-Promotion Agreement between ALZA Corporation and Abbott
Laboratories, dated as of June 21, 1999
<PAGE>
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned, hereunto duly authorized.
ALZA CORPORATION
/s/ Peter D. Staple
------------------------------
By: Peter D. Staple
Senior Vice President and
General Counsel
Date: June 25, 1999
<PAGE>
EXHIBIT INDEX
Exhibit 2.1 Agreement and Plan of Merger by and among ALZA Corporation, a
Delaware corporation, Abbott Laboratories, an Illinois
corporation, and AC Merger Sub Inc., a Delaware corporation, dated
as of June 21, 1999, including exhibits thereto
Exhibit 99.1 Press Release June 21, 1999.
Exhibit 99.2 Co-Promotion Agreement between ALZA Corporation and Abbott
Laboratories, dated as of June 21, 1999
Exhibit 99.3 Co-Promotion Agreement between ALZA Corporation and Abbott
Laboratories, dated as of June 21, 1999
<PAGE>
EXHIBIT 2.1
AGREEMENT AND PLAN OF MERGER
Among
ALZA CORPORATION,
ABBOTT LABORATORIES
and
AC MERGER SUB INC.
Dated as of June 21, 1999
<PAGE>
Table of Contents
<TABLE>
<CAPTION>
ARTICLE I.
The Merger; Closing; Effective Time
<S> <C> <C>
1.1. The Merger............................................................ 1
1.2. Closing............................................................... 2
1.3. Effective Time........................................................ 2
ARTICLE II.
Certificate of Incorporation and Bylaws of the Surviving Corporation
2.1. The Certificate of Incorporation...................................... 2
2.2. The Bylaws............................................................ 2
ARTICLE III.
Officers, Directors and Management
3.1. Directors of Surviving Corporation.................................... 2
3.2. Officers of Surviving Corporation..................................... 3
ARTICLE IV.
Effect of the Merger on Capital Stock; Exchange of Certificates
4.1. Effect on Capital Stock............................................... 3
4.2. Exchange of Certificates for Shares................................... 4
4.3. Dissenters' Rights.................................................... 6
4.4. Adjustments to Prevent Dilution....................................... 7
4.5. Convertible Debentures; Warrants...................................... 7
ARTICLE V.
Representations and Warranties
5.1. Representations and Warranties of the Company......................... 8
5.2. Representations and Warranties of Parent and Merger Sub...............23
</TABLE>
i
<PAGE>
<TABLE>
<S> <C> <C>
ARTICLE VI.
Covenants
6.1. Interim Operations....................................................28
6.2. Acquisition Proposals.................................................31
6.3. Information Supplied..................................................32
6.4. Stockholders Meeting..................................................33
6.5. Filings; Other Actions; Notification..................................34
6.6. Access; Consultation..................................................36
6.7. Affiliates............................................................37
6.8. Stock Exchange Listing................................................38
6.9. Publicity.............................................................38
6.10. Employee Benefits.....................................................38
6.11. Expenses..............................................................40
6.12. Indemnification; Directors' and Officers' Insurance...................40
6.13. Takeover Statutes.....................................................42
6.14. Confidentiality.......................................................43
6.15. Tax-Free Reorganization...............................................43
ARTICLE VII.
Conditions
7.1. Conditions to Each Party's Obligation to Effect the Merger............43
7.2. Conditions to Obligations of Parent and Merger Sub....................44
7.3. Conditions to Obligation of the Company...............................45
ARTICLE VIII.
Termination
8.1. Termination by Mutual Consent.........................................46
8.2. Termination by Either Parent or the Company...........................46
8.3. Termination by the Company............................................47
8.4. Termination by Parent.................................................48
8.5. Effect of Termination and Abandonment.................................48
ARTICLE IX.
Miscellaneous and General
9.1. Certain Definitions...................................................50
</TABLE>
ii
<PAGE>
<TABLE>
<S> <C> <C>
9.2. Survival..............................................................52
9.3. Modification or Amendment.............................................52
9.4. Waiver of Conditions..................................................53
9.5. Counterparts..........................................................53
9.6. GOVERNING LAW AND VENUE; WAIVER OF JURY TRIAL.........................53
9.7. Notices...............................................................54
9.8. Entire Agreement......................................................55
9.9. No Third Party Beneficiaries..........................................56
9.10. Obligations of Parent and of the Company..............................56
9.11. Severability..........................................................56
9.12. Interpretation........................................................56
9.13. Assignment............................................................56
Exhibits
Exhibit A.................................................Stockholder Agreement
Exhibit B.................................................Stockholder Agreement
</TABLE>
iii
<PAGE>
Index of Defined Terms
<TABLE>
<CAPTION>
Term Section
- ---- -------
<S> <C>
5% Debenture Indenture....................................................4.5(a)
5% Debenture Trustee......................................................4.5(a)
5% Debentures.............................................................5.1(b)
5-1/4% Debenture Indenture................................................4.5(b)
5-1/4% Debenture Trustee..................................................4.5(b)
5-1/4% Debentures.........................................................5.1(b)
Acquisition Proposal......................................................6.2(a)
Activities to Date...............................................5.1(p)(1)(A)(i)
Affiliates...................................................................9.1
Agreement...............................................................preamble
Audit Date................................................................5.1(f)
Bankruptcy and Equity Exception...........................................5.1(c)
Bylaws.......................................................................2.2
Certificate...............................................................4.1(a)
Certificate of Merger........................................................1.3
Charter......................................................................2.1
Charter and Bylaw Provisions..............................................5.1(j)
Chase.....................................................................5.1(c)
Closing......................................................................1.2
Closing Date.................................................................1.2
Code.........................................................................9.1
Company.................................................................preamble
Company Affiliate's Letter................................................6.7(a)
Company Disclosure Letter....................................................5.1
Company IP Rights......................................................5.1(r)(1)
Company Option........................................................6.10(b)(i)
Company Preferred Shares..................................................5.1(b)
Company Representatives...................................................6.2(a)
Company Required Consents..............................................5.1(d)(1)
Company Share.............................................................4.1(a)
Company Shares............................................................4.1(a)
Company Stock Plans.......................................................5.1(b)
Company's Executive Officers.................................................9.1
Company's Reports.........................................................5.1(e)
Compensation and Benefit Plans.........................................5.1(h)(i)
Competition Laws.............................................................9.1
Computer Systems..........................................................5.1(s)
Confidentiality Agreement...................................................6.14
Contracts..............................................................5.1(d)(2)
</TABLE>
iv
<PAGE>
<TABLE>
<S> <C>
Convertible Debentures....................................................5.1(b)
Crescendo....................................................................9.1
Crescendo Certificate of Incorporation.................................5.1(t)(2)
Crescendo Payments.....................................................5.1(t)(2)
Crescendo Products.....................................................5.1(t)(2)
DGCL.........................................................................9.1
Delaware Courts...........................................................9.6(a)
Effective Time...............................................................1.3
Environmental Law............................................................9.1
ERISA........................................................................9.1
ERISA Affiliate..............................................................9.1
Exchange Act.................................................................9.1
Exchange Agent............................................................4.2(a)
Exchange Ratio............................................................4.1(a)
Excluded Company Shares...................................................4.1(a)
FDCA.........................................................................9.1
GAAP.........................................................................9.1
Governmental Entity....................................................5.1(d)(1)
Hazardous Substance..........................................................9.1
HSR Act......................................................................9.1
Indemnified Parties......................................................6.12(a)
IRS..........................................................................9.1
Laws.........................................................................9.1
Licenses.........................................................5.1(p)(1)(A)(i)
Material Adverse Effect......................................................9.1
Merger..................................................................recitals
Merger Consideration......................................................4.1(a)
Merger Sub..............................................................preamble
Merrill Lynch.............................................................5.1(c)
Modified Recommendation Stockholder Rejection Termination.................8.5(b)
NYSE.........................................................................9.1
Order.....................................................................7.1(c)
Parent..................................................................preamble
Parent Affiliate's Letter.................................................6.7(a)
Parent Common Stock.......................................................4.1(a)
Parent Disclosure Letter.....................................................5.2
Parent Preferred Shares................................................5.2(b)(1)
Parent Required Consents...............................................5.2(d)(1)
Parent Stock Plans.....................................................5.2(b)(1)
Parent's Reports..........................................................5.2(e)
PBGC.........................................................................9.1
Pension Plan..........................................................5.1(h)(ii)
Permits......................................................................9.1
</TABLE>
v
<PAGE>
<TABLE>
<S> <C>
Person.......................................................................9.1
Pooling Affiliates........................................................6.7(a)
Pooling Requirements....................................................recitals
Products............................................................5.1(p)(1)(A)
Prospectus/Proxy Statement...................................................6.3
Purchase Plans........................................................6.10(a)(i)
Restricted Share.........................................................6.10(b)
Requisite Vote............................................................5.1(c)
Rule 145 Affiliates.......................................................6.7(a)
S-4 Registration Statement...................................................6.3
SEC..........................................................................9.1
Securities Act...............................................................9.1
Significant Agreements....................................................5.1(q)
Significant Investees........................................................9.1
Significant Subsidiaries.....................................................9.1
Stockholders Meeting.........................................................6.4
Subsequent Transaction....................................................6.5(e)
Subsidiary...................................................................9.1
Substitute Option.....................................................6.10(b)(i)
Substitute Restricted Shares.............................................6.10(b)
Superior Proposal.........................................................6.2(a)
Surviving Corporation........................................................1.1
Takeover Statute..........................................................5.1(j)
Tax..........................................................................9.1
Tax Return...................................................................9.1
Taxable......................................................................9.1
Taxes........................................................................9.1
Termination Date.............................................................8.2
Termination Fee...........................................................8.5(b)
Warrant Agreement.........................................................4.5(c)
Warrants..................................................................5.1(b)
Year 2000 Compliance......................................................5.1(s)
Waiting Period...............................................................8.2
</TABLE>
vi
<PAGE>
AGREEMENT AND PLAN OF MERGER
----------------------------
This AGREEMENT AND PLAN OF MERGER (this "Agreement"), dated as of June 21,
---------
1999, is among ALZA CORPORATION, a Delaware corporation (the "Company"), ABBOTT
-------
LABORATORIES, an Illinois corporation ("Parent"), and AC MERGER SUB INC., a
------
Delaware corporation that is a wholly owned subsidiary of Parent ("Merger Sub").
----------
RECITALS
WHEREAS, the respective Boards of Directors of each of Parent, Merger Sub
and the Company have approved and declared advisable this Agreement and the
merger of Merger Sub with and into the Company (the "Merger") upon the terms and
------
subject to the conditions set forth in this Agreement;
WHEREAS, the parties intend, by executing and delivering this Agreement, to
adopt a plan of reorganization within the meaning of Section 368(a) of the Code,
and to cause the Merger to qualify as a "reorganization" as therein defined;
WHEREAS, for financial accounting purposes, it is intended that the Merger
shall be accounted for as a "pooling-of-interests" in accordance with the
requirements of Opinion No. 16 "Business Combinations" of the Accounting
Principles Board of the American Institute of Certified Public Accountants, as
amended and/or interpreted by the rules and regulations of the SEC and
applicable pronouncements by the Financial Accounting Standards Board, the
Emerging Issues Task Force and the American Institute of Certified Public
Accountants (collectively, with the rules and regulations of the SEC, the
"Pooling Requirements");
- ---------------------
WHEREAS, the Company, Parent and Merger Sub desire to make certain
representations, warranties, covenants and agreements in connection with this
Agreement.
NOW, THEREFORE, in consideration of the premises, and of the
representations, warranties, covenants and agreements contained in this
Agreement, the parties agree as follows:
ARTICLE I.
The Merger; Closing; Effective Time
-----------------------------------
1.1 The Merger. Upon the terms and subject to the conditions set forth in
----------
this Agreement, at the Effective Time, Merger Sub shall be merged with and into
the Company and the separate corporate existence of Merger Sub shall thereupon
cease. The Company shall be the surviving corporation in the Merger (sometimes
referred to as the "Surviving
---------
<PAGE>
Corporation") and shall continue to be governed by the laws of the State of
- -----------
Delaware, and the separate corporate existence of the Company, with all its
rights, privileges, immunities, powers and franchises, shall continue unaffected
by the Merger except as set forth in Article II and Article III. The Merger
shall have the effects specified in the DGCL.
1.2 Closing. The closing of the Merger (the "Closing") shall take place
------- -------
(i) at the offices of Mayer, Brown & Platt, 190 South LaSalle Street, Chicago,
Illinois, at 9:00 A.M., local time, on the second business day after the date on
which the last to be fulfilled or waived of the conditions set forth in Article
VII (other than those conditions that by their nature are to be satisfied at the
Closing, but subject to the fulfillment or waiver of those conditions) shall be
satisfied or waived in accordance with this Agreement or (ii) at such other
place and time and/or on such other date as the Company and Parent may agree in
writing (the "Closing Date").
------------
1.3 Effective Time. As soon as practicable following the Closing, the
--------------
Company and Parent will cause a Certificate of Merger (the "Certificate of
--------------
Merger") to be executed, acknowledged and filed with the Secretary of State of
- ------
the State of Delaware as provided in Section 251 of the DGCL. The Merger shall
become effective at the time when the Certificate of Merger has been duly filed
with the Secretary of State of the State of Delaware or such other time as shall
be agreed upon by the parties and set forth in the Certificate of Merger in
accordance with the DGCL (the "Effective Time").
--------------
ARTICLE II.
Certificate of Incorporation and Bylaws of the Surviving Corporation
--------------------------------------------------------------------
2.1 The Certificate of Incorporation. The certificate of incorporation of
--------------------------------
Merger Sub as in effect immediately prior to the Effective Time shall be the
certificate of incorporation of the Surviving Corporation (the "Charter"), until
-------
duly amended as provided therein or by applicable law.
2.2 The Bylaws. The bylaws of Merger Sub in effect at the Effective Time
----------
shall be the bylaws of the Surviving Corporation (the "Bylaws"), until
------
thereafter amended as provided therein or by applicable law.
ARTICLE III
Officers, Directors and Management
----------------------------------
3.1 Directors of Surviving Corporation. The directors of Merger Sub at
----------------------------------
the Effective Time shall, from and after the Effective Time, be the directors of
the Surviving Corporation until their successors have been duly elected or
appointed and qualified or until their earlier death, resignation or removal in
accordance with the Charter and the Bylaws.
2
<PAGE>
3.2 Officers of Surviving Corporation. The officers of the Company at the
---------------------------------
Effective Time shall, from and after the Effective Time, be the officers of the
Surviving Corporation until their successors have been duly elected or appointed
and qualified or until their earlier death, resignation or removal in accordance
with the Charter and the Bylaws.
ARTICLE IV.
Effect of the Merger on Capital Stock; Exchange of Certificates
---------------------------------------------------------------
4.1 Effect on Capital Stock. At the Effective Time, the Merger shall have
-----------------------
the following effects on the capital stock of the Company and Merger Sub,
without any action on the part of the holder of any capital stock of the Company
or Merger Sub:
(a) Merger Consideration. Each share of common stock, $0.01 par value per
--------------------
share, of the Company (each a "Company Share" and, collectively, the
-------------
"Company Shares") issued and outstanding immediately prior to the
--------------
Effective Time (but not including Company Shares that are owned by
Parent, Merger Sub or any other direct or indirect subsidiary of
Parent or Company Shares that are owned by the Company or any direct
or indirect Subsidiary of the Company, and in each case not held on
behalf of third parties (collectively, "Excluded Company Shares")),
-----------------------
shall be converted into and become exchangeable for 1.20 shares (the
"Exchange Ratio") of Common Stock, no par value, of Parent ("Parent
-------------- ------
Common Stock"), subject to adjustment as provided in Section 4.4 (the
------------
"Merger Consideration"). At the Effective Time, all Company Shares
--------------------
shall no longer be outstanding, shall be canceled and retired and
shall cease to exist, and each certificate (a "Certificate") formerly
-----------
representing any of such Company Shares (other than Excluded Company
Shares) shall thereafter represent only the right to the Merger
Consideration and the right, if any, to receive pursuant to Section
4.2(e) cash in lieu of the fractional shares into which such Company
Shares have been converted pursuant to this Section 4.1(a) and any
distribution or dividend pursuant to Section 4.2(c), in each case
without interest.
(b) Cancellation of Excluded Company Shares. Each Excluded Company Share
---------------------------------------
issued and outstanding immediately prior to the Effective Time shall,
by virtue of the Merger and without any action on the part of the
holder thereof, no longer be outstanding, shall be canceled and
retired without payment of any consideration therefor and shall cease
to exist.
3
<PAGE>
(c) Merger Sub. At the Effective Time, each share of Common Stock, par
----------
value $0.01 per share, of Merger Sub issued and outstanding immediately
prior to the Effective Time shall be converted into one share of common
stock of the Surviving Corporation, and the Surviving Corporation shall
thereby become a wholly owned subsidiary of Parent.
4.2 Exchange of Certificates for Shares.
-----------------------------------
(a) Exchange Fund. Prior to the Effective Time, Parent shall appoint a
-------------
bank or trust company, or a subsidiary thereof, having net capital of
not less than $100 million, with the Company's prior approval, which
shall not be unreasonably withheld, to act as exchange agent for the
purposes of exchanging Certificates for Merger Consideration (the
"Exchange Agent"). At or prior to the Effective Time, Parent shall
--------------
deposit with the Exchange Agent, in trust for the benefit of holders of
Company Shares, certificates representing shares of Parent Common Stock
issuable pursuant to Section 4.1(a). Parent agrees to make available to
the Exchange Agent from time to time as needed, cash sufficient to pay
cash in lieu of fractional shares in accordance with Section 4.2(e).
(b) Exchange Procedures. Promptly after the Effective Time, the Surviving
-------------------
Corporation shall cause the Exchange Agent to mail to each holder of
record as of the Effective Time of a Certificate in respect of Company
Shares (other than holders of a Certificate in respect of Excluded
Company Shares) (i) a letter of transmittal specifying that delivery of
the Certificates shall be effected, and that risk of loss and title to
the Certificates shall pass, only upon delivery of the Certificates (or
affidavits of loss and a reasonable undertaking to indemnify the
Company in lieu thereof) to the Exchange Agent, such letter of
transmittal to be in such form and have such other provisions as Parent
and the Company may reasonably agree, and (ii) instructions for
exchanging the Certificates for (A) certificates representing shares of
Parent Common Stock and (B) any cash in lieu of fractional shares
determined in accordance with Section 4.2(e) plus any cash dividends
and any other dividends or other distributions that such holder has the
right to receive pursuant to the provisions of this Article IV. Subject
to Section 4.2(h), upon surrender of a Certificate for cancellation to
the Exchange Agent together with such letter of transmittal, duly
executed, the holder of such Certificate shall be entitled to receive
in exchange therefor (x) a certificate representing that number of
whole shares of Parent Co mmon Stock that such holder is entitled to
receive pursuant
4
<PAGE>
to this Section 4.2, and (y) a check in the amount (after giving effect
to any required tax withholdings) of (A) any cash in lieu of fractional
shares determined in accordance with Section 4.2(e) plus (B) any cash
dividends and any other dividends or other distributions that such
holder has the right to receive pursuant to the provisions of this
Section 4.2. The Certificate so surrendered shall forthwith be
canceled. No interest will be paid or accrued on any amount payable
upon due surrender of any Certificate. In the event of a transfer of
ownership of Company Shares that occurred prior to the Effective Time,
but is not registered in the transfer records of the Company, a
certificate representing the proper number of shares of Parent Common
Stock, together with a check for any cash in lieu of fractional shares
to be paid upon due surrender of the Certificate and any other
dividends or distributions in respect thereof, may be issued and/or
paid to such a transferee if the Certificate formerly representing such
Company Shares is presented to the Exchange Agent, accompanied by all
documents required to evidence and effect such transfer and to evidence
that any applicable stock transfer taxes have been paid. If any
certificate for shares of Parent Common Stock is to be issued in a name
other than that in which the Certificate surrendered in exchange
therefor is registered, it shall be a condition of such exchange that
the Person requesting such exchange shall pay any transfer or other
taxes required by reason of the issuance of certificates for shares of
Parent Common Stock in a name other than that of the registered holder
of the Certificate surrendered, or shall establish to the satisfaction
of Parent or the Exchange Agent that such tax has been paid or is not
applicable.
(c) Distributions with Respect to Unexchanged Shares; Voting.
--------------------------------------------------------
(1) Whenever a dividend or other distribution is declared by Parent in
respect of Parent Common Stock, the record date for which is at or after the
Effective Time, that declaration shall include dividends or other
distributions in respect of all shares of Parent Common Stock issuable
pursuant to this Agreement. No dividends or other distributions so declared
in respect of such Parent Common Stock shall be paid to any holder of any
unsurrendered Certificate until such Certificate is surrendered for exchange
in accordance with this Section 4.2. Subject to the effect of applicable
laws, following surrender of any such Certificate, there shall be issued or
paid to the holder of the certificates representing whole shares of Parent
Common Stock issued in exchange for such Certificate, without interest, (A)
at the time of such surrender, the dividends or other distributions with a
record date that is at or after the Effective Time and a payment date on or
prior to the date of issuance of such whole shares of Parent Common Stock
and not previously paid and
5
<PAGE>
(B) at the appropriate payment date, the dividends or other distributions
payable with respect to such whole shares of Parent Common Stock with a
record date after the Effective Time but with a payment date subsequent to
surrender. For purposes of dividends or other distributions in respect of
shares of Parent Common Stock, all shares of Parent Common Stock to be
issued pursuant to the Merger shall be deemed issued and outstanding as of
the Effective Time.
(ii) Registered holders of unsurrendered Certificates shall be entitled to
vote after the Effective Time at any meeting of Parent stockholders with a
record date at or after the Effective Time the number of whole shares of
Parent Common Stock represented by such Certificates, regardless of whether
such holders have exchanged their Certificates.
(d) Transfers. After the Effective Time, there shall be no transfers on
---------
the stock transfer books of the Company of the Company Shares that were
outstanding immediately prior to the Effective Time.
(e) Fractional Shares. Notwithstanding any other provision of this
-----------------
Agreement, no fractional shares of Parent Common Stock will be issued
and any holder of Company Shares entitled to receive a fractional share
of Parent Common Stock but for this Section 4.2(e) shall be entitled to
receive in lieu thereof an amount in cash (without interest) determined
by multiplying such fraction (rounded to the nearest one-hundredth of a
share) by the average closing price of a share of Parent Common Stock,
as reported in The Wall Street Journal, New York City edition, on the
five (5) trading days immediately prior to the Effective Time.
(f) Termination of Exchange Period; Unclaimed Stock. Any shares of Parent
-----------------------------------------------
Common Stock and any portion of the cash, dividends or other
distributions with respect to the Parent Common Stock deposited by
Parent with the Exchange Agent (including the proceeds of any
investments thereof) that remain unclaimed by the stockholders of the
Company 180 days after the Effective Time shall be paid to Parent. Any
stockholders of the Company who have not theretofore complied with this
Article IV shall thereafter be entitled to look only to Parent for
payment of their shares of Parent Common Stock and any cash, dividends
and other distributions in respect thereof issuable and/or payable
pursuant to Section 4.1, Section 4.2(c) and Section 4.2(e) upon due
surrender of their Certificates (or affidavits of loss and a reasonable
undertaking to indemnify the Company in lieu thereof), in each case,
without any interest thereon. Notwithstanding the
6
<PAGE>
foregoing, none of Parent, the Surviving Corporation, the Exchange
Agent or any other Person shall be liable to any former holder of
Company Shares for any amount properly delivered to a public official
pursuant to applicable abandoned property, escheat or similar laws.
(g) Lost, Stolen or Destroyed Certificates. In the event any Certificate
--------------------------------------
shall have been lost, stolen or destroyed, upon the making of an
affidavit of that fact by the Person claiming such Certificate to be
lost, stolen or destroyed and the posting by such Person of a bond in
the form customarily required by Parent as indemnity against any claim
that may be made against it with respect to such Certificate, Parent
will issue the shares of Parent Common Stock and the Exchange Agent
will distribute such stock, any cash, dividends and other distributions
in respect thereof issuable or payable in exchange for such lost,
stolen or destroyed Certificate pursuant to Section 4.1, Section 4.2(c)
and Section 4.2(e), in each case, without interest.
(8) Affiliates. Notwithstanding anything in this Agreement to the
----------
contrary, Certificates surrendered for exchange by any Pooling
Affiliate or Rule 145 Affiliate (as determined pursuant to Section 6.7)
of the Company shall not be exchanged until Parent has received a
written agreement from such Person as provided in Section 6.7.
4.3. Dissenters' Rights. In accordance with Section 262 of the DGCL, no
------------------
appraisal rights will be available to holders of Company Shares in connection
with the Merger.
4.4. Adjustments to Prevent Dilution. In the event that prior to the
-------------------------------
Effective Time, solely as a result of reclassification, stock split (including a
reverse split), or stock dividend or stock distribution made on a pro rata basis
to all holders of stock of the entity making such a stock dividend or stock
distribution, there is a change in the number of Company Shares or shares of
Parent Common Stock outstanding or issuable upon the conversion, exchange or
exercise of securities or rights convertible or exchangeable into or exercisable
for Company Shares or shares of Parent Common Stock issued and outstanding, the
Exchange Ratio shall be equitably adjusted to eliminate the effects of such
event.
4.5 Convertible Debentures; Warrants.
--------------------------------
(a) 5% Debentures. At the Effective Time, the Company and Parent shall
-------------
execute a supplemental indenture satisfying the requirements of Sections
10.1(a) and (c), 11.1, 11.2 and 14.6 of the 5% Debenture Indenture dated as
of April 23, 1996 (the "5% Debenture Indenture") between the Company and
----------------------
The Chase Manhattan Bank, N.A., as Trustee (the "5% Debenture Trustee"),
--------------------
and the Company shall use its reasonable
7
<PAGE>
best efforts to cause the 5% Debenture Trustee to execute such supplemental
indenture. The Company shall give the notice required by Section 14.10(3)
of the 5% Debenture Indenture at least 15 days prior to the Effective Time.
Within 20 days after the Effective Time, Parent shall cause the Surviving
Corporation to give the notice required by Section 14.6 of the 5% Debenture
Indenture. On or before the 30th day after the Effective Time, Parent shall
cause the Surviving Corporation to give the notice required by Section 15.2
of the 5% Debenture Indenture.
(b) 5-1/4% Debentures. At the Effective Time, the Company and Parent
-----------------
shall execute a supplemental indenture satisfying the requirements of
Sections 9.1(2) and 11.14 of the Indenture dated as of July 1, 1994 (the
"5-1/4% Debenture Indenture") between the Company and The Chase Manhattan
---------------------------
Bank, N.A., as Trustee (the "5-1/4% Debenture Trustee"), and the Company
------------------------
shall use its reasonable best efforts to cause the 5-1/4% Debenture
Trustee to execute such supplemental indenture. Within 15 days after the
Effective Time, Parent shall cause the Surviving Corporation to give the
notice required by Section 3.9(b) of the 5-1/4% Debenture Indenture. The
Company and Parent shall comply with the requirements of Article 5 of the
5-1/4% Debenture Indenture.
(c) Warrants. At least 20 days prior to the record date (or expected
--------
record date) for determining stockholders entitled to vote at the
Stockholders Meeting, and at least 20 days prior to the Effective Time, the
Company shall send written notice of the Merger and the other transactions
contemplated by this Agreement to the Warrant Agent (as defined in the
Warrant Agreement dated as of May 14, 1993 between the Company and The
First National Bank of Boston (the "Warrant Agreement")) and each Holder
-----------------
(as defined in the Warrant Agreement) of Warrants in the manner specified
in Section 6.2 of the Warrant Agreement. At the Effective Time, the
Company and Parent shall execute a supplement to the Warrant Agreement
satisfying the requirements of Sections 5.4 and 11 thereof, and the Company
shall use its reasonable best efforts to cause the Warrant Agent to execute
such supplement.
ARTICLE V.
Representations and Warranties
------------------------------
5.1 Representations and Warranties of the Company. Except as set forth in
---------------------------------------------
the corresponding sections or subsections of the disclosure letter, dated the
date of this Agreement, delivered by the Company to Parent (the "Company
-------
Disclosure Letter") (it being understood that the omission of an item from a
- -----------------
section or subsection of the Company Disclosure Letter shall not cause a breach
of this Agreement if such item is disclosed in another section or subsection of
the Company Disclosure Letter in a manner which makes the
8
<PAGE>
item understandably applicable to the section or subsection from which such
item is omitted), the Company represents and warrants to Parent and Merger Sub
that:
(a) Organization, Good Standing and Qualification. Each of the Company and
---------------------------------------------
its Subsidiaries is a corporation duly organized, validly existing and
in good standing under the laws of its respective jurisdiction of
organization and has all requisite corporate or similar power and
authority to own and operate its properties and assets and to carry on
its business as presently conducted and is qualified to do business and
is in good standing as a foreign corporation in each jurisdiction where
the ownership or operation of its properties or conduct of its business
requires such qualification, except where the failure to be so
qualified or in good standing is not, when taken together with all
other such failures, reasonably likely to have a Material Adverse
Effect on it. The Company has made available to Parent a complete and
correct copy of its certificate of incorporation and bylaws, each as
amended to date. Such certificate of incorporation and bylaws are in
full force and effect.
(b) Capital Structure. The authorized capital stock of the Company
-----------------
consists of 300,000,000 Company Shares, of which 101,143,167 Company
Shares were issued and outstanding and none were held in treasury as of
the close of business on June 17, 1999, and 100,000 shares of Preferred
Stock, par value $0.01 per share (the "Company Preferred Shares"), none
------------------------
of which were outstanding as of the date hereof. All of the outstanding
Company Shares have been duly authorized and are validly issued, fully
paid and nonassessable. Other than Company Shares subject to issuance
as set forth below or that are permitted to become subject to issuance
pursuant to Section 6.1(a)(iv) or (vii) of this Agreement, the Company
has no Company Shares, Company Preferred Shares or other shares of
capital stock reserved for or otherwise subject to issuance. As of the
date of this Agreement, the Company has outstanding $500,000,000
aggregate principal amount of 5% convertible subordinated debentures
due 2006 (the "5% Debentures") and $945,481,000 aggregate principal
-------------
amount at maturity of 5-1/4% zero coupon convertible subordinated
debentures due 2014 (the "5-1/4% Debentures" and, together with the 5%
-----------------
Debentures, the "Convertible Debentures") which, in the aggregate, are
----------------------
convertible into 25,371,112 Company Shares. As of the date of this
Agreement, the Company has outstanding warrants to purchase 966,798
Company Shares at an exercise price of $65.00 per Company Share (the
"Warrants"). As of June 17, 1999, there were 9,785,067 Company Shares
--------
that the Company was obligated to issue pursuant to the
9
<PAGE>
Company's stock plans, each of which are listed in Section 5.1(b) of the
Company Disclosure Letter (collectively, the "Company Stock Plans"). Each of
-------------------
the outstanding shares of capital stock or other securities of each of the
Company's Significant Subsidiaries is duly authorized, validly issued, fully
paid and nonassessable and owned by the Company or a direct or indirect
wholly owned Subsidiary of the Company, free and clear of any lien, pledge,
security interest, claim or other encumbrance. Except as set forth above,
there are no preemptive or other outstanding rights, options, warrants,
conversion rights, stock appreciation rights, redemption rights, repurchase
rights, agreements, arrangements or commitments to issue or sell any shares
of capital stock, other securities or assets of the Company or any of its
Significant Subsidiaries or any securities or obligations convertible or
exchangeable into or exercisable for, or giving any Person a right to
subscribe for or acquire, any shares of capital stock, other securities or
assets of the Company or any of its Significant Subsidiaries, and no
securities or obligations evidencing such rights are authorized, issued or
outstanding. The Company does not have outstanding any bonds, debentures,
notes or other debt obligations the holders of which have the right to vote
or, except for the Convertible Debentures, convertible into or exercisable
for securities having the right to vote with the stockholders of the Company
on any matter. No Company Shares are held by a Subsidiary of the Company.
(c) Corporate Authority; Approval and Fairness. The Company has all
------------------------------------------
requisite corporate power and authority and has taken all corporate action
necessary in order to execute, deliver and perform its obligations under
this Agreement and, subject only to adoption of this Agreement by the
holders of at least a majority of the outstanding Company Shares (the
"Requisite Vote") and the Company Required Consents, to consummate the
--------------
Merger. This Agreement has been duly executed and delivered by the Company
and is a valid and binding agreement of the Company enforceable against the
Company in accordance with its terms, subject to bankruptcy, insolvency,
fraudulent transfer, reorganization, moratorium and similar laws of general
applicability relating to or affecting creditors' rights and to general
equity principles (the "Bankruptcy and Equity Exception"). The Board of
-------------------------------
Directors of the Company (A) has unanimously approved and declared advisable
this Agreement and the Merger and the other transactions contemplated by
this Agreement and (B) has received the opinions of its financial advisors,
Chase Securities Inc. ("Chase") and Merrill Lynch & Co. ("Merrill Lynch"),
----- -------------
in a customary form and to the
10
<PAGE>
effect that the Exchange Ratio is fair to the holders of the Company
Shares from a financial point of view.
(d) Governmental Filings; No Violations.
-----------------------------------
(1) Other than the filings and/or notices (A) pursuant to Section 1.3,
(B) under the HSR Act, the Securities Act and the Exchange Act, (C)
pursuant to the European Community Merger Control Regulation, (D) to
comply with state securities or "blue-sky" laws and (E) to comply with
any other relevant Competition Laws (including such laws in Canada
and, if necessary, Japan) (such filings and/or notices of the Company
being the "Company Required Consents"), no notices, reports or other
-------------------------
filings are required to be made by the Company with, nor are any
consents, registrations, approvals, permits or authorizations required
to be obtained by the Company from, any governmental or regulatory
authority, court, agency, commission, body or other governmental
entity ("Governmental Entity"), in connection with the execution and
-------------------
delivery of this Agreement by the Company and the consummation by the
Company of the Merger and the other transactions contemplated by this
Agreement, except those that the failure to make or obtain are not,
individually or in the aggregate, reasonably likely to have a Material
Adverse Effect on the Company and prevent, materially delay or
materially impair the Company's ability to consummate the transactions
contemplated by this Agreement.
(2) The execution, delivery and performance of this Agreement by the
Company do not, and the consummation by the Company of the Merger and
the other transactions contemplated by this Agreement will not,
constitute or result in (A) a breach or violation of, or a default
under, the Company's certificate of incorporation or bylaws or the
comparable governing instruments of any of the Company's Significant
Investees or, (B) a breach or violation of, or a default under, the
acceleration of any obligations or the creation of a lien, pledge,
security interest or other encumbrance on its assets or the assets of
any of the Company's Significant Investees (with or without notice,
lapse of time or both) pursuant to, any agreement, lease, contract,
note, mortgage, indenture, arrangement or other obligation (whether
oral or written) ("Contracts") binding upon the Company or any of its
---------
Significant Investees or any Law or governmental or non-governmental
permit or license to which the Company or any of its Significant
Investees is subject or (C) any change in the rights or obligations of
any party under any Contracts to which the Company or its Significant
Investees are a party, except, in the case of clauses (B) or (C)
above, for any breach, violation, default, acceleration, creation or
change that, individually or in the aggregate, is not reasonably
likely to have a Material Adverse Effect on the Company and prevent,
materially delay or materially
11
<PAGE>
impair the Company's ability to consummate the transactions contemplated by this
Agreement. The Company Disclosure Letter sets forth a correct and complete list
of Contracts of the Company and its Significant Investees pursuant to which
consents or waivers are or may be required prior to consummation of the
transactions contemplated by this Agreement other than those where the failure
to obtain such consents or waivers is not, individually or in the aggregate,
reasonably likely to have a Material Adverse Effect on the Company and is not,
individually or in the aggregate, reasonably likely to prevent or materially
impair the Company's ability to consummate the transactions contemplated by this
Agreement.
(e) Reports; Financial Statements. The Company has filed with the SEC all
-----------------------------
required forms, reports, registration statements and documents required to
be filed by it with the SEC since December 31, 1996. The Company has made
available to Parent each registration statement, report, proxy statement or
information statement filed by the Company since December 31, 1996,
including the Company's Annual Report on Form 10-K for the years ended
December 31, 1996, December 31, 1997 and December 31, 1998 and the Company's
Quarterly Report on Form 10-Q for the quarter ended March 31, 1999 in the
form (including exhibits, annexes and any amendments thereto) filed with the
SEC (collectively, including any such reports filed subsequent to the date
of this Agreement, the "Company's Reports"). As of their respective dates,
-----------------
the Company's Reports complied as to form with all applicable requirements
under the Securities Act, the Exchange Act and the rules and regulations
thereunder and did not contain any untrue statement of a material fact or
omit to state a material fact required to be stated therein or necessary to
make the statements made therein, in light of the circumstances in which
they were made, not misleading. Each of the consolidated balance sheets
included in or incorporated by reference into the Company's Repo rts
(including the related notes and schedules) fairly presents the consolidated
financial position of the Company and its Subsidiaries as of its date and
each of the consolidated statements of income, stockholders' equity and of
cash flows included in or incorporated by reference into the Company's
Reports (including any related notes and schedules) fairly presents the
consolidated results of operations, retained earnings and cash flows, as the
case may be, of the Company and its Subsidiaries for the periods set forth
therein (subject, in the case of unaudited statements, to the absence of
notes (to the extent permitted by the rules applicable to Form 10-Q) and to
normal year-end audit adjustments that will not be material in amount or
effect), in each case in accordance with GAAP consistently applied during
the periods involved, except as may be
12
<PAGE>
noted therein. To the Company's knowledge, as of the date of this Agreement,
no Person or "group" "beneficially owns" 5% or more of the Company's
outstanding voting securities, with the terms "beneficially owns" and
"group" having the meanings ascribed to them under Rule 13d-3 and Rule 13d-5
under the Exchange Act.
(f) Absence of Certain Changes. Except as disclosed in the Company's Reports
--------------------------
filed prior to the date of this Agreement or as expressly contemplated by
this Agreement, since December 31, 1998 (the "Audit Date"), the Company and
----------
its Subsidiaries have conducted their respective businesses only in, and
have not engaged in any material transaction other than in accordance with,
the ordinary and usual course of such businesses and there has not been: (i)
any change in the financial condition, liabilities and assets (taken
together), business or results of operations of the Company and its
Subsidiaries, except those changes that are not, individually or in the
aggregate, reasonably likely to have a Material Adverse Effect on the
Company; (ii) any damage, destruction or other casualty loss with respect to
any asset or property owned, leased or otherwise used by the Company or any
of its Subsidiaries, whether or not covered by insurance, which damage,
destruction or loss is reasonably likely, individually or in the aggregate,
to have a Material Adverse Effect on the Company; (iii) any declaration,
setting aside or payment of any dividend or other distribution in respect of
the Company's capital stock; or (iv) any change by the Company in accounting
principles, practices or methods, except as required by GAAP. Since the
Audit Date, except as provided for in this Agreement, in the Company
Disclosure Letter or as disclosed in the Company's Reports filed prior to
the date of this Agreement, there has not been any increase in the salary,
wage, bonus, grants, awards, benefits or other compensation payable or that
could become payable by the Company or any of its Subsidiaries to directors,
officers or key employees or any amendment of any of the Company's
Compensation and Benefit Plans other than increases or amendments in the
normal and usual course of the Company's business (which may include normal
periodic performance reviews and related compensation and benefit increases
and the provision of new individual compensation and benefits for promoted
or newly hired officers and employees on terms consistent with past
practice).
(g) Litigation and Liabilities. Except as disclosed in the Company's
--------------------------
Reports filed prior to the date of this Agreement, there are no (i) civil,
criminal or administrative actions, suits, claims, hearings, investigations
or proceedings pending or, to the actual knowledge of
13
<PAGE>
the Company's Executive Officers, threatened against the Company or any of
its Subsidiaries or (ii) obligations or liabilities of the Company or any of
its Subsidiaries, whether or not accrued, contingent or otherwise and
whether or not required to be disclosed, including those relating to matters
involving any Environmental Law, except in each case for those that are not,
individually or in the aggregate, reasonably likely (x) to have a Material
Adverse Effect on the Company and (y) to prevent, materially delay or
materially impair the Company's ability to consummate the transactions
contemplated by this Agreement. The litigation matters set forth in Section
5.1(g) of the Company Disclosure Letter, taken as a whole, are not
reasonably likely to have a Material Adverse Effect on the Company.
(h) Employee Benefits.
-----------------
(i) Except as set forth in Section 5.1(h) of the Company Disclosure Letter, none
of the Company or any ERISA Affiliate maintains, is a party to, participates in
or has any liability or contingent liability with respect to any employee
benefit plan (within the meaning of Section 3(3) of ERISA) or any bonus,
deferred compensation, pension, retirement, profit-sharing, thrift, savings,
employee stock ownership, stock bonus, stock purchase, restricted stock, stock
option, employment, consulting, termination, severance, compensation, medical,
health or fringe benefit plan, or other plan, program, agreement, policy or
arrangement for any agents, consultants, employees, directors, former employees
or former directors of the Company and or any ERISA Affiliate which does not
constitute an employee benefit plan (which employee benefit plans and other
plans, programs, agreements, policies and arrangements are collectively referred
to as the "Compensation and Benefit Plans"). A true and correct copy of each
------------------------------
Compensation and Benefit Plan and, to the extent applicable, copies of the most
recent annual report, actuarial report, accountant's opinion of the plan's
financial statements, summary plan description and IRS determination letter with
respect to any Compensation and Benefit Plans and any trust agreements or
insurance contracts forming a part of such Compensation and Benefit Plans has
been made available by the Company to Parent prior to the date of this
Agreement. In the case of any Compensation and Benefit Plan which is not in
written form, the Company has supplied to Parent an accurate description of such
Compensation and Benefit Plan as in effect on the date of this Agreement.
(ii) All Compensation and Benefit Plans have been administered in substantial
compliance with all requirements of applicable law, including the Code and
ERISA, and no event has occurred which will or could cause any such Compensation
and Benefit Plan to fail to comply with such requirements
14
<PAGE>
and no notice has been issued by any governmental authority questioning or
challenging such compliance. There have been no acts or omissions by the Company
or any ERISA Affiliate which have given rise to or may give rise to fines,
penalties, taxes or related charges under Section 502 of ERISA or Chapters 43,
47, 68 or 100 of the Code for which the Company or any ERISA Affiliate may be
liable. Each of the Compensation and Benefit Plans that is an "employee pension
benefit plan" within the meaning of Section 3(2) of ERISA, other than a
multiemployer plan (as defined in Section 3(37) of ERISA), each a "Pension
-------
Plan," and that is intended to be qualified under Section 401(a) of the Code has
- ----
received a favorable determination letter from the IRS which covers all changes
in law for which the remedial amendment period (within the meaning of Section
401(b) of the Code and applicable regulations) has expired and none of the
Company nor any of its ERISA Affiliates is aware of any circumstances likely to
result in revocation of any such favorable determination letter. There is no
pending or, to the knowledge of the Company's Executive Officers, threatened
material litigation relating to its Compensation and Benefit Plans. Neither the
Company nor any of the ERISA Affiliates has engaged in a transaction with
respect to any of the Compensation and Benefit Plans that, assuming the taxable
period of such transaction expired as of the date of this Agreement, would
subject the Company or any of the ERISA Affiliates to a material tax or penalty
imposed by either Section 4975 of the Code or Section 502 of ERISA.
(iii) All contributions required to be made under the terms of any of the
Compensation and Benefit Plans as of the date of this Agreement have been timely
made or have been reflected on the most recent consolidated balance sheet filed
or incorporated by reference in the Company's Reports filed prior to the date of
this Agreement.
(iv) None of the Company or any ERISA Affiliate have any obligations for post-
employment health and life benefits under any of the Compensation and Benefit
Plans, except as set forth in the Company's Reports filed prior to the date of
this Agreement or as required by applicable law.
(v) Except as set forth in Section 5.1(h)(v) of the Company Disclosure Letter,
the consummation of the Merger (or the approval of the Merger by stockholders of
the Company) and the other transactions contemplated by this Agreement will not
(x) entitle any employees or directors of the Company or any employees of any of
the Company's ERISA Affiliates to severance pay, directly or indirectly, upon
termination of employment or otherwise, (y) accelerate the time of payment or
vesting or trigger any payment of compensation or benefits under, increase the
amount payable or trigger any other material obligation pursuant to, any of the
Compensation and Benefit
15
<PAGE>
Plans or (z) result in any breach or violation of, or a default under, any of
the Compensation and Benefit Plans.
(vi) None of the Compensation and Benefit Plans is a multiemployer plan, none of
the Compensation and Benefit Plans is otherwise subject to Title IV of ERISA and
none of the Company or any of the ERISA Affiliates have contributed or been
obligated to contribute to a multiemployer plan or any other plan which is
subject to Title IV of ERISA.
(vii) Prior to the date of this Agreement, the Company has made its 1999 annual
grant of stock based awards under its Compensation and Benefit Plans and does
not intend to make any additional grants of stock based awards until its 2000
annual grant of stock based awards under its Compensation and Benefit Plans
except as may be expressly permitted by Section 6.1(a)(iv).
(viii) Except as set forth in Section 5.1(h)(viii) of the Company's Disclosure
Letter, no person is eligible or may become eligible for benefits under the
Company's Executive Severance Plan.
(i) Compliance with Laws. Except as set forth in the Company's Reports
--------------------
filed prior to the date of this Agreement, the businesses of each of the
Company and its Subsidiaries have not been, and are not being, conducted in
violation of any Laws except for violations or possible violations that are
not, individually or in the aggregate, reasonably likely to have a Material
Adverse Effect on the Company and are not, individually or in the aggregate,
reasonably likely to prevent, materially delay or materially impair the
Company's ability to consummate the transactions contemplated by this
Agreement. Except as set forth in the Company's Reports filed prior to the
date of this Agreement, no investigation or review by any Governmental
Entity with respect to the Company or any of its Subsidiaries is pending or,
to the actual knowledge of the Company's Executive Officers, threatened,
nor, to the actual knowledge of the Company's Executive Officers, has any
Governmental Entity indicated an intention to conduct the same, except for
those the outcome of which are not, individually or in the aggregate,
reasonably likely to have a Material Adverse Effect on the Company and are
not, individually or in the aggregate, reasonably likely to prevent,
materially delay or materially impair the Company's ability to consummate
the transactions contemplated by this Agreement. To the actual knowledge of
the Company's Executive Officers, no material change is required in the
Company's or any of its Subsidiaries' processes, properties or procedures in
order to comply with any such Laws, and the Company
16
<PAGE>
has not received any notice or c ommunication of any material noncompliance
with any such Laws that has not been cured as of the date of this Agreement,
except for such changes and noncompliance that are not, individually or in
the aggregate, reasonably likely to have a Material Adverse Effect on the
Company or prevent, materially delay or materially impair the Company's
ability to consummate the transactions contemplated by this Agreement. Each
of the Company and its Subsidiaries has all Permits necessary to conduct its
business as presently conducted, except for those the absence of which are
not, individually or in the aggregate, reasonably likely to have a Material
Adverse Effect on the Company or prevent, materially delay or materially
impair the Company's ability to consummate the transactions contemplated by
this Agreement.
(j) Takeover Statutes; Charter and Bylaw Provisions. The Board of
-----------------------------------------------
Directors of the Company has taken all appropriate and necessary actions
such that either Parent or Merger Sub, as "interested stockholders", will be
permitted at any time to enter into one or more "business combinations"
(within the meaning of Section 203(c)(3) of the DGCL) with the Company,
despite the execution and delivery of this Agreement, and despite the
consummation of the transactions contemplated by this Agreement. No other
"fair price," "moratorium," "control share acquisition" or other similar
anti-takeover statute or regulation (each a "Takeover Statute") as in effect
----------------
on the date of this Agreement is applicable to the Company, the Company
Shares, the Merger or the other transactions contemplated by this Agreement.
No anti-takeover provision contained in the Company's certificate of
incorporation, including Article 10 thereof, or its bylaws (collectively,
"Charter and Bylaw Provisions") is, or at the Effective Time will be,
----------------------------
applicable to the Merger or the other transactions contemplated by this
Agreement in any manner that would prevent or make materially burdensome to
Parent the Merger or the other transactions contemplated by this Agreement.
(k) Environmental Matters. Except as disclosed in the Company's Reports
---------------------
filed prior to the date of this Agreement and except for such matters that,
alone or in the aggregate, are not reasonably likely to have a Material
Adverse Effect on the Company: (i) each of the Company and its Subsidiaries
has complied with all applicable Environmental Laws; (ii) the properties
currently owned or operated by the Company or any of its Subsidiaries
(including soils, groundwater, surface water, buildings or other structures)
are not contaminated with any Hazardous Substances; (iii) the properties
formerly owned or operated by the
17
<PAGE>
Company or any of its Subsidiaries were not contaminated with Hazardous Subs
tances during the period of ownership or operation by the Company or any of
its Subsidiaries; (iv) neither the Company nor any of its Subsidiaries is
subject to liability for any Hazardous Substance disposal or contamination
on any third party property; (v) neither the Company nor any of its
Subsidiaries has been associated with any release or threat of release of
any Hazardous Substance; (vi) neither the Company nor any of its
Subsidiaries has received any notice, demand, letter, claim or request for
information alleging that the Company or any of its Subsidiaries may be in
violation of or liable under any Environmental Law; (vii) neither the
Company nor any of its Subsidiaries is subject to any orders, decrees,
injunctions or other arrangements with any Governmental Entity or is subject
to any indemnity or other agreement with any third party relating to
liability under any Environmental Law or relating to Hazardous Substances;
and (viii) there are no circumstances or conditions involving the Company or
any of its Subsidiaries that could reasonably be expected to result in any
claims, liability, investigations, costs or restrictions on the ownership,
use, or transfer of any of the Company's properties pursuant to any
Environmental Law.
(l) Accounting and Tax Matters. Neither the Company nor any of its
--------------------------
Subsidiaries or Pooling Affiliates has taken or agreed to take any action,
nor do the Company's Executive Officers have any actual knowledge of any
fact or circumstance, that would prevent Parent from accounting for the
business combination to be effected by the Merger as a "pooling-of-
interests" in accordance with the Pooling Requirements or prevent the Merger
and the other transactions contemplated by this Agreement from qualifying as
a "reorganization" within the meaning of Section 368(a) of the Code. The
Company and its Subsidiaries have provided to its independent auditors all
information requested by such auditors to assess whether the Merger can be
properly accounted for as a "pooling-of-interests" in accordance with the
Pooling Requirements, and have fully cooperated with such auditors with
respect to all reasonable requests made in connection with such assessment.
(m) Taxes. The Company and each of its Subsidiaries have prepared in good
-----
faith and duly and timely filed (taking into account any extension of time
within which to file) all material Tax Returns required to be filed by any
of them at or before the Effective Time and all such filed Tax Returns are
complete and accurate in all material respects. The Company and each of its
Subsidiaries as of the Effective Time (x) will
18
<PAGE>
have paid or adequately provided for all Taxes that they are required to pay
prior to the Effective Time, and (y) will have withheld all United States
federal, state and local income taxes, FICA, FUTA and other Taxes,
including, without limitation, similar foreign Taxes, required to be
withheld from amounts owing to any employee, creditor or third party, except
for such amounts that, alone or in the aggregate, are not reasonably likely
to have a Material Adverse Effect on the Company. As of the date of this
Agreement, there are not pending or threatened in writing, any audits,
examinations, investigations or other proceedings in respect of Taxes or Tax
matters. There are not, to the actual knowledge of the Company's Executive
Officers, any unresolved questions, claims or outstanding proposed or
assessed deficiencies concerning the Company or any of its Subsidiaries' Tax
liability that are reasonably likely to have a Material Adverse Effect on
the Company. Neither the Company nor any of its Subsidiaries has any
liability with respect to income, franchise or similar Taxes in excess of
the amounts accrued in respect of such Taxes that are reflected in the
financial statements included in the Company's Reports, except such excess
liabilities as are not, individually or in the aggregate, reasonably likely
to have a Material Adverse Effect on the Company. Neither the Company nor
any of its Subsidiaries has executed any waiver of any statute of
limitations on, or extended the period for the assessment or collection of,
any Tax. Except as previously disclosed to Parent, no payments to be made to
any of the officers and employees of the Company or its Subsidiaries will,
as a result of consummation of the Merger, be subject to the deduction
limitations under Sections 280G or 162(m) of the Code.
(n) Labor Matters. Neither the Company nor any of its Subsidiaries is the
-------------
subject of any material proceeding asserting that the Company or any of its
Subsidiaries has committed an unfair labor practice or is seeking to compel
the Company to bargain with any labor union or labor organization nor is
there pending or, to the knowledge of the Company's Executive Officers,
threatened, nor has there been for the past five years, any labor strike,
dispute, walkout, work stoppage, slow-down or lockout involving the Company
or any of its Subsidiaries, except in each case as is not, individually or
in the aggregate, reasonably likely to have a Material Adverse Effect on the
Company.
(o) Brokers and Finders. Neither the Company nor any of its officers,
-------------------
directors or employees has employed any broker or finder or incurred any
liability for any brokerage fees, commissions or finders' fees in
19
<PAGE>
connection with the Merger or the other transactions contemplated by this
Agreement except that the Company has employed Chase and Merrill Lynch as
the Company's financial advisors. True and complete copies of all engagement
letters and other Contracts under which Chase or Merrill Lynch may be
entitled to any fees, expense reimbursement, indemnification or other
payment from the Company or any of its Subsidiaries have been furnished to
Parent.
(p) Regulatory Compliance.
---------------------
(1) (A) With respect to each of the Company's and its Subsidiaries' products
and, to the extent applicable, products under development and the products and,
to the extent applicable, products under development that the Company is
entitled to license from Crescendo (collectively, "Products"), (i) the Company,
--------
its Subsidiaries and, to the knowledge of the Company's Executive Officers,
Crescendo have obtained all applicable approvals, clearances, authorizations,
licenses and registrations required by United States or foreign governments or
government agencies, to permit any manufacturing, distribution, sales, marketing
or human research activities of the Company, its Subsidiaries and, to the
knowledge of the Company's Executive Officers, Crescendo to date (the
"Activities to Date") with respect to each Product (collectively, "Licenses");
------------------ --------
(ii) the Company, its Subsidiaries and, to the knowledge of the Company's
Executive Officers, Crescendo are in compliance in all material respects with
all terms and conditions of each License and with all requirements pertaining to
the Activities to Date with respect to each Product which is not required to be
the subject of a License; (iii) the Company, its Subsidiaries and, to the
knowledge of the Company's Executive Officers, Crescendo are in compliance in
all material respects with all applicable requirements (as set forth in relevant
statutes and regulations) regarding registration, licensure or notification for
each site (in any country) at which each Product is manufactured, processed,
packed, held for distribution or from which and into which it is distributed;
and (iv) to the extent any Product is intended for export from the United
States, the Company, its Subsidiaries and, to the knowledge of the Company's
Executive Officers, Crescendo are in compliance in all material respects with
either all FDA requirements for marketing or 21 U.S.C. (S)381(e) or (S)382; (B)
all manufacturing operations performed by or on behalf of the Company, its
Subsidiaries and, to the knowledge of the Company's Executive Officers,
Crescendo have been and are being conducted in full compliance with current good
manufacturing practice, including, but not limited to, the good manufacturing
practice regulations issued by the FDA and counterpart requirements in Canada,
the European Union and other countries; (C) all nonclinical laboratory studies
of Products under development, as described in
20
<PAGE>
21 C.F.R. (S)58.3(d), sponsored by the Company, its Subsidiaries and, to the
knowledge of the Company's Executive Officers, Crescendo have been and are being
conducted in full compliance with the good laboratory practice regulations set
forth in 21 C.F.R. Part 58 and counterpart requirements in the European Union
and other countries; and (D) the Company, its Subsidiaries and, to the knowledge
of the Company's Executive Officers, Crescendo are in full compliance with all
reporting requirements for all Licenses or plant registrations described in
clause (1)(A) above, including, but not limited to, the adverse event reporting
requirements for drugs in 21 C.F.R. Parts 312 and 314; except, in the case of
the preceding clauses (1)(A) through (1)(D), for any such failures to obtain or
noncompliance which, individually or in the aggregate, would not have a Material
Adverse Effect on the Company. Without limiting the generality of the foregoing
definition of "Licenses," such definition shall specifically include, with
respect to the United States, new drug applications, abbreviated new drug
applications, product license applications, investigational new drug
applications, premarket approval applications, premarket notifications under
Section 510(k) of the FDCA, and investigational device exemptions, and product
export applications issued by the FDA.
(2) To the knowledge of the Company, neither the Company, Crescendo, their
respective Subsidiaries nor any of their officers, employees or agents has made
any untrue statement of a material fact or fraudulent statement to the FDA or
any foreign equivalent, failed to disclose a fact required to be disclosed to
the FDA or any foreign equivalent, or committed any act, made any statement, or
failed to make any statement, that would reasonably be expected to provide a
basis for the FDA to invoke its policy respecting, "Fraud, Untrue Statements of
Material Facts, Bribery, and Illegal Gratuities," set forth in 56 Fed. Reg.
46191 (September 10, 1991) or any foreign equivalent to invoke its equivalent
policy.
(3) The Company has, prior to execution of this Agreement, made available to
Parent copies of or made available for Parent's review any and all documents in
its or any of its Subsidiaries' possession that the Company believes are
material to assessing the Company's or any of its Subsidiaries' compliance with
the FDCA and the Comprehensive Drug Abuse Prevention and Control Act of 1970 and
implementing regulations, including, without limitation, copies in its
possession of (i) all 483s issued during the last three years, (ii) any
administrative or judicial order, ruling or agreement issued or entered into
during the last three years in which the Company, any of its Subsidiaries, or
any of their respective predecessor companies were a named party or were
identified as an interested person, or (iii) any recall notice or order relating
to any Product during the last two years.
21
<PAGE>
(q) Significant Agreements. Section 5.1(q) of the Company Disclosure
----------------------
Letter sets forth a complete and correct list of: (i) all Contracts required
to be filed as an exhibit to the Company's Reports filed prior to the date
hereof; (ii) all Contracts in effect as of the date of this Agreement that
are reasonably expected to require the payment (whether by or to the Company
or any of its Subsidiaries) of $15,000,000 or more in the aggregate or
payments in any twelve-month period aggregating $4,000,000 or more; (iii)
all Contracts between the Company and any of its Subsidiaries, on the one
hand, and Crescendo and any of its Subsidiaries, on the other hand; (iv) all
in-licenses or Contracts calling for the purchase or other acquisition by
the Company or any of its Subsidiaries of rights to Products that generate
or are reasonably expected to generate $10,000,000 or more of annualized
revenues; and (v) all Contracts between the Company and any of its
Subsidiaries, on the one hand, and any Affiliate of the Company, on the
other hand (the Contracts described in (i) through (v), the "Significant
-----------
Agreements"). The Company has heretofore made available to Parent complete
----------
and correct copies of each of the Significant Agreements, each as amended or
modified to the date hereof (including any waivers with respect thereto).
Each of the Significant Agreements is in full force and effect and
enforceable in accordance with its terms, subject to the Bankruptcy and
Equity Exception, except in each case where the failure to be in full force
and effect and enforceable would not, individually or in the aggregate, be
reasonably likely to have a Material Adverse Effect on the Company. None of
the Company, any of its Subsidiaries or, to the knowledge of the Company's
Executive Officers, Crescendo has received any notice (written or oral) of
cancellation or termination of, or any expression or indication of an
intention or desire to cancel or terminate, any of the Significant
Agreements except in each case for those that are not, individually or in
the aggregate, reasonably likely to have a Material Adverse Effect on the
Company. No Significant Agreement is the subject of, or, to the knowledge of
the Company's Executive Officers, has been threatened to be made the subject
of, any arbitration, suit or other legal proceeding except in each case for
those that are not, individually or in the aggregate, reasonably likely to
have a Material Adverse Effect on the Company. With respect to any
Significant Agreement which by its terms will terminate as of a certain date
unless renewed or unless an option to extend such Significant Agreement is
exercised, neither the Company, any of its Subsidiaries nor, to the
knowledge of the Company's Executive Officers, Crescendo has received any
notice (written or oral), or otherwise has any knowledge, that any such
Significant Agreement will not be, or is not likely to be,
22
<PAGE>
so renewed or that any such extension option will not be exercised except in
each case for those that are not, individually or in the aggregate,
reasonably likely to have a Material Adverse Effect on the Company. There
exists no event of default or occurrence, condition or act on the part of
the Company or any of its Subsidiaries or, to the knowledge of the Company's
Executive Officers, on the part of the other parties to the Significant
Agreements which constitutes or would constitute (with notice or lapse of
time or both) a breach of or default under any of the Significant Agreements
except in each case for those that are not, individually or in the
aggregate, reasonably likely to have a Material Adverse Effect on the
Company.
(r) Intellectual Property Rights.
----------------------------
(1) The Company, its Subsidiaries and, to the knowledge of the Company's
Executive Officers, Crescendo own or have the right to use all intellectual
property material to the conduct of their respective businesses (such
intellectual property and such rights are collectively referred to herein as the
"Company IP Rights"). Except under the Agreements disclosed in Section 5.1(q) of
-----------------
the Company Disclosure Letter, no royalties or other payments relating to the
use of intellectual property rights are payable by the Company, its
Subsidiaries, or, to the knowledge of the Company's Executive Officers,
Crescendo to any Person with respect to commercialization of any products
presently sold, manufactured by or for or under development by the Company,
Crescendo and their respective Subsidiaries that are in excess of $2,000,000 per
year for any single product.
(2) The execution, delivery and performance of this Agreement by the Company and
the consummation by the Company of the transactions contemplated hereby will not
(A) constitute a material breach by the Company, its Subsidiaries or, to the
knowledge of the Company's Executive Officers, Crescendo of any material
instrument or agreement governing any Company IP Rights, (B) cause the
modification of any terms of any material licenses or agreements relating to any
Company IP Rights including but not limited to the modification of the effective
rate of any royalties or other payments provided for in any such license or
agreement, (C) cause the forfeiture or termination of any material Company IP
Rights, (D) give rise to a right of forfeiture or termination of any material
Company IP Rights or (E) materially impair the right of the Company, its
Subsidiaries, the Surviving Corporation, Parent or, to the knowledge of the
Company's Executive Officers, Crescendo to make, have made, offer for sale, use,
sell, export or license any material Company IP Rights or portion thereof.
23
<PAGE>
(3) Except in each case as is not, individually or in the aggregate, reasonably
likely to have a Material Adverse Effect on the Company, neither the
manufacture, marketing, license, export, sale or intended use of any Product by
the Company, its Subsidiaries or, to the knowledge of the Company's Executive
Officers, Crescendo nor the current use by the Company, its Subsidiaries or, to
the knowledge of the Company's Executive Officers, Crescendo, of any Company IP
Rights (A) violates any license or agreement between the Company, Crescendo or
any of their respective Subsidiaries and any third party or (B) infringes any
patents or other intellectual property rights of any other party; and there is
no pending or, to the knowledge of the Company's Executive Officers, threatened
claim or litigation contesting the validity, ownership or right to use, sell,
license or dispose of any Company IP Rights, or asserting that any Company IP
Rights or the proposed use, sale, export, license or disposition thereof, or the
manufacture, use or sale of any Products, conflicts or will conflict with the
rights of any other party.
(4) The Company has heretofore made available to Parent a worldwide list of all
patents, trade names, registered trademarks and registered service marks, and
applications for any of the foregoing, owned or possessed by the Company, its
Subsidiaries or, to the knowledge of the Company's Executive Officers, Crescendo
and true and complete copies of such materials have been made available to
Parent.
(5) The Company has provided to Parent a true and complete copy of the
Company's, its Subsidiaries' and, to the knowledge of the Company's Executive
Officers, Crescendo's standard form or forms of employee confidentiality
agreements and other standard agreements relating to rights to inventions or
other intellectual property and the Company, its Subsidiaries and, to the
knowledge of the Company's Executive Officers, Crescendo have taken all
commercially reasonably steps to ensure that all employees have executed such an
agreement. All consultants or third parties with access to proprietary
information of the Company, its Subsidiaries and, to the knowledge of the
Company's Executive Officers, Crescendo have executed appropriate non-disclosure
agreements.
(s) Year 2000 Compliance. The Company has instituted processes and
--------------------
controls to attain Year 2000 Compliance, as that term is defined below, and
the foreseeable expenses or other liabilities associated with the process of
securing full Year 2000 Compliance would not be reasonably expected to have
a Material Adverse Effect on the Company. "Year 2000 Compliance" means,
--------------------
except for any noncompliance that would not be reasonably expected to cause
a
24
<PAGE>
Material Adverse Effect on the Company, that such hardware or software used
by the Comp any or any of its Subsidiaries including, but not limited to,
microcode, firmware, system and application programs, files, databases,
computer services, and microcontrollers, including those embedded in
computer and non-computer equipment (the "Computer Systems") will:
----------------
(1) process date data from at least the years 1900 through 2101 without error or
interruption;
(2) maintain functionality with respect to the introduction processing, or
output of records containing dates falling on or after January 1, 2000; and
(3) be interoperable with other software or hardware which may deliver records
to, receive records from, or interact with such Computer Systems in the
course of conducting the business of the Company, including processing data
and manufacturing the products of the Company.
(t) Crescendo Pharmaceuticals Corporation.
-------------------------------------
(1) The Company owns 1,000 shares of Class B Common Stock of Crescendo free and
clear of any lien, pledge, security interest, claim or other encumbrance. Such
1,000 shares constitute all of the issued and outstanding shares of Class B
Common Stock of Crescendo.
(2) The Company's option to purchase all of the outstanding shares of Class A
Common Stock of Crescendo is in full force and effect as of the date hereof and
is enforceable in accordance with its terms as set forth in ARTICLE FIFTH of the
Restated Certificate of Incorporation of Crescendo, a true and correct copy of
which is attached as Section 5.1(t)(2) of the Company Disclosure Letter (the
"Crescendo Certificate of Incorporation"). As of the date hereof, (i) the
--------------------------------------
aggregate of the worldwide Product Payments, Developed Technology Royalties and
Technical Evaluation Product Payments (as such terms are defined in the
Crescendo Certificate of Incorporation) (the "Crescendo Payments") made by or
------------------
due from the Company to Crescendo with respect to all Licensed Products,
Developed Technology Products and Technical Evaluation Products (as such terms
are defined in the Crescendo Certificate of Incorporation) (the "Crescendo
---------
Products") for the four calender quarters immediately preceding the date hereof
- --------
is approximately $500,000, (ii) the aggregate of the average quarterly Crescendo
Payments made by or due from the Company to Crescendo with respect to all
Crescendo Products which
25
<PAGE>
have not been commercially sold during each of the four calender
quarters immediately preceding the date hereof is approximately
$500,000, and (iii) the aggregate of all amounts paid by or due from
Crescendo under the Development Agreement (as defined in the Crescendo
Certificate of Incorporation) is approximately $163,000,000. The
Company hereby represents and warrants that it has not exercised its
payment buy-out option with respect to any of the Crescendo Products.
(3) As of the date hereof, the License Agreement dated December 16,
1998 by and between the Company and Crescendo, a true and correct copy
of which is attached as Section 5.1(t)(3) of the Company Disclosure
Letter, is the only license agreement that has been executed by the
Company and Crescendo pursuant to the License Option Agreement dated
September 5, 1997 by and between the Company and Crescendo.
5.2 Representations and Warranties of Parent and Merger Sub. Except as
-------------------------------------------------------
set forth in the corresponding sections or subsections of the disclosure letter,
dated the date of this Agreement, delivered by Parent to the Company (the
"Parent Disclosure Letter"), Parent, on behalf of itself and Merger Sub,
- -------------------------
represents and warrants to the Company that:
(a) Organization, Good Standing and Qualification. Each of Parent and
---------------------------------------------
its Subsidiaries is a corporation duly organized, validly existing
and in good standing under the laws of its respective jurisdiction
of organization and has all requisite corporate or similar power
and authority to own and operate its properties and assets and to
carry on its business as presently conducted and is qualified to
do business and is in good standing as a foreign corporation in
each jurisdiction where the ownership or operation of its
properties or conduct of its business requires such qualification,
except where the failure to be so qualified or in good standing is
not, when taken together with all other such failures, reasonably
likely to have a Material Adverse Effect on it. Parent has made
available to Company a complete and correct copy of its articles
of incorporation and bylaws, each as amended to date. Such
articles of incorporation and bylaws are in full force and effect.
(b) Capital Structure.
-----------------
(1) The authorized capital stock of Parent consists of 2,400,000,000
shares of Parent Common Stock, of which 1,520,806,248 were issued and
outstanding and 17,591,970 shares were held in treasury as of the
close of business on June 18, 1999, and 1,000,000 shares of Preferred
Stock, par value $1.00 per share (the "Parent Preferred Shares"), of
-----------------------
which no shares were outstanding as of the date hereof. All of the
outstanding shares of Parent
26
<PAGE>
Common Stock have been duly authorized and are validly issued, fully paid and
nonassessable. As of the date of this Agreement, other than Parent Common Stock
subject to issuance as set forth below, Parent has no shares of Parent Common
Stock or Parent Preferred Shares reserved for or subject to issuance. As of June
18, 1999, there were not more than 70,405,072 shares of Parent Common Stock that
Parent was obligated to issue pursuant to Parent's stock plans, each of which
are listed in Section 5.2(b) of the Parent Disclosure Letter (collectively, the
"Parent Stock Plans"). Except as set forth above, as of the date of this
------------------
Agreement, there are no preemptive or other outstanding rights, options,
warrants, conversion rights, stock appreciation rights, redemption rights,
repurchase rights, agreements, arrangements or commitments to issue or to sell
any shares of capital stock or other securities of Parent or any securities or
obligations convertible or exchangeable into or exercisable for, or giving any
Person a right to subscribe for or acquire, any securities of Parent, and no
securities or obligations evidencing such rights are authorized, issued or
outstanding. As of the date of this Agreement, Parent does not have outstanding
any bonds, debentures, notes or other debt obligations the holders of which have
the right to vote (or convertible into or exercisable for securities having the
right to vote) with the stockholders of Parent on any matter.
(2) The authorized capital stock of Merger Sub consists of 1,000 shares of
Common Stock, par value $0.01 per share, all of which are validly issued and
outstanding. All of the issued and outstanding capital stock of Merger Sub is,
and at the Effective Time will be, owned by Parent, and there are (i) no other
shares of capital stock or other voting securities of Merger Sub, (ii) no
securities of Merger Sub convertible into or exchangeable for shares of capital
stock or other voting securities of Merger Sub and (iii) no options or other
rights to acquire from Merger Sub, and no obligations of Merger Sub to issue,
any capital stock, other voting securities or securities convertible into or
exchangeable for capital stock or other voting securities of Merger Sub. Merger
Sub has not conducted any business prior to the date of this Agreement and has
no, and prior to the Effective Time will have no, assets, liabilities or
obligations of any nature other than those incident to its formation and
pursuant to this Agreement and the Merger and the other transactions
contemplated by this Agreement.
(c) Corporate Authority and Approval. Parent and Merger Sub each has all
--------------------------------
requisite corporate power and authority and each has taken all corporate
action necessary in order to execute, deliver and perform its obligations
under this Agreement, subject only to the Parent Required Consents, to
consummate the Merger. This Agreement has been duly executed and delivered
by Parent and Merger Sub and is a valid and
27
<PAGE>
binding agreement of Parent and Merger Sub, enforceable against each of
Parent and Merger Sub in accordance with its terms, subject to the
Bankruptcy and Equity Exception. The shares of Parent Common Stock, when
issued pursuant to this Agreement, will be validly issued, fully paid and
nonassessable, and no stockholder of Parent will have any preemptive right
of subscription or purchase in respect thereof.
(d) Governmental Filings; No Violations.
-----------------------------------
(1) Other than the filings and/or notices (A) pursuant to Section 1.3, (B) under
the HSR Act, the Securities Act and the Exchange Act, (C) pursuant to the
European Community Merger Control Regulation, (D) to comply with state
securities or "blue-sky" laws and (E) to comply with any other relevant
Competition Laws (including such laws in Canada and, if necessary, Japan) (such
filings and/or notices of Parent being the "Parent Required Consents"), no
------------------------
notices, reports or other filings are required to be made by Parent with, nor
are any consents, registrations, approvals, permits or authorizations required
to be obtained by Parent from, any Governmental Entity, in connection with the
execution and delivery of this Agreement by Parent and the consummation by
Parent of the Merger and the other transactions contemplated by this Agreement,
except those that the failure to make or obtain are not, individually or in the
aggregate, reasonably likely to have a Material Adverse Effect on Parent and are
not, individually or in the aggregate, reasonably likely to prevent, materially
delay or materially impair Parent's ability to consummate the transactions
contemplated by this Agreement.
(2) The execution, delivery and performance of this Agreement by Parent do not,
and the consummation by Parent of the Merger and the other transactions
contemplated by this Agreement will not, constitute or result in (A) a breach or
violation of, or a default under, Parent's articles of incorporation or bylaws
or the comparable governing instruments of any of its Significant Subsidiaries
or any Significant Investees, (B) a breach or violation of, or a default under,
the acceleration of any obligations or the creation of a lien, pledge, security
interest or other encumbrance on its assets or the assets of any of Parent's
Significant Investees (with or without notice, lapse of time or both) pursuant
to, any Contracts binding upon Parent or any of its Significant Investees or any
Law or governmental or non-governmental permit or license to which Parent or any
of its Significant Investees is subject or (C) any change in the rights or
obligations of any party under any Contracts to which Parent or its Significant
Investees are a party, except, in the case of clauses (B) or (C) above, for any
breach, violation, default, acceleration, creation or change that, individually
or in the aggregate, is not reasonably likely to have a Material Adverse Effect
on Parent and is not, individually or
28
<PAGE>
in the aggregate, reasonably likely to prevent, materially delay or materially
impair Parent's ability to consummate the transactions contemplated by this
Agreement. The Parent Disclosure Letter sets forth a correct and complete list
of Contracts of Parent and its Significant Investees pursuant to which consents
or waivers are or may be required prior to consummation of the transactions
contemplated by this Agreement other than those where the failure to obtain such
consents or waivers is not, individually or in the aggregate, reasonably likely
to have a Material Adverse Effect on Parent and is not, individually or in the
aggregate, reasonably likely to prevent or materially impair Parent's ability to
consummate the transactions contemplated by this Agreement.
(e) Reports; Financial Statements. Parent has made available to the
-----------------------------
Company each registration statement, report, proxy statement or information
statement prepared by Parent since December 31, 1996, including Parent's
Annual Report on Form 10-K for the years ended December 31, 1996, December
31, 1997 and December 31, 1998 and Parent's Quarterly Report on Form 10-Q
for the quarter ended March 31, 1999 in the form (including exhibits,
annexes and any amendments thereto) filed with the SEC (collectively,
including any such reports filed subsequent to the date of this Agreement,
"Parent's Reports"). As of their respective dates, Parent's Reports complied
----------------
as to form with all applicable requirements under the Securities Act, the
Exchange Act and the rules and regulations thereunder and did not contain
any untrue statement of a material fact or omit to state a material fact
required to be stated therein or necessary to make the statements made
therein, in light of the circumstances in which they were made, not
misleading. Each of the consolidated balance sheets included in or
incorporated by reference into Parent's Reports (including the related notes
and schedules) fairly presents the consolidated financial position of Parent
and its Subsidiaries as of its date and each of the consolidated statements
of income, shareholders' investment and cash flows included in or
incorporated by reference into Parent's Reports (including any related notes
and schedules) fairly presents the consolidated results of operations,
statement of shareholders' investment and cash flows, as the case may be, of
Parent and its Subsidiaries for the periods set forth therein (subject, in
the case of unaudited statements, to the absence of notes (to the extent
permitted by the rules applicable to Form 10-Q) and to normal year-end audit
adjustments that will not be material in amount or effect), in each case in
accordance with GAAP consistently applied during the periods involved,
except as may be noted therein. Except as set forth in Section 5.2(e) of the
Parent Disclosure Letter, to Parent's knowledge, as of the date of this
Agreement, no Person or "group" "beneficially
29
<PAGE>
owns" 5% or more of Parent's outstanding voting securities, with the terms
"beneficially owns" and "group" having the meanings ascribed to them under
Rule 13d-3 and Rule 13d-5 under the Exchange Act.
(f) Absence of Certain Changes. Except as disclosed in Parent's Reports
--------------------------
filed prior to the date of this Agreement or as expressly contemplated by
this Agreement, since the Audit Date, there has not been: (i) any change in
the financial condition, liabilities and assets (taken together), business
or results of operations of Parent and its Subsidiaries, except those
changes that are not, individually or in the aggregate, reasonably likely to
have a Material Adverse Effect on Parent; (ii) any damage, destruction or
other casualty loss with respect to any asset or property owned, leased or
otherwise used by Parent or any of its Subsidiaries, whether or not covered
by insurance, which damage, destruction or loss is reasonably likely,
individually or in the aggregate, to have a Material Adverse Effect on
Parent; or (iii) any change by Parent in accounting principles, practices or
methods, except as required by GAAP.
(g) Accounting and Tax Matters. Neither Parent nor any of its Subsidiaries
--------------------------
or Pooling Affiliates has taken or agreed to take any action, nor do
Parent's executive officers have any actual knowledge of any fact or
circumstance, that would prevent Parent from accounting for the business
combination to be effected by the Merger as a "pooling-of-interests" in
accordance with the Pooling Requirements or prevent the Merger and the other
transactions contemplated by this Agreement from qualifying as a
"reorganization" within the meaning of Section 368(a) of the Code.
(h) Continuation of Operations. Parent intends to cause the Surviving
--------------------------
Corporation to continue to maintain significant operations in the Silicon
Valley area of California.
30
<PAGE>
ARTICLE VI.
Covenants
---------
6.1 Interim Operations. Except as set forth in the corresponding sections
------------------
or subsections of the Company Disclosure Letter and the Parent Disclosure
Letter, as appropriate:
(a) The Company covenants and agrees as to itself and its Subsidiaries
that, after the date of this Agreement and prior to the Effective
Time (unless Parent shall otherwise approve in writing and except
as (x) otherwise required by applicable Law, in which case, the
Company shall provide Parent with prior reasonable notice of such
requirement, or (y) expressly contemplated by this Agreement):
(i) Its business and that of its Subsidiaries shall be conducted only
in the ordinary and usual course and, to the extent consistent
therewith, it and its Subsidiaries shall use their reasonable best
efforts to preserve their business organizations intact and maintain
their existing relations and goodwill with customers, suppliers,
regulators, distributors, creditors, lessors, employees and business
associates; provided, however, that no action by the Company or its
-------- -------
Subsidiaries with respect to matters specifically addressed by any
other provision of this Section 6.1(a) shall be deemed a breach of
this Section 6.1(a)(i) unless such action would constitute a breach of
one or more such other provisions;
(ii) It shall not: (A) amend its certificate of incorporation or
bylaws; (B) split, combine, subdivide or reclassify its outstanding
shares of capital stock; (C) declare, set aside or pay any dividend
payable in cash, stock or property in respect of any capital stock; or
(D) repurchase, redeem or otherwise acquire, except in connection with
commitments existing as of the date of this Agreement under the
Company Stock Plans but subject to the Company's obligations under
subparagraph (iii) below, or permit any of its Subsidiaries to
purchase or otherwise acquire, any shares of its capital stock or any
securities convertible into or exchangeable or exercisable for any
shares of its capital stock;
(iii) Neither it nor any of its Subsidiaries shall take any action
that would prevent the Merger from qualifying for "pooling-of-
interests" accounting treatment in accordance with the Pooling
Requirements or as a "reorganization" within the meaning of Section
368(a) of the Code or that would cause any of its representations and
warranties in this Agreement to become untrue in any material respect;
31
<PAGE>
(iv) Neither it nor any of its ERISA Affiliates shall: (A) accelerate,
amend or change the period of exercisability of or terminate,
establish, adopt, enter into, make any new grants or awards of stock-
based compensation or other benefits under any Compensation and
Benefit Plans including expanding participation in any severance pay
plan; (B) amend or otherwise modify any Compensation and Benefit
Plans; or (C) increase the salary, wage, bonus or other compensation
of any directors, officers or employees, except, in the case of (A),
(B) and (C), (x) for grants or awards to employees below the level of
Vice President of it or its Subsidiaries under existing Compensation
and Benefit Plans in such amounts and on such terms as are consistent
with past practice, (y) in the normal and usual course of its business
(which may include normal periodic performance reviews and related
compensation and benefit increases and the provision of individual
Company Compensation and Benefit Plans consistent with past practice
for promoted or newly hired employees below the level of Vice
President on terms consistent with past practice), or (z) for actions
necessary to satisfy existing contractual obligations under
Compensation and Benefit Plans existing as of the date of this
Agreement or as required under the terms of this Agreement; provided,
--------
that it shall not take such action unless it shall have provided
Parent with prior reasonable notice;
(v) Neither it nor any of its Subsidiaries shall incur, repay or
retire prior to maturity or refinance any indebtedness for borrowed
money or guarantee any such indebtedness or issue, sell, repurchase or
redeem prior to maturity any debt securities or warrants or rights to
acquire any debt securities or guarantee any debt securities of
others, in all such cases in excess of, in the aggregate, $10,000,000
plus amounts equal to any existing indebtedness described in Section
4.5 that the Company is required to repurchase prior to the Effective
Time;
(vi) Neither it nor any of its Subsidiaries shall make any capital
expenditures in an aggregate amount in excess of the aggregate amount
reflected in the Company's capital expenditure budget for the fiscal
year ending December 31, 1999, a copy of which has been provided to
Parent;
(vii) Neither it nor any of its Subsidiaries shall issue, deliver,
sell, pledge or encumber shares of any class of its capital stock or
any securities convertible or exchangeable into, any rights, warrants
or options to acquire, or any bonds, debentures, notes or other debt
obligations having the right to vote or convertible or exercisable for
any such shares except Company Shares issued pursuant to options and
other awards outstanding on the date of this Agreement under the
Company Stock Plans or otherwise permitted by Section 6.1(a)(iv);
32
<PAGE>
(viii) Neither it nor any of its Subsidiaries shall authorize,
propose or announce an intention to authorize or propose, or enter
into an agreement with respect to, any merger, consolidation or
business combination (other than the Merger), or any purchase, sale,
lease, license or other acquisition or disposition of any business or
of a material amount of assets or securities;
(ix) It shall not make any material change in its accounting policies
or procedures, other than any such change that is required by GAAP, or
revalue any assets, including, without limitation, writing down the
value of material inventory or writing off notes or accounts
receivable in a material amount other than as required by GAAP;
(x) It shall not release, assign, settle or compromise any material
claims or litigation or make any material tax election or settle or
compromise any material United States federal, state, local or foreign
tax liability; and
(xi) Neither it nor any of its Subsidiaries shall authorize or enter
into any agreement to violate any of the foregoing.
(b) Parent covenants and agrees as to itself and its Subsidiaries
that, after the date of this Agreement and prior to the Effective
Time (unless the Company shall otherwise approve in writing and
except as (x) otherwise required by applicable Law, in which case,
Parent shall provide the Company with prior reasonable notice of
such requirement, or (y) expressly contemplated by this
Agreement):
(i) It shall remain principally a diversified health care products and
services company;
(ii) It shall not: (A) reclassify its shares of capital stock or (B)
declare, set aside or pay any dividend payable in cash, stock (other
than Parent Common Stock) or property in respect of any capital stock,
except (x) for regular quarterly cash dividends or (y) for a dividend
that would be received by the holders of the Company Common Stock on
an equivalent basis per share of Parent Common Stock after the
Effective Time;
(iii) Neither it nor any of its Subsidiaries shall take any action
that would prevent the Merger from qualifying for "pooling-of-
interests" accounting treatment in accordance with the Pooling
Requirements or as a "reorganization" within the meaning of Section
368(a) of the Code or that would cause any of its representations and
warranties in this Agreement to become untrue in any material respect;
33
<PAGE>
(iv) Neither it nor any of its Subsidiaries shall authorize, propose
or announce an intention to authorize or propose, or enter into an
agreement with respect to, any merger, consolidation or business
combination, or any purchase, sale, lease, license or other
acquisition of any business or a material amount of assets or
securities, in all such cases, with any of the entities identified in
Section 6.1(b) of the Company Disclosure Letter; and
(v) Neither it nor any of its Subsidiaries shall authorize or enter
into any agreement to violate any of the foregoing.
(c) Parent and the Company agree that any written approval of Parent
or of the Company obtained under Section 6.1(a) or 6.1(b) must be
signed on behalf of the appropriate party by the Chief Executive
Officer or Chief Financial Officer of Parent or of the Company or
Senior Vice President, Pharmaceutical Operations of Parent or
Group Vice President, ALZA Technologies, of the Company.
6.2 Acquisition Proposals.
---------------------
(a) The Company agrees that neither it nor any of its Subsidiaries nor
any of the officers and directors of it or its Subsidiaries shall,
and that it shall direct and use its best efforts to cause its and
its Subsidiaries' employees, agents and representatives (including
any investment banker, attorney or accountant retained by it or
any of its Subsidiaries) (the Company, its Subsidiaries and their
officers, directors, employees, agents and representatives being
referred to as the "Company Representatives") not to, directly or
-----------------------
indirectly, initiate, solicit, encourage or otherwise facilitate
any inquiries or the making of any proposal or offer with respect
to a merger, reorganization, share exchange, consolidation,
business combination, recapitalization, liquidation, dissolution
or similar transaction involving it, or any purchase or sale of
the consolidated assets (including stock of its Subsidiaries) of
it or any of its Subsidiaries, taken as a whole, having an
aggregate value equal to 10% or more of its market capitalization,
or any purchase or sale of, or tender or exchange offer for, 10%
or more of its or any of its Subsidiaries' equity securities (any
such proposal or offer being hereinafter referred to as an
"Acquisition Proposal"). The Company further agrees that neither
--------------------
it nor any of its Subsidiaries nor any of the officers and
directors of it or its Subsidiaries shall, and that it shall
direct and use its best efforts to cause the Company
Representatives not to, directly or indirectly, have any
discussion with or provide any confidential information or data to
any Person relating to or in contemplation of an Acquisition
Proposal
34
<PAGE>
or engage in any ne gotiations concerning an Acquisition Proposal, or
otherwise facilitate any effort or attempt to make or implement an
Acquisition Proposal; provided, however, that nothing contained in this
-------- -------
Agreement shall prevent either the Company or its Board of Directors from:
(A) complying with Rule 14d-9 and Rule 14e-2 promulgated under the Exchange
Act with regard to an Acquisition Proposal; (B) engaging in any discussions
or negotiations with or providing any information to, any Person in
response to an unsolicited bona fide written Acquisition Proposal by any
such Person; or (C) subject to the obligation of the Company pursuant to
Section 6.4 to duly convene a Stockholders Meeting at which a vote of the
stockholders of the Company shall be taken regarding the adoption of this
Agreement and the approval of the transactions contemplated by this
Agreement, recommending such an unsolicited bona fide written Acquisition
Proposal to the stockholders of the Company if, and only to the extent
that, with respect to the actions referred to in clauses (B) or (C), (i)
the Board of Directors of the Company concludes in good faith (after
consultation with its outside legal counsel and its financial advisor) that
such Acquisition Proposal is reasonably capable of being completed, taking
into account all legal, financial, regulatory and other aspects of the
proposal and the Person making the proposal, and would, if consummated,
result in a transaction more favorable to the Company's stockholders from a
financial point of view than the transaction contemplated by this Agreement
(a "Superior Proposal"), (ii) the Board of Directors of the Company
-----------------
determines in good faith after consultation with outside legal counsel that
the failure to take such action would result in the reasonable likelihood
that the Board of Directors would breach its fiduciary duties to the
Company's stockholders under applicable Law and (iii) prior to providing
any information or data to any Person in connection with an Acquisition
Proposal by any such Person, the Board of Directors of the Company shall
receive from such Person an executed confidentiality agreement on terms
substantially similar to those contained in the confidentiality agreement
previously entered into between Parent and the Company in connection with
their consideration of the Merger; provided, that such confidentiality
--------
agreement shall contain terms that allow the Company to comply with its
obligations under this Section 6.2.
(b) The Company agrees that it will immediately cease and cause to be
terminated any existing activities, discussions or negotiations with any
parties conducted heretofore with respect to any Acquisition Proposal. The
Company agrees that it will take the necessary steps to promptly inform
each Company Representative of the obligations undertaken in
35
<PAGE>
Section 6.2(a). The Company agrees that it will notify Parent
promptly, but in any event within twenty-four (24) hours, if any
such inquiries, proposals or offers are received by, any such
information is requested from, or any such discussions or
negotiations are sought to be initiated or continued with, any
Company Representative indicating, in connection with such
notice, the name of such Person making such inquiry, proposal,
offer or request and the substance of any such inquiries,
proposals or offers. The Company thereafter shall keep Parent
informed, on a timely basis, of the status and terms of any such
inquiries, proposals or offers and the status of any such
discussions or negotiations. The Company also agrees that it will
promptly request each Person that has heretofore executed a
confidentiality agreement in connection with its consideration of
any Acquisition Proposal to return all confidential information
heretofore furnished to such Person by or on behalf of the
Company or any of its Subsidiaries.
6.3 Information Supplied. The Company and Parent each agrees, as to
--------------------
itself and its Subsidiaries, that none of the information supplied or to be
supplied by it or its Subsidiaries for inclusion or incorporation by reference
in (i) the Registration Statement on Form S-4 to be filed with the SEC by Parent
in connection with the issuance of shares of Parent Common Stock in the Merger
(including the joint proxy statement and prospectus (the "Prospectus/Proxy
----------------
Statement") constituting a part thereof) (the "S-4 Registration Statement")
- --------- --------------------------
will, at the time the S-4 Registration Statement becomes effective under the
Securities Act, and (ii) the Prospectus/Proxy Statement and any amendment or
supplement thereto will, at the date of mailing to stockholders and at the time
of the meeting of stockholders of the Company to be held in connection with the
Merger, in any such case, contain any untrue statement of a material fact or
omit to state any material fact required to be stated therein or necessary in
order to make the statements therein, in light of the circumstances under which
they were made, not misleading. If at any time prior to the Effective Time any
information relating to Parent or the Company, or any of their respective
Affiliates, officers or directors, is discovered by Parent or the Company which
should be set forth in an amendment or supplement to any of the S-4 Registration
Statement or the Prospectus/Proxy Statement, so that any of such documents would
not include any misstatement of a material fact or would omit to state any
material fact required to be stated therein or necessary to make the statements
therein, in the light of the circumstances under which they were made, not
misleading, the party which discovers such information shall promptly notify the
other parties to this Agreement and an appropriate amendment or supplement
describing such information shall be promptly filed by the appropriate party
with the SEC and, to the extent required by law, disseminated to the
stockholders of the Company.
6.4 Stockholders Meeting. Subject to Section 8.3(b), the Company will
--------------------
take, in accordance with applicable Law and its certificate of incorporation and
bylaws, all action necessary to convene a meeting of holders of Company Shares
(the "Stockholders Meeting")
--------------------
36
<PAGE>
as promptly as practicable after the S-4 Registration Statement is declared
effective to consider and vote upon the adoption of this Agreement. The
Company's Board of Directors shall (i) recommend that the stockholders of the
Company adopt this Agreement and thereby approve the transactions contemplated
by this Agreement and (ii) take all lawful action (including the solicitation of
proxies) to solicit such adoption; provided, however, that the Company's Board
--------- -------
of Directors may, at any time prior to the Effective Time, withdraw, modify or
change any such recommendation to the extent that the Company's Board of
Directors determines in good faith, after consultation with outside legal
counsel, that such withdrawal, modification or change of its recommendation is
required by its fiduciary duties to the Company's stockholders under applicable
Law; provided, further, that, subject to Section 8.3(b), regardless of whether
-------- -------
the Company's Board of Directors has withdrawn, modified or changed its
recommendation to the stockholders regarding the adoption of this Agreement or
the approval of the transactions contemplated by this Agreement, the Company
shall as promptly as practicable after the S-4 Registration Statement is
declared effective duly convene and complete the Stockholders Meeting and cause
a vote of the stockholders to be taken at such Stockholders Meeting regarding
the adoption of this Agreement and the approval of the transactions contemplated
by this Agreement.
6.5 Filings; Other Actions; Notification.
------------------------------------
(a) Parent and the Company shall promptly prepare and file with the
SEC the Prospectus/Proxy Statement, and Parent shall prepare and
file with the SEC the S-4 Registration Statement as promptly as
practicable. Parent and the Company each shall use its reasonable
best efforts to have the S-4 Registration Statement declared
effective under the Securities Act as promptly as practicable
after such filing, and promptly thereafter mail the
Prospectus/Proxy Statement to the stockholders of the Company.
Parent shall also use its reasonable best efforts to obtain prior
to the effective date of the S-4 Registration Statement all
necessary state securities law or "blue sky" permits and approvals
required in connection with the Merger and the other transactions
contemplated by this Agreement and will pay all expenses incident
thereto.
(b) The Company and Parent each shall use its respective reasonable
best efforts to cause to be delivered to the other party and its
directors letters of its independent auditors, dated (i) the date
on which the S-4 Registration Statement shall become effective and
(ii) the Closing Date, and addressed to the other party and its
directors, in form and substance customary for "comfort" letters
delivered by independent public accountants in connection with
registration statements similar to the S-4 Registration Statement.
37
<PAGE>
(c) The Company and Parent shall cooperate with each other and, subject to
Sections 6.5(d) and (e), use (and shall cause their respective Subsidiaries
to use) their respective reasonable best efforts (i) to take or cause to be
taken all actions, and do or cause to be done all things, necessary, proper
or advisable on their part under this Agreement and applicable Laws to
consummate and make effective the Merger and the other transactions
contemplated by this Agreement as soon as practicable, including (A)
obtaining opinions of their respective accountants and attorneys referred
to in Section 6.5(b) and Article VII of this Agreement, (B) preparing and
filing as promptly as practicable all documentation to effect all necessary
applications, notices, petitions, filings and other documents including,
without limitation, filings under the HSR Act, (C) instituting court
actions and other proceedings necessary to obtain the approvals required to
consummate the Merger or the other transactions contemplated by this
Agreement or defending or otherwise opposing all court actions and other
proceedings instituted by a Governmental Entity or other Person under the
Competition Laws or otherwise for purposes of preventing the consummation
of the Merger and the other transactions contemplated by this Agreement,
and (D) to prepare prior to, and to execute and deliver at, the Closing
supplements to the 5% Debenture Indenture, the 5- 1/4% Debenture Indenture
and the Warrant Agreement in accordance with Sections 4.5(a), (b) and (c)
and (ii) to obtain as promptly as practicable all consents, registrations,
approvals, permits and authorizations necessary or advisable to be obtained
from any third party and/or any Governmental Entity in order to consummate
the Merger and the other transactions contemplated by this Agreement.
Subject to applicable Laws relating to the exchange of information, Parent
and the Company shall have the right to review in advance, and to the
extent practicable each will consult the other on, all the information
relating to Parent or the Company, as the case may be, and any of their
respective Subsidiaries, that appear in any filing made with, or written
materials submitted to, any third party and/or any Governmental Entity in
connection with the Merger and the other transactions contemplated by this
Agreement. In exercising the foregoing right, each of the Company and
Parent shall act reasonably and as promptly as practicable.
(d) Notwithstanding anything to the contrary in this Agreement, (i) the
Company shall not, without Parent's prior written consent, commit to any
divestitures, licenses or hold separate or similar arrangements (or allow
its Subsidiaries to commit to any divestitures, licenses or hold separate
or similar arrangements), and the Company shall commit to,
38
<PAGE>
and shall use reasonable best efforts to effect (and shall cause its
Subsidiaries to commit to and use reasonable best efforts to effect), any
such divestitures, licenses or hold separate or similar arrangements as
Parent shall request in order to obtain approval of the transactions
contemplated by this Agreement under applicable Competition Laws and (ii)
except as set forth in Section 6.5(e), neither Parent nor any of its
Subsidiaries shall be required to agree (with respect to (x) Parent or its
Subsidiaries or (y) the Company or its Subsidiaries) to any divestitures,
licenses or hold separate or similar arrangements in order to obtain
approval of the transactions contemplated by this Agreement under
applicable Competition Laws if such divestitures, licenses or arrangements
would reasonably be expected to have a Material Adverse Effect on Parent or
the Company or a material adverse effect on the expected benefits of the
Merger to Parent.
(e) Notwithstanding anything to the contrary in this Agreement, nothing in
this Section 6.5 or any other part of this Agreement shall require Parent
to refrain from entering into any agreement with respect to, or issuing
Parent Common Stock or other consideration in connection with, a business
combination with, or an acquisition of, all or part of a third party (a
"Subsequent Transaction"), and such actions by Parent shall not cause a
-----------------------
breach of this Agreement, except that Parent shall not, prior to the
Effective Time, enter into any agreement or understanding providing for any
business combination with or an acquisition of a majority of the stock or
assets of, any of the entities identified in Section 6.1(b) of the Company
Disclosure Letter. In the event of a Subsequent Transaction, Parent shall
agree to any divestitures, licenses or hold separate or similar
arrangements necessary in order to obtain approval of the transactions
contemplated by this Agreement under applicable Competition Laws that would
not otherwise have been required in order to obtain such approval but for
the Subsequent Transaction.
(f) The Company and Parent each shall, upon request by the other, furnish
the other with all information concerning itself, its Subsidiaries,
directors, officers and stockholders and such other matters as may be
reasonably necessary or advisable in connection with the Prospectus/Proxy
Statement, the S-4 Registration Statement or any other statement, filing,
notice or application made by or on behalf of Parent, the Company or any of
their respective Subsidiaries to any third party and/or any Governmental
Entity in connection with the Merger and the transactions contemplated by
this Agreement.
39
<PAGE>
(g) The Company and Parent each shall keep the other apprised of the
status of matters relating to completion of the transactions
contemplated by this Agreement, including promptly furnishing the
other with copies of notice or other communications received by
Parent or the Company, as the case may be, or any of its
Subsidiaries, from any third party and/or any Governmental Entity
with respect to the Merger and the other transactions
contemplated by this Agreement. Each of the Company and Parent
shall give prompt notice to the other of any change that is
reasonably likely to result in a Material Adverse Effect on it or
of any failure of any conditions to the other party's obligations
to effect the Merger set forth in Article VII.
(h) The Company will promptly provide Parent with copies of any
communication that is issued, prepared or otherwise becomes
available from the date of this Agreement until the Effective
Time which bears significantly and adversely upon the regulatory
status of the Products or the facilities of the Company or any of
its Subsidiaries or the facilities of the material suppliers of
the Company (including its Subsidiaries), including, without
limitation, any warning letter, notice of violation, approval or
non-approval letter/order or withdrawal letter/order from a
Governmental Entity respecting such facilities or Products.
(i) Parent agrees to reduce (if necessary) the number of "tainted
treasury shares" (within the contemplation of the Pooling
Requirements) attributable to Parent such that the attribution to
Parent of "tainted treasury shares" under the Pooling
Requirements shall not prevent Parent from accounting for the
business combination to be effected by the Merger as a "pooling-
of-interests" in accordance with the Pooling Requirements by the
date that is three business days after all of the conditions set
forth in Article VII other than Section 7.1(e) have been
satisfied or, if applicable, waived.
6.6 Access; Consultation. Upon reasonable notice, and except as may be
--------------------
prohibited by applicable Law, the Company shall (and shall cause its
Subsidiaries to) afford Parent's employees, agents and representatives
(including any investment banker, attorney or accountant retained by Parent or
any of its Subsidiaries) reasonable access, during normal business hours
throughout the period prior to the Effective Time, to the Company's properties,
books, contracts and records and, during such period, the Company shall (and
shall cause its Subsidiaries to) furnish promptly to Parent all information
concerning the Company's business, properties and personnel as may reasonably be
requested; provided that no investigation pursuant to this Section 6.6 shall
--------
affect or be deemed to modify any
40
<PAGE>
representation or warranty made by the Company under this Agreement; and
provided, further, that the foregoing shall not require the Company to permit
- -------- -------
any inspection, or to disclose any information, that in the reasonable judgment
of the Company would result in the disclosure of any trade secrets of third
parties or violate any of the Company's obligations with respect to
confidentiality if the Company shall have used all reasonable efforts to obtain
the consent of such third party to such inspection or disclosure. All requests
for information made pursuant to this Section 6.6 shall be directed to an
executive officer of the Company or such Person as may be designated by any such
executive officer, as the case may be. Parent will hold any such information
that is non-public in confidence in accordance with the Confidentiality
Agreement.
6.7 Affiliates.
----------
(a) Each of the Company and Parent shall deliver to the other a letter
identifying all Persons whom such party believes to be, at the
date of the Stockholders Meeting, affiliates of such party for
purposes of applicable interpretations regarding use of the
"pooling-of-interests" accounting method ("Pooling Affiliates")
------------------
and, in the case of the Company, affiliates of the Company for
purposes of Rule 145 under the Securities Act ("Rule 145
--------
Affiliates"). Each of the Company and Parent shall use all
----------
reasonable efforts to cause each Person who is identified as a
Pooling Affiliate or Rule 145 Affiliate in the letter referred to
above to deliver to Parent promptly after execution of this
Agreement a written agreement, in the form attached as Exhibit A,
---------
in the case of a Pooling Affiliate or Rule 145 Affiliate of the
Company (the "Company Affiliate's Letter"), and Exhibit B, in the
--------------------------
case of a Pooling Affiliate of Parent (the "Parent Affiliate's
------------------
Letter"). Prior to the Effective Time, each of the Company and
------
Parent shall use all reasonable efforts to cause each additional
Person who is identified as a Pooling Affiliate or Rule 145
Affiliate after the date of the Stockholders Meeting to execute
the applicable written agreement as set forth in this Section 6.7,
as soon as practicable after such Person is identified.
(b) Shares of Parent Common Stock issued to Pooling Affiliates of the
Company in exchange for Company Shares shall not be transferable
until such time as financial results covering at least 30 days of
combined operations of Parent and the Company shall have been
published within the meaning of Section 201.01 of the SEC's
Codification of Financial Reporting Policies, regardless of
whether each such Pooling Affiliate has provided the written
agreement referred to in this Section, except to the extent
permitted by, and in accordance with, SEC Accounting Series
Release 135 and SEC Staff
41
<PAGE>
Accounting Bulletins 65 and 76. Any Company Shares held by any
such Pooling A ffiliate shall not be transferable, regardless of
whether such Pooling Affiliate has provided the applicable written
agreement referred to in this Section, if such transfer, either
alone or in the aggregate with other transfers by Pooling
Affiliates, would preclude Parent's ability to account for the
business combination to be effected by the Merger as a pooling of
interests. The Company shall not register the transfer of any
Certificate unless such transfer is made in compliance with the
foregoing.
6.8 Stock Exchange Listing. To the extent they are not already listed,
----------------------
Parent shall use its reasonable best efforts to cause the shares of Parent
Common Stock to be issued in the Merger to be approved for listing on the NYSE
and on all other stock exchanges on which shares of Parent Common Stock are then
listed, subject to official notice of issuance, prior to the Closing Date.
6.9 Publicity. The initial press release with respect to the Merger shall
---------
be a joint press release. Thereafter, unless otherwise required by applicable
Law or pursuant to any listing agreement with or rules of a securities exchange,
the Company and Parent shall consult with each other prior to issuing any press
releases or otherwise making public announcements with respect to the Merger and
the other transactions contemplated by this Agreement and prior to making any
filings with any third party and/or any Governmental Entity (including any
securities exchange) with respect thereto.
6.1 Employee Benefits.
-----------------
(a) Stock Options.
-------------
(i) At the Effective Time, each outstanding option to purchase Company
Shares (a "Company Option") under the Company Stock Plans, whether
--------------
vested or unvested, shall be converted to an option to acquire, on the
same terms and conditions as were applicable under such Company
Option, the same number of shares of Parent Common Stock as the holder
of such Company Option would have been entitled to receive pursuant to
the Merger had such holder exercised such Company Option in full
immediately prior to the Effective Time (rounded down to the nearest
whole number) (a "Substitute Option"), at an exercise price per share
-----------------
(rounded up to the nearest whole cent) equal to (y) the aggregate
exercise price for the Company Shares otherwise purchasable pursuant
to such Company Option divided by (z) the number of full shares of
Parent Common Stock deemed purchasable pursuant to such Company Option
in accordance with the foregoing. Notwithstanding the foregoing, each
purchase right granted under the Company's Employee Stock Purchase
Plan or the Company's Supplemental Employee Stock Purchase Plan
42
<PAGE>
(the "Purchase Plans") that is outstanding at the Effective Time shall
--------- -----
be converted to a right to acquire upon the same terms and conditions
as were applicable to such right immediately before the Effective
Time, that number of shares (rounded down to the nearest whole share)
of Parent Common Stock equal to the Exchange Ratio multiplied by the
number of Company Shares for which such purchase right would otherwise
have been exercisable determined as of the relevant grant date under
the applicable Purchase Plan at a purchase price per share equal to
85% of the lower of (A) the fair market value of a Company Share on
the relevant grant date divided by the Exchange Ratio or (B) the fair
market value of a share of Parent Common Stock on the relevant
purchase date.
(ii) As promptly as practicable after the Effective Time, the
Surviving Corporation shall deliver to the participants in the Company
Stock Plans appropriate notices setting forth such participants'
rights pursuant to the Substitute Options.
(b) Restricted Stock. At the Effective Time, each Company Share which
----------------
is subject to restrictions or forfeiture risks (a "Restricted
----------
Share") under the Company Stock Plans shall be converted to the
-----
same number of shares of Parent Common Stock as the holder of
such Restricted Share would have been entitled to receive
pursuant to the Merger had the Restricted Share not been subject
to restrictions or forfeiture risks immediately prior to the
Effective Time (rounded down to the nearest whole share), which
shares of Parent Common Stock shall be subject to the same
restrictions and forfeiture risks as the Restricted Share
("Substitute Restricted Shares").
----------------------------
(c) Conversion and Registration. At or prior to the Effective Time,
---------------------------
the Company shall make all necessary arrangements with respect to
the Company Stock Plans to permit the conversion of the
unexercised Company Options into Substitute Options and the
conversion of Restricted Shares into Substitute Restricted Shares
pursuant to this Section 6.10 and, within three days of the
Effective Time, Parent shall use its reasonable best efforts to
file with the SEC a registration statement on Form S-8 or other
appropriate form covering shares of Parent Common Stock issuable
pursuant to all Substitute Options and Substitute Restricted
Shares with respect to Parent Common Stock and shall use its
reasonable best efforts to cause such registration statement to
become effective as soon as possible after filing and to maintain
the effectiveness thereof.
43
<PAGE>
(d) Benefits. Each Compensation and Benefit Plan shall, as
--------
of the Effective Time, be the obligation of Parent and
the Surviving Corporation. For the period beginning on
the Effective Date and ending on December 31, 1999,
Parent shall cause the Surviving Corporation to
continue in effect the Compensation and Benefit Plans
as in effect as of the Effective Time; provided,
--------
however, t hat nothing in the foregoing provisions of
-------
this sentence shall (i) prevent Parent or the Surviving
Corporation from amending any Compensation and Benefit
Plan to the extent required by Law, or (ii) require
Parent or the Surviving Corporation to continue any
equity-based or equity-related plan. Notwithstanding
the foregoing, Parent shall continue the Purchase Plans
in effect until at least the first purchase date under
the Purchase Plans following the Effective Time. For
periods after December 31, 1999, employees of the
Surviving Corporation shall be eligible to participate
in employee benefit plans, programs, policies and
arrangements which provide benefits that, in the
aggregate, are materially comparable in value to those
provided to similarly situated employees of Parent
employed in the United States.
(e) Service Credit. In the event that, at or after the Effective Time,
--------------
employees of the Company and its Subsidiaries become eligible to
participate in a vacation pay program of Parent or its affiliates, such
employees will be given credit under that vacation pay program for their
service with the Company and its Subsidiaries for periods prior to the
Effective Time to the same extent that such service was taken into account
for purposes of the vacation pay program for which they were eligible
immediately prior to the Effective Time.
6.11. Expenses. Whether or not the Merger is consummated, all costs and
--------
expenses incurred in connection with this Agreement and the Merger and the other
transactions contemplated by this Agreement shall be paid by the party incurring
such expense, except that expenses incurred in connection with the filing fee
for the S-4 Registration Statement, printing and mailing the Prospectus/Proxy
Statement, the S-4 Registration Statement and the filing fees under the HSR Act
and any other Competition Law filings shall be shared equally by Parent and the
Company.
6.12. Indemnification; Directors' and Officers' Insurance.
---------------------------------------------------
(a) The Certificate of Incorporation and Bylaws of the Surviving
Corporation shall contain, and Parent shall cause the Surviving
Corporation to fulfill and honor, provisions with respect to
indemnification and exculpation that are substantially identical
to those set forth in the certificate of incorporation and
bylaws of the Company as of the date of this Agreement, which
provisions shall not
44
<PAGE>
be amended, repealed or otherwise modified for a period of six years from
the Effective Time in any manner that would adversely affect the rights
thereunder of any of the Indemnified Parties. "Indemnified Parties" shall
-------------------
include each person who is or was a director, officer or employee of the
Company or any Subsidiary of the Company at any time before the Effective
Time, and each person who serves or has in the past served at the request
of the Company or any Subsidiary of the Company as a director, officer,
trustee, partner, fiduciary, employee or agent of another corporation,
partnership, joint venture, trust, pension or other employee benefit plan
or enterprise at any time before the Effective Time.
(b) Any Indemnified Party wishing to claim indemnification under paragraph
(a) of this Section 6.12 shall promptly notify the Surviving Corporation,
upon learning of any such claim, action, suit, proceeding or investigation,
but the failure to so notify shall not relieve the Surviving Corporation of
any liability it may have to such Indemnified Party if such failure does
not materially prejudice the Surviving Corporation. The Surviving
Corporation may, at its own expense: (i) participate in the defense of any
claim, suit, action or proceeding; or (ii) at any time during the course of
any such claim, suit, action or proceeding, assume the defense thereof,
unless the Indemnified Parties (or any of them) determine in good faith
(after consultation with legal counsel) that there is, under applicable
standards of professional conduct, a conflict or any significant issue
between the positions of Parent and such Indemnified Parties, provided that
--------
the Surviving Corporation's counsel shall be reasonably satisfactory to the
Indemnified Parties. If the Surviving Corporation assumes such defense,
the Indemnified Parties shall have the right (but not the obligation) to
participate in the defense thereof and to employ counsel, at their own
expense, separate from the counsel employed by the Surviving Corporation.
Whether or not the Surviving Corporation chooses to assume the defense of
any such claim, suit, action or proceeding, all of the parties hereto shall
cooperate in the defense thereof. If the Surviving Corporation fails to so
assume the defense thereof, the Indemnified Parties may retain counsel
reasonably satisfactory to the Surviving Corporation and the Surviving
Corporation shall pay the reasonable fees and expenses of such counsel
promptly after statements therefor are received; provided, further, that
-------- -------
the Indemnified Parties on whose behalf expenses are advanced provide (x) a
written affirmation of their good faith belief that the standard of conduct
necessary for indemnification under Section 145 of the DGCL has been met,
and (y) an undertaking to repay such
45
<PAGE>
advances if it is ultimately determined that such Indemnified Party is not
entitled to indemnification under Section 145 of the DGCL. Neither Parent
nor the Surviving Corporation shall be liable for any settlement effected
without its written consent (which consent shall not be unreasonably
withheld or delayed); provided, that, in the event that any claim or claims
--------
for indemnification are asserted or made within such a period of six years
after the Effective Time, all rights to indemnification in respect of any
such claim or claims (and the matters giving rise thereto) shall continue
until the disposition of any and all such claim or claims (and the matters
giving rise thereto). The Indemnified Parties as a group may retain only
one law firm (in addition to local counsel) to represent them with respect
to a single action unless any Indemnified Party determines in good faith
(after consultation with legal counsel) that there is, under applicable
standards of professional conduct, a conflict on any significant issue
between the positions of any two or more Indemnified Parties. In the event
Parent or the Surviving Corporation or any of their respective successors
or assigns (i) consolidates with or merges into any other Person and shall
not be the continuing or surviving corporation or entity of such
consolidation or merger, or (ii) transfers or conveys all or substantially
all of its properties and assets to any Person, then, and in each such
case, to the extent necessary to effectuate the purposes of this Section
6.12, proper provision shall be made so that the successors and assigns of
Parent and the Surviving Corporation assume the obligations set forth in
this Section 6.12, and none of the actions described in clause (i) or (ii)
shall be taken until such provision is made.
(c) Without limiting any of the obligations of Parent or the Surviving
Corporation set forth elsewhere in this Section 6.12, for a period of six
years after the Effective Time, Parent shall cause the Surviving
Corporation to maintain in effect, to the extent available, directors' and
officers' liability insurance covering those persons who are currently
covered by the Company's directors' and officers' liability insurance
policy on terms comparable to those applicable under the policy of
directors' and officers' liability insurance currently maintained by the
Company; provided, however, that in no event shall Parent or the Surviving
-------- -------
Corporation be required to expend in excess of 150% of the annual premium
currently paid by the Company for such coverage, and that if the annual
premiums of such insurance coverage exceed such amount, the Surviving
Corporation shall be obligated instead to obtain a policy with the greatest
coverage for a cost not exceeding such amount. The provisions of this
Section 6.12(c) shall be deemed to
46
<PAGE>
have been satisfied if prepaid policies have been obtained by the
Company prior to the Closing, which policies provide such directors
and officers with coverage for an aggregate period of six years
with respect to claims arising from facts or events that occurred
on or before the Effective Time, including, without limitation, in
respect of the transactions contemplated by this Agreement and for
a premium not in excess of the aggregate of the premiums set forth
in the preceding sentence. If such prepaid policies have been
obtained by the Company prior to the Closing, Parent shall and
shall cause the Surviving Corporation to maintain such policies in
full force and effect, and continue to honor the Company's
obligations thereunder.
(d) Parent shall cause the Surviving Corporation to perform its
obligations under this Section 6.12 and shall, in addition,
guarantee, as co-obligor with the Surviving Corporation, the
performance of such obligations by the Surviving Corporation
subject to the limits imposed on the Surviving Corporation under
the DGCL.
(e) The obligations of Parent or the Surviving Corporation under this
Section 6.12 are subject to the conditions that each Indemnified
Party shall comply with the reasonable requests of the Surviving
Corporation or Parent in defending or settling any action hereunder
and that any Indemnified Party shall approve any proposed
settlement of any such action if (i) such settlement involves no
finding or admission of any liability by any Indemnified Party, and
(ii) the sole relief provided in connection with such settlement is
monetary damages that are paid in full by the Surviving Corporation
or Parent.
(f) Parent agrees to pay, or cause the Surviving Corporation to pay,
all expenses, including reasonable attorneys' fees, that may be
incurred by the Indemnified Parties in successfully enforcing the
indemnity and other rights under this Section 6.12.
(g) The provisions of this Section 6.12 are intended to be for the
benefit of, and shall be enforceable by, each of the Indemnified
Parties, their heirs and their representatives.
6.13. Takeover Statutes. If any Takeover Statute is or may become
-----------------
applicable to the Merger or the other transactions contemplated by this
Agreement, each of Parent and the Company and their respective Boards of
Directors shall grant such approvals and take such actions as are necessary so
that the Merger and such transactions may be consummated as promptly as
practicable on the terms contemplated by this Agreement or by the Merger and
otherwise act to eliminate or minimize the effects of such statute or regulation
on the Merger
47
<PAGE>
or such transactions. The Company's Board of Directors shall take all actions,
including the adoption of any resolutions, as may be necessary or reasonably
requested by Parent to assure that any Charter and Bylaw Provisions are not, and
at the Effective Time will not be, applicable to the Merger and the other
transactions contemplated by this Agreement in any manner that would prevent or
make materially burdensome to Parent the Merger or the other transactions
contemplated by this Agreement.
6.14. Confidentiality. The Company and Parent each acknowledge and confirm
---------------
that it has entered into a Confidentiality Agreement, dated May 24, 1999 (the
"Confidentiality Agreement"), and that the Confidentiality Agreement shall
- --------------------------
remain in full force and effect in accordance with its terms except for the
provisions of Paragraphs 4, 5 and 11 thereof which shall be of no further force
or effect, in each such case, whether or not the Merger is consummated.
6.15. Tax-Free Reorganization. Parent, Merger Sub, and the Company shall
-----------------------
each use its best efforts to cause the Merger to be treated as a reorganization
with the meaning of Section 368(a) of the Code and to obtain an opinion of its
respective counsel as contemplated by Sections 7.2(c) and 7.3(c), respectively.
ARTICLE VII
Conditions
----------
7.1 Conditions to Each Party's Obligation to Effect the Merger. The
----------------------------------------------------------
respective obligation of each party to effect the Merger is subject to the
satisfaction or waiver, if applicable, at or prior to the Effective Time of each
of the following conditions:
(a) Stockholder Approval. This Agreement shall have been duly adopted by
--------------------
holders of Company Shares constituting the Requisite Vote;
(b) NYSE Listing. The shares of Parent Common Stock issuable to the
------------
Company stockholders pursuant to this Agreement shall have been
approved for listing (either before or after the execution of this
Agreement) on the NYSE upon official notice of issuance;
(c) Laws and Orders. No Governmental Entity of competent jurisdiction
---------------
shall have enacted, issued, promulgated, enforced or entered any Law
(whether temporary, preliminary or permanent) that is in effect and
restrains, enjoins or otherwise prohibits consummation of the Merger
or the other transactions contemplated by this Agreement or permits
consummation of the Merger or the other transactions contemplated by
this Agreement under applicable Competition Laws but, except as
provided in Section 6.5(e), subject to any divestitures, licenses or
hold separate or similar arrangements if such divestitures, licenses
or hold
48
<PAGE>
separate or similar arrangements would reasonably be expected to have
a Material Ad verse Effect on Parent or the Company or a material
adverse effect on the expected benefits of the Merger to Parent
(collectively, an "Order"), and no Governmental Entity shall have
-----
instituted, and no authoritative source at a Governmental Entity
shall have threatened to institute, any proceeding seeking any such
Order;
(d) S-4. The S-4 Registration Statement shall have become effective under
---
the Securities Act. No stop order suspending the effectiveness of the
S-4 Registration Statement shall have been issued, and no proceedings
for that purpose shall have been initiated or be threatened by the
SEC; and
(e) Pooling. Each of Parent and the Company shall have received a letter
-------
from its independent public accounting firm to the effect that the
Merger should qualify for "pooling-of-interests" accounting
treatment.
7.2 Conditions to Obligations of Parent and Merger Sub. The obligations
--------------------------------------------------
of Parent and Merger Sub to effect the Merger are also subject to the
satisfaction or waiver by Parent at or prior to the Effective Time of the
following conditions:
(a) Representations and Warranties. The representations and warranties of
------------------------------
the Company set forth in this Agreement (i) to the extent qualified
by Material Adverse Effect shall be true and correct, (ii) to the
extent not qualified by Material Adverse Effect shall be true and
correct (except that this clause (ii) shall be deemed satisfied so
long as any failures of such representations and warranties to be
true and correct, taken together, would not reasonably be expected to
have a Material Adverse Effect on the Company and, solely with
respect to Sections 5.1(j) and 5.1(l), would not reasonably be
expected to have a material adverse effect on the expected benefits
of the Merger to Parent), and (iii) in Section 5.1(b) shall be true
and correct within an aggregate of no more than 25,000 shares of
Company Common Stock, in the case of each of (i), (ii) and (iii), as
of the date of this Agreement and (except to the extent such
representations and warranties speak as of an earlier date) as of the
Closing Date as though made on and as of the Closing Date, and Parent
shall have received a certificate signed on behalf of the Company by
an executive officer of the Company to such effect;
(b) Performance of Obligations of the Company. The Company shall have
-----------------------------------------
performed in all material respects all obligations required to be
performed by it under this Agreement at or prior to the Closing Date,
49
<PAGE>
the Company's stockholder s at the Stockholders Meeting shall have
voted to adopt this Agreement and to approve the transactions
contemplated by this Agreement and Parent shall have received a
certificate signed on behalf of the Company by an executive officer
of the Company to such effect;
(c) Tax Opinion. Parent shall have received the opinion of Mayer, Brown &
-----------
received the opinion of Heller Ehrman White & McAuliffe, counsel to
the Company, dated the Closing Date, in each case to the effect that
the Merger will be treated for U.S. federal income tax purposes as a
reorganization within the meaning of Section 368(a) of the Code, and
that each of Parent, Merger Sub and the Company will be a party to
that reorganization within the meaning of Section 368(b) of the Code.
In rendering such opinions, such counsel may rely upon reasonable
representations and certificates of Parent, Merger Sub and the
Company and certain stockholders or shareholders of Parent, Merger
Sub and the Company; and Parent, Merger Sub and the Company will
make, and each of them agrees to use its reasonable best efforts to
cause such of its respective stockholders or shareholders to make,
such representations and deliver such certificates; and
(d) Governmental Consents. The waiting period applicable to the
---------------------
consummation of the Merger under the HSR Act shall have expired or
been terminated and any material consents to the transactions
contemplated under this Agreement required under the European
Community Merger Control Regulation or other applicable Competition
Laws, as well as other material Company Required Consents and Parent
Required Consents, shall have been obtained, in each case without
requiring any divestitures, licenses or hold separate or similar
arrangements in order to obtain approval of the transactions
contemplated by this Agreement under applicable Competition Laws if
such divestitures, licenses or hold separate or similar arrangements
would reasonably be expected to have a Material Adverse Effect on
Parent or the Company or a material adverse effect on the expected
benefits of the Merger to Parent.
7.3 Conditions to Obligation of the Company. The obligation of the
---------------------------------------
Company to effect the Merger is also subject to the satisfaction or waiver by
the Company at or prior to the Effective Time of the following conditions:
(a) Representations and Warranties. The representations and warranties of
------------------------------
Parent and Merger Sub set forth in this Agreement (i) to the extent
50
<PAGE>
qualified by Material Adverse Effect shall be true and correct, and (ii) to
the extent not qualified by Material Adverse Effect shall be true and
correct (except that this clause (ii) shall be deemed satisfied so long as
any failures of such representations and warranties to be true and correct,
taken together, would not reasonably be expected to have a Material Adverse
Effect on Parent), in the case of each of (i) and (ii), as of the date of
this Agreement and (except to the extent such representations and warranties
speak as of an earlier date) as of the Closing Date as though made on and as
of the Closing Date, and the Company shall have received a certificate
signed on behalf of Parent by an executive officer of Parent to such effect;
(b) Performance of Obligations of Parent and Merger Sub. Each of Parent
---------------------------------------------------
and Merger Sub shall have performed in all material respects all obligations
required to be performed by it under this Agreement at or prior to the
Closing Date, and the Company shall have received a certificate signed on
behalf of Parent and Merger Sub by an executive officer of Parent to such
effect;
(c) Tax Opinion. The Company shall have received the opinion of Heller
-----------
Ehrman White & McAuliffe, counsel to the Company, dated the Closing Date,
and Parent shall have received the opinion of Mayer, Brown & Platt, counsel
to Parent, dated the Closing Date, in each case to the effect that the
Merger will be treated for U.S. federal income tax purposes as a
reorganization within the meaning of Section 368(a) of the Code, and that
each of Parent, Merger Sub and the Company will be a party to that
reorganization within the meaning of Section 368(b) of the Code. In
rendering such opinions, such counsel may rely upon reasonable
representations and certificates of Parent, Merger Sub and the Company and
certain stockholders or shareholders of Parent, Merger Sub and the Company;
and Parent, Merger Sub and the Company will make, and each of them agrees to
use its reasonable best efforts to cause such of its respective stockholders
or shareholders to make, such representations and deliver such certificates;
and
(d) Governmental Consents. The waiting period applicable to the
---------------------
consummation of the Merger under the HSR Act shall have expired or been
terminated and any material consents to the transactions contemplated under
this Agreement required under the European Community Merger Control
Regulation or other applicable Competition Laws, as well as other material
Company Required Consents and Parent Required Consents, shall have been
obtained.
51
<PAGE>
ARTICLE VII
Termination
-----------
8.1 Termination by Mutual Consent. This Agreement may be terminated and
-----------------------------
the Merger may be abandoned at any time prior to the Effective Time, whether
before or after the approval by stockholders of the Company referred to in
Section 7.1(a), by mutual written consent of the Company and Parent, through
action of their respective Boards of Directors.
8.2 Termination by Either Parent or the Company. This Agreement may be
-------------------------------------------
terminated and the Merger may be abandoned at any time prior to the Effective
Time by action of the Board of Directors of either Parent or the Company if (i)
the Merger shall not have been consummated prior to December 31, 1999 (the
"Termination Date"); provided, however, that either party shall have the option
- ----------------- -------- -------
to extend the Termination Date (and all references herein to the Termination
Date shall mean such extended date) for an additional period of time not to
exceed 90 days if the reason that the Merger has not been consummated by such
date is that either (A) the condition set forth in Section 7.2(d) has not been
satisfied due to the lack of expiration or termination of the waiting period
under the HSR Act (the "Waiting Period") or the failure to obtain the necessary
--------------
consents and approvals under applicable Competition Laws and Parent or the
Company are still attempting to achieve the expiration or termination of the
Waiting Period or to obtain such necessary consents and approvals under
applicable Competition Laws or are contesting whether the Waiting Period has
expired or been terminated or the refusal of the relevant Governmental Entities
to give such consents or approvals in court or through other applicable
proceedings, or (B) the condition set forth in Section 7.1(c) has not been
satisfied due to any Order that has been enacted, issued, promulgated, enforced
or entered by any Governmental Entity pursuant to applicable Competition Laws or
due to the institution or threatened institution by any Governmental Entity of
any proceeding seeking any such Order pursuant to applicable Competition Laws;
(ii) the Stockholders Meeting shall have been held and completed and the
adoption of this Agreement by the Company's stockholders referred to in Section
7.1(a) shall not have occurred; or (iii) any Order permanently restraining,
enjoining or otherwise prohibiting consummation of the Merger shall become final
and non-appealable (whether before or after the adoption or approval by the
stockholders of the Company); provided, that the right to terminate this
--------
Agreement pursuant to clause (i) above shall not be available to any party that
has breached in any material respect its obligations under this Agreement in any
manner that shall have proximately contributed to the failure of the Merger to
be consummated on or before the Termination Date.
8.3 Termination by the Company.
--------------------------
(a) This Agreement may be terminated and the Merger may be abandoned
at any time prior to the Effective Time, whether before or after
the adoption of this Agreement by the stockholders of the Company
52
<PAGE>
referred to in Section 7.1(a), by action of the Board of
Directors of the Company if there has been a material breach by
Parent or Merger Sub of any representation, warranty, covenant or
agreement contained in this Agreement which (x) would result in a
failure of a condition set forth in Section 7.3(a) or 7.3(b) and
(y) cannot be or is not cured prior to the Termination Date.
(b) This Agreement may be terminated and the Merger may be abandoned
by the Company at any time prior to the Stockholders Meeting if
the Board of Directors of the Company shall approve a Superior
Proposal; provided, however, that: (i) the Company shall have
-------- -------
complied with Section 6.2; (ii) the Board of Directors of the
Company shall have reasonably concluded in good faith, prior to
giving effect to all concessions which may be offered the Company
by Parent pursuant to clause (iv) below, on the basis of the
advice of its financial advisors and outside counsel, that such
proposal is a Superior Proposal; (iii) the Company shall have (A)
notified Parent in writing of its receipt of such Superior
Proposal, (B) further notified Parent in such writing that the
Company intends to enter into a binding agreement for such
Superior Proposal subject to clause (iv) below and (C) attached
the most current written version of such Superior Proposal (or a
summary containing all material terms and conditions of such
Superior Proposal) to such notice; and (iv) Parent does not make,
within five business days after receipt of the Company's written
notice pursuant to clause (iii) above, an offer that the Board of
Directors of the Company shall have reasonably concluded in good
faith on the basis of the advice of its financial advisors and
outside counsel is at least as favorable to the stockholders
of the Company as the Superior Proposal; provided, further,
-------- -------
that it shall be a condition to termination pursuant to this
Section 8.3(b) that the Company shall have made the payment of the
Termination Fee to Parent required by Section 8.5(b).
8.4 Termination by Parent. This Agreement may be terminated and the
---------------------
Merger may be abandoned at any time prior to the Effective Time, before or after
the approval by the stockholders of the Company referred to in Section 7.1(a)
and before or after the Stockholders Meeting, by action of the Board of
Directors of Parent if:
(a) the Board of Directors of the Company shall have (i) withdrawn,
adversely modified or changed its approval or recommendation of
this Agreement as a result of the existence of an Acquisition
Proposal or a publicly announced intention (whether or not
conditional) to make an Acquisition Proposal, (ii) failed to
reconfirm its recommendation of this Agreement to the Company's
stockholders within 15 business days
53
<PAGE>
after a written request by Parent to do so as a result of the
existence of an Acquisition Proposal or a publicly announced intention
(whether or not conditional) to make an Acquisition Proposal or (iii)
approved or recommended a Superior Proposal; or
(b) there has been a material breach by the Company of any representation,
warranty, covenant or agreement contained in this Agreement which (x)
would result in a failure of a condition set forth in Section 7.2(a)
or 7.2(b) and (y) cannot be or is not cured prior to the Termination
Date.
8.5 Effect of Termination and Abandonment.
-------------------------------------
(a) In the event of termination of this Agreement and the abandonment of
the Merger pursuant to this Article VIII, this Agreement (other than
as set forth in Section 9.2) shall become void and of no effect with
no liability (other than as set forth in Sections 6.11, 6.14 and
8.5(b) or in the proviso at the end of this sentence) or obligation on
the part of any party to this Agreement or of any of its directors,
officers, employees, agents, legal or financial advisors or other
representatives; provided, however, that no such termination shall
-------- -------
relieve any party to this Agreement from any liability for damages
resulting from any breach of this Agreement.
(b) In the event that (i) an Acquisition Proposal shall have been made to
the Company or shall have been made directly to stockholders generally
or any Person shall have publicly announced an intention (whether or
not conditional) to make an Acquisition Proposal and thereafter (A)
the Board of Directors of the Company has not withdrawn, adversely
modified or changed its approval or recommendation of this Agreement,
the Stockholders meeting is held and completed and the Company's
stockholders do not adopt this Agreement at the Stockholders Meeting,
(B) this Agreement is terminated by either Parent or the Company, and
(C) within 12 months of the termination of this Agreement, the Company
enters into a definitive agreement with any third party with respect
to an Acquisition Proposal or an Acquisition Proposal is consummated,
(ii) an Acquisition Proposal shall have been made to the Company or
have been made directly to stockholders generally or any Person shall
have publicly announced an intention (whether or not conditional) to
make an Acquisition Proposal and thereafter (A) the Board of Directors
of the Company has withdrawn, adversely modified or changed its
approval or recommendation of this Agreement, the Stockholders Meeting
is held and completed and the Company's stockholders do not
54
<PAGE>
adopt this Agreement at the Stockholders Meeting and (B) this Agreement is
terminated by either Parent or the Company (a termination under the
circumstances described in this clause (ii) being a "Modified
--------
Recommendation Stockholder Rejection Termination"), (iii) this Agreement is
------------------------------------------------
terminated by Parent pursuant to Section 8.4(a) or (b) (but, with respect
to Section 8.4(b), solely with respect to a breach of Section 6.2), or (iv)
this Agreement is terminated by the Company pursuant to Section 8.3(b),
then the Company shall pay Parent a fee equal to $210,000,000 (the
"Termination Fee"), which amount shall be in addition to any expenses to be
----------------
paid pursuant to Section 6.11, and shall be payable by wire transfer of
same day funds. The Termination Fee required to be paid pursuant to this
Section 8.5(b) shall be made prior to, and shall be a precondition of, the
effectiveness of a termination of this Agreement by the Company pursuant to
Section 8.3(b) or a Modified Recommendation Stockholder Rejection
Termination by the Company. Any other payment required to be made pursuant
to this Section 8.5(b) shall be made to Parent not later than two business
days after the earliest of (i) the entering into of a definitive agreement
with respect to, or the consummation of, an Acquisition Proposal, as
applicable, (ii) a termination pursuant to Section 8.4(a) or (b) and (iii)
a Modified Recommendation Stockholder Rejection Termination by Parent. The
Company acknowledges that the agreements contained in this Section 8.5(b)
are an integral part of the transactions contemplated by this Agreement,
and that, without these agreements, Parent and Merger Sub would not enter
into this Agreement. Accordingly, if the Company fails to pay promptly the
amount due pursuant to this Section 8.5(b), and, in order to obtain such
payment, Parent or Merger Sub commences a suit which results in a judgment
against the Company for the fee set forth in this paragraph (b), the
Company shall pay to Parent or Merger Sub its costs and expenses (including
attorneys' fees) in connection with such suit, together with interest on
the amount of the fee at the prime rate of Citibank N.A. in effect on the
date such payment was required to be made.
55
<PAGE>
ARTICLE IX.
Miscellaneous and General
-------------------------
9.1 Certain Definitions. Terms defined elsewhere in this Agreement shall
-------------------
have the meanings set forth therein for all purposes of this Agreement, unless
otherwise specified to the contrary. The following terms shall have the
following meanings:
"Affiliates" shall have the meaning set forth in Rule 12b-2 under the
----------
Exchange Act.
"Code" means the Internal Revenue Code of 1986, as amended.
----
"Company's Executive Officers" means the Company's Chief Executive Officer,
----------------------------
Senior Vice Presidents, Group Vice Presidents and Senior Director of
Intellectual Property.
"Competition Laws" includes the HSR Act, the European Community Merger
----------------
Control Regulation, and any other antitrust or competition Law of the United
States of America, the European Community or any other nation, province,
territory or jurisdiction which must be satisfied or complied with in order to
consummate and make effective the Merger or the other transactions contemplated
by this Agreement.
"Crescendo" means Crescendo Pharmaceuticals Corporation, a Delaware
---------
corporation.
"DGCL" means the Delaware General Corporation Law.
----
"Environmental Law" means any Law relating to: (A) the protection,
-----------------
investigation or restoration of the environment, health, safety, or natural
resources; (B) the handling, use, presence, disposal, release or threatened
release of any Hazardous Substance; or (C) noise, odor, wetlands, pollution,
contamination or any injury or threat of injury to persons or property or
notifications to government agencies or the public in connection with any
Hazardous Substance.
"ERISA" means the Employee Retirement Income Security Act of 1974, as
-----
amended.
"ERISA Affiliate" means any corporation or trade or business which,
---------------
together with the Company, is a member of a controlled group of Persons or a
group of trades or businesses under common control with the Company within the
meaning of Sections 414(b), (c), (m) or (o) of the Code.
"Exchange Act" means the Securities Exchange Act of 1934, as amended.
------------
"FDA" means the U.S. Food and Drug Administration.
---
56
<PAGE>
"FDCA" means the Federal Food, Drug and Cosmetic Act, as amended.
----
"GAAP" means U.S. generally accepted accounting principles.
----
"Hazardous Substance" means any substance that is listed, classified or
-------------------
regulated pursuant to any Environmental Law, including any petroleum product or
by-product, asbestos-containing material, lead-containing paint or plumbing,
polychlorinated biphenyls, electromagnetic fields, microwave transmission,
radioactive materials or radon.
"HSR Act" means the Hart-Scott-Rodino Antitrust Improvements Act of 1976,
-------
as amended.
"IRS" means the Internal Revenue Service.
---
"Laws" means any law, statute, ordinance, regulation, judgment, order,
----
decree, injunction, arbitration award, license, authorization, opinion, agency
requirement or permit of any Governmental Entity or common law.
"Material Adverse Effect" means, with respect to any Person, a material
-----------------------
adverse effect on the financial condition, assets and liabilities (taken
together), results of operations or business of such Person and its
Subsidiaries, taken as a whole; provided, however, that none of the following
-------- -------
shall be deemed to constitute and shall not be taken into account in determining
the occurrence of a Material Adverse Effect with respect to a party: (i) any
effect arising from or relating to general business or economic conditions which
does not affect such party in any materially disproportionate manner; (ii) any
effect relating to or affecting, with respect to the Company, the pharmaceutical
industry generally or, with respect to Parent, the health care products and
services industries generally, in either such case, which does not affect such
party in a materially disproportionate manner; (iii) any effect arising from or
relating to the announcement or pendency of the Merger; or (iv) any effect
arising from or relating to change in accounting rules or procedures announced
by the Financial Accounting Standards Board.
"NYSE" means the New York Stock Exchange.
----
"PBGC" means the Pension Benefit Guaranty Corporation.
----
"Permits" means permits, licenses, franchises, variances, exemptions,
-------
orders and other governmental authorizations, consents and approvals.
"Person" means any individual, corporation (including not-for-profit),
------
general or limited partnership, limited liability company, joint venture,
estate, trust, association, organization, Governmental Entity or other entity of
any kind or nature.
57
<PAGE>
"SEC" means the Securities and Exchange Commission.
---
"Securities Act" means the Securities Act of 1933, as amended.
--------------
"Significant Investees" means, with respect to any Person, Significant
---------------------
Subsidiaries of such Person and any entity in which such Person has an equity
interest of 20% or more excluding, with respect to the Company, Durect
Corporation, ProQuest Investments L.P., TechAMP International L.P. and P/A
Charleston Road LLC.
"Significant Subsidiaries" with respect to any Person has the meaning set
------------------------
forth in Rule 1-02(w) of Regulation S-X promulgated pursuant to the Exchange Act
and includes any Subsidiaries that if aggregated would together constitute
Significant Subsidiaries.
"Subsidiary" means, with respect to any Person, any entity, whether
----------
incorporated or unincorporated, of which at least 50% of the stock, securities
or other ownership interests having by their terms ordinary voting power to
elect at least 50% of the Board of Directors or other persons performing similar
functions is directly or indirectly owned by such Person excluding, with respect
to the Company, P/A Charleston Road LLC, a California limited liability company.
"Tax" (including, with correlative meaning, the terms "Taxes" and
--- -----
"Taxable") includes all federal, state, local and foreign income, profits,
-------
franchise, gross receipts, environmental, customs duty, capital stock,
severance, stamp, payroll, sales, employment, unemployment, disability, use,
property, withholding, excise, production, value added, occupancy and other
taxes, duties or assessments of any nature whatsoever, together with all
interest, penalties and additions imposed with respect to such amounts and any
interest in respect of such penalties and additions.
"Tax Return" includes all federal, state, local and foreign returns and
----------
reports (including elections, declarations, disclosures, schedules, estimates
and information returns) required to be supplied to a Tax authority relating to
Taxes.
9.2 Survival. Article II, Article III, Article IV and this Article IX
--------
(other than Section 9.5 (Counterparts)), and the agreements of the Company,
Parent and Merger Sub contained in Sections 6.7(b) (Affiliates), 6.10 (Employee
Benefits), 6.11 (Expenses) and 6.12 (Indemnification; Directors' and Officers'
Insurance) shall survive the consummation of the Merger. This Article IX (other
than Section 9.3 (Modification or Amendment), Section 9.4 (Waiver of Conditions)
and Section 9.13 (Assignment)) and the agreements of the Company, Parent and
Merger Sub contained in Section 6.11 (Expenses), Section 6.14 (Confidentiality)
and Section 8.5 (Effect of Termination and Abandonment) shall survive the
termination of this Agreement. All other representations, warranties, covenants
and agreements in this Agreement shall not survive the consummation of the
Merger or the termination of this Agreement.
58
<PAGE>
9.3 Modification or Amendment. Subject to the provisions of applicable
-------------------------
Law, at any time prior to the Effective Time, the parties to this
Agreement may modify or amend this Agreement, by written agreement
executed and delivered by duly authorized officers of the respective
parties.
9.4 Waiver of Conditions.
--------------------
(a) Any provision of this Agreement may be waived prior to the
Effective Time if, and only if, such waiver is in writing and
signed by an authorized representative of the party against whom
the waiver is to be effecti ve.
(b) No failure or delay by any party in exercising any right, power or
privilege under this Agreement shall operate as a waiver thereof
nor shall any single or partial exercise thereof preclude any
other or further exercise thereof or the exercise of any other
right, power or privilege. Except as otherwise provided in this
Agreement, the rights and remedies herein provided shall be
cumulative and not exclusive of any rights or remedies provided by
Law.
9.5 Counterparts. This Agreement may be executed in any number of
------------
counterparts, each such counterpart being deemed to be an original instrument,
and all such counterparts shall together constitute the same agreement.
9.6 GOVERNING LAW AND VENUE; WAIVER OF JURY TRIAL.
---------------------------------------------
(a) THIS AGREEMENT SHALL BE DEEMED TO BE MADE IN AND IN ALL RESPECTS
SHALL BE INTERPRETED, CONSTRUED AND GOVERNED BY AND IN ACCORDANCE
WITH THE LAW OF THE STATE OF DELAWARE WITHOUT REGARD TO THE
CONFLICT OF LAW PRINCIPLES THEREOF. The parties hereby irrevocably
and unconditionally consent to submit to the exclusive
jurisdiction of the courts of the State of Delaware and of the
United States of America located in Wilmington, Delaware (the
"Delaware Courts") for any litigation arising out of or relating
---------------
to this Agreement and the transactions contemplated by this
Agreement (and agree not to commence any litigation relating
thereto except in such Delaware Courts), waive any objection to
the laying of venue of any such litigation in the Delaware Courts
and agree not to plead or claim in any Delaware Court that such
litigation brought therein has been brought in an inconvenient
forum.
59
<PAGE>
(b) EACH PARTY ACKNOWLEDGES AND AGREES THAT ANY CONTROVERSY
WHICH MAY ARISE UNDER THIS AGREEMENT IS LIKELY TO INVOLVE
COMPLICATED AND DIFFICULT ISSUES, AND THEREFORE EACH SUCH
PARTY HEREBY IRREVOCABLY AND UNCONDITIONALLY WAIVES ANY
RIGHT SUCH PARTY MAY HAVE TO A TRIAL BY JURY IN RESPECT
OF ANY LITIGATION DIRECTLY OR INDIRECTLY ARISING OUT OF
OR RELATING TO THIS AGREEMENT, OR THE TRANSACTIONS
CONTEMPLATED BY THIS AGREEMENT. EACH PARTY CERTIFIES AND
ACKNOWLEDGES THAT (i) NO REPRESENTATIVE, AGENT OR
ATTORNEY OF ANY OTHER PARTY HAS REPRESENTED, EXPRESSLY OR
OTHERWISE, THAT SUCH OTHER PARTY WOULD NOT, IN THE EVENT
OF LITIGATION, SEEK TO ENFORCE THE FOREGOING WAIVER, (ii)
EACH SUCH PARTY UNDERSTANDS AND HAS CONSIDERED THE
IMPLICATIONS OF THIS WAIVER, (iii) EACH SUCH PARTY MAKES
THIS WAIVER VOLUNTARILY, AND (iv) EACH SUCH PARTY HAS
BEEN INDUCED TO ENTER INTO THIS AGREEMENT BY, AMONG OTHER
THINGS, THE MUTUAL WAIVERS AND CERTIFICATIONS IN THIS
SECTION 9.6.
9.7 Notices. Notices, requests, instructions or other documents to be
-------
given under this Agreement shall be in writing and shall be deemed given, (i)
three business days following sending by registered or certified mail, postage
prepaid, (ii) when sent if sent by facsimile, provided that a copy of the fax is
promptly sent by U.S. mail, (iii) when delivered, if delivered personally to the
intended recipient, and (iv) one business day later, if sent by overnight
delivery via a national courier service, and in each case, addressed to a party
at the following address for such party:
If to Parent or Merger Sub:
Abbott Laboratories
100 Abbott Park Road
Abbott Park, Illinois 60064-3500
Attention: Chief Executive Officer
Fax: (847) 938-6277
and
Abbott Laboratories
100 Abbott Park Road
Abbott Park, Illinois 60064-3500
60
<PAGE>
Attention: General Counsel
Fax: (847) 938-6277
with a copy to:
Scott J. Davis and James T. Lidbury
Mayer, Brown & Platt
190 South LaSalle Street
Chicago, Illinois 60603
Fax: (312) 701-7711
and if to the Company:
ALZA Corporation
950 Page Mill Road
Palo Alto, California 94304
Attention: Chief Executive Officer
Fax: (650) 496-8819
and
ALZA Corporation
950 Page Mill Road
Palo Alto, California 94304
Attention: General Counsel
Fax: (650) 494-5561
with a copy to:
Sarah A. O'Dowd
Heller Ehrman White & McAuliffe
525 University Avenue
Palo Alto, California 94301
Fax: (650) 324-0638
and
Brian J. McCarthy
Skadden, Arps, Slate, Meagher & Flom LLP
300 South Grand Avenue
Suite 3400
Los Angeles, California 90071
Fax: (213) 687-5600
61
<PAGE>
or to such other persons or addresses as may be designated in writing by the
party to receive such notice as provided above.
9.8 Entire Agreement. This Agreement (including any exhibits to this
----------------
Agreement), the Confidentiality Agreement, the Company Disclosure Letter and the
Parent Disclosure Letter constitute the entire agreement, and supersede all
other prior agreements, understandings, representations and warranties both
written and oral, among the parties with respect to the subject matter of this
Agreement. EACH PARTY TO THIS AGREEMENT AGREES THAT, EXCEPT FOR THE
REPRESENTATIONS AND WARRANTIES CONTAINED IN THIS AGREEMENT, NEITHER PARENT AND
MERGER SUB NOR THE COMPANY MAKES ANY REPRESENTATIONS OR WARRANTIES, AND EACH
HEREBY DISCLAIMS ANY OTHER REPRESENTATIONS OR WARRANTIES MADE BY ITSELF OR ANY
OF ITS OFFICERS, DIRECTORS, EMPLOYEES, AGENTS, FINANCIAL AND LEGAL ADVISORS OR
OTHER REPRESENTATIVES, WITH RESPECT TO THE EXECUTION AND DELIVERY OF THIS
AGREEMENT OR THE TRANSACTIONS CONTEMPLATED BY THIS AGREEMENT, NOTWITHSTANDING
THE DELIVERY OR DISCLOSURE TO THE OTHER OR THE OTHER'S REPRESENTATIVES OF ANY
DOCUMENTATION OR OTHER INFORMATION WITH RESPECT TO ANY ONE OR MORE OF THE
FOREGOING.
9.9 No Third Party Beneficiaries. Except as provided in Section 6.10
----------------------------
(Benefits) and Section 6.12 (Indemnification; Directors' and Officers'
Insurance), this Agreement is not intended to confer upon any Person other than
the parties to this Agreement any rights or remedies under this Agreement.
9.10 Obligations of Parent and of the Company. Whenever this Agreement
----------------------------------------
requires a Subsidiary of Parent to take any action, such requirement shall be
deemed to include an undertaking on the part of Parent to cause such Subsidiary
to take such action. Whenever this Agreement requires a Subsidiary of the
Company to take any action, such requirement shall be deemed to include an
undertaking on the part of the Company to cause such Subsidiary to take such
action and, after the Effective Time, on the part of the Surviving Corporation
to cause such Subsidiary to take such action.
9.11 Severability. The provisions of this Agreement shall be deemed
------------
severable and the invalidity or unenforceability of any provision shall not
affect the validity or enforceability or the other provisions of this Agreement.
If any provision of this Agreement, or the application thereof to any Person or
any circumstance, is invalid or unenforceable, (a) a suitable and equitable
provision shall be substituted therefor in order to carry out, so far as may be
valid and enforceable, the intent and purpose of such invalid or unenforceable
provision and (b) the remainder of this Agreement and the application of such
provision to other Persons or circumstances shall not be affected by such
invalidity or unenforceability, nor shall such invalidity or unenforceability
affect the validity or enforceability of such provision, or the application
thereof, in any other jurisdiction.
62
<PAGE>
9.12. Interpretation. The table of contents and headings in this
--------------
Agreement are for convenience of reference only, do not constitute part of this
Agreement and shall not be deemed to limit or otherwise affect any of the
provisions of this Agreement. Where a reference in this Agreement is made to a
Section or Exhibit, such reference shall be to a Section of or Exhibit to this
Agreement unless otherwise indicated. Whenever the words "include," "includes"
or "including" are used in this Agreement, they shall be deemed to be followed
by the words "without limitation."
9.13. Assignment. This Agreement shall not be assignable; provided,
---------- ---------
however, that Parent may designate prior to the Effective Time, by written
- --------
notice to the Company, another wholly owned direct or indirect Subsidiary to be
a party to the Merger in lieu of Merger Sub, in which event all references in
this Agreement to Merger Sub shall be deemed references to such other Subsidiary
(except with respect to representations and warranties made in this Agreement,
with respect to Merger Sub as of the date of this Agreement) and all
representations and warranties made herein with respect to Merger Sub as of the
date of this Agreement shall also be made with respect to such other Subsidiary
as of the date of such designation. Any assignment in contravention of the
preceding sentence shall be null and void.
<PAGE>
IN WITNESS WHEREOF, this Agreement has been duly executed and delivered by
the duly authorized officers of the parties to this Agreement as of the date
first written above.
ALZA CORPORATION
By: /s/ Ernest Mario
------------------------------------
Name: Ernest Mario
Title: Chairman & CEO
ABBOTT LABORATORIES
By: /s/ Miles D. White
------------------------------------
Name: Miles D. White
Title: Chairman of the Board
and Chief Executive Officer
AC MERGER SUB INC.
By: /s/ Arthur J. Higgins
------------------------------------
Name: Arthur J. Higgins
Title: President
<PAGE>
EXHIBIT A
---------
STOCKHOLDER AGREEMENT
This STOCKHOLDER AGREEMENT, dated as of June ____, 1999 (this "Agreement")
is between ABBOTT LABORATORIES, an Illinois corporation ("Parent"), and the
undersigned stockholder ("Stockholder") of ALZA CORPORATION, a Delaware
corporation (the "Company"). Capitalized terms not otherwise defined in this
Agreement have the meanings ascribed to them in the Merger Agreement (as defined
below).
RECITALS
--------
A. Parent and the Company have entered into an Agreement and Plan of
Merger, dated as of June 21, 1999 (the "Merger Agreement"), pursuant to which AC
Merger Sub Inc., a Delaware corporation and a wholly owned subsidiary of Parent
("Merger Sub"), will merge with and into the Company (the "Merger"), with the
Company surviving the Merger and becoming a wholly owned subsidiary of Parent;
B. Pursuant to the Merger Agreement, at the Effective Time, outstanding
shares of Company Common Stock, including any Company Common Stock owned by
Stockholder, will be converted into the right to receive shares of Parent Common
Stock;
C. It is a condition to each party's obligation to effect the Merger that
(i) legal counsel to the Company and Parent shall have delivered their
respective opinions to the effect that the Merger will constitute a
reorganization within the meaning of Section 368(a) of the Internal Revenue Code
of 1986, as amended (the "Code"), and Parent, Merger Sub and the Company each
will be a party to the reorganization within the meaning of Section 368(b) of
the Code, and (ii) the independent public accounting firms for the Company and
Parent shall have delivered their respective opinions to the effect that the
Merger will qualify for pooling-of-interests accounting treatment;
D. The execution and delivery of this Agreement by Stockholder is a
material inducement to Parent to enter into the Merger Agreement; and
E. Stockholder has been advised that Stockholder may be deemed to be an
"affiliate" of the Company, as such term is used (i) for purposes of paragraphs
(c) and (d) of Rule 145 of the Securities and Exchange Commission (the
"Commission") under the Securities Act of 1933, as amended (the "Act"), or (ii)
in the Commission's Accounting Series Releases 130 and 135, as amended, although
nothing contained herein shall be construed as an admission by Stockholder that
Stockholder is in fact an affiliate of the Company.
<PAGE>
NOW, THEREFORE, intending to be legally bound, the parties agree as
follows:
1. Acknowledgments by Stockholder. Stockholder acknowledges and
------------------------------
understands that the representations, warranties and covenants made by
Stockholder set forth in this Agreement will be relied upon by Parent, the
Company and their respective affiliates, counsel and accounting firms, and that
substantial losses and damages may be incurred by such persons if Stockholder's
representations, warranties or covenants are breached. Stockholder has
carefully read this Agreement and the Merger Agreement and has consulted with
such legal counsel and financial advisers as Stockholder has deemed appropriate
in connection with the execution of this Agreement.
2. Compliance with Rule 145 and the Act.
------------------------------------
(a) Stockholder has been advised that (i) the issuance of shares of
Parent Common Stock in connection with the Merger is expected to be effected
pursuant to a Registration Statement filed by Parent on Form S-4, and the resale
of such shares will be subject to the restrictions set forth in Rule 145 under
the Act unless such shares are otherwise transferred pursuant to an effective
registration statement under the Act or an appropriate exemption from
registration, and (ii) Stockholder may be deemed to be an affiliate of the
Company. Stockholder accordingly agrees not to sell, pledge, transfer or
otherwise dispose of any shares of Parent Common Stock issued to Stockholder in
the Merger unless (i) such sale, pledge, transfer or other disposition is made
in conformity with the requirements of Rule 145 under the Act, (ii) such sale,
pledge, transfer or other disposition is made pursuant to an effective
registration statement under the Act, or (iii) Stockholder delivers to Parent a
written opinion of counsel, in form and substance reasonably acceptable to
Parent, to the effect that such sale, pledge, transfer or other disposition is
otherwise exempt from registration under the Act.
(b) Parent will give stop transfer instructions to its transfer agent
with respect to any Parent Common Stock received by Stockholder pursuant to the
Merger, and there will be placed on the certificates representing such Parent
Common Stock, or any substitutions therefor, legends stating in substance:
"THE SHARES REPRESENTED BY THIS CERTIFICATE WERE ISSUED PURSUANT TO A
BUSINESS COMBINATION WHICH IS BEING ACCOUNTED FOR AS A POOLING OF
INTERESTS, IN A TRANSACTION TO WHICH RULE 145 PROMULGATED UNDER THE
SECURITIES ACT OF 1933 APPLIES, AND MAY ONLY BE TRANSFERRED IN CONFORMITY
WITH RULE 145, PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT, OR IN
ACCORDANCE WITH A WRITTEN OPINION OF COUNSEL, REASONABLY ACCEPTABLE TO THE
ISSUER, IN FORM AND SUBSTANCE TO THE EFFECT THAT SUCH TRANSFER IS EXEMPT
FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933. SUCH SHARES MAY NOT BE
TRANSFERRED UNTIL SUCH TIME AS PARENT SHALL HAVE
<PAGE>
PUBLISHED FINANCIAL RESULTS COVERING AT LEAST 30 DAYS OF COMBINED
OPERATIONS WITH THE COMPANY."
and
"THE SHARES REPRESENTED BY THIS CERTIFICATE MAY NOT BE OFFERED, SOLD,
PLEDGED, TRANSFERRED OR OTHERWISE DISPOSED OF EXCEPT IN ACCORDANCE WITH THE
REQUIREMENTS OF THE CONDITIONS SPECIFIED IN THE STOCKHOLDER AGREEMENT DATED
AS OF JUNE __, 1999 BETWEEN THE HOLDER OF THIS CERTIFICATE AND PARENT, A
COPY OF WHICH AGREEMENT MAY BE INSPECTED BY THE HOLDER OF THIS CERTIFICATE
AT THE PRINCIPAL OFFICES OF PARENT OR FURNISHED BY PARENT TO THE HOLDER OF
THIS CERTIFICATE UPON WRITTEN REQUEST AND WITHOUT CHARGE."
The legends set forth above shall be removed (by delivery of a substitute
certificate without such legends), and Parent shall so instruct its transfer
agent, if a registration statement respecting the sale of the shares has been
declared effective under the Act or if Stockholder delivers to Parent (i)
satisfactory written evidence that the shares have been sold in compliance with
Rule 145 (in which case, the substitute certificate will be issued in the name
of the transferee), or (ii) an opinion of counsel, in form and substance
reasonably acceptable to Parent, to the effect that sale of the shares by the
holder thereof is no longer subject to Rule 145.
3. Covenants Related to Pooling of Interests.
-----------------------------------------
(a) During the period beginning on the date 30 days prior to the
Closing Date (as defined in the Merger Agreement) and ending on the day after
Parent has published (within the meaning of Section 201.01 of the Commission's
Codification of Financial Reporting Policies) financial results covering at
least 30 days of combined operations of Parent and the Company (the "Restricted
Period"), Stockholder will not sell, exchange, transfer, pledge, distribute or
otherwise dispose of or grant any option, establish any "short" or "put"-
equivalent position with respect to or enter into any similar transaction
(through derivatives or otherwise) intended to have or having the effect,
directly or indirectly, or reducing its risk relative to (i) any shares of
Company Common Stock owned by Stockholder or (ii) any shares of Parent Common
Stock received by Stockholder in connection with the Merger. The parties
acknowledge that sales of Parent Common Stock issuable on exercise of stock
options solely to provide for payment of the exercise price of such stock
options simultaneously with the exercise of such stock options shall not
constitute such reduction of relative risk.
(b) Notwithstanding anything to the contrary contained in Section
3(a), Stockholder will be permitted, during the Restricted Period, (ii) to sell,
exchange, transfer, pledge, distribute or otherwise dispose of or grant any
option, establish any "short" or "put"-equivalent position with respect to or
enter into any similar transaction (through derivatives or otherwise)
3
<PAGE>
intended to have or having the effect, directly or indirectly, of reducing its
risk relative to any shares of Company Common Stock or Parent Common Stock
received by Stockholder in connection with the Merger (a "Transfer") equal to
the lesser of (A) 10% of the Company Common Stock, or equivalent post-Merger
Parent Common Stock, owned by Stockholder and (B) Stockholder's pro rata portion
of 1% of the total number of outstanding shares of Company Common Stock, or
equivalent post-Merger Parent Common Stock, owned by Stockholder and all other
stockholders of the Company (in each of clause (A) and clause (B) above as
measured as of the date of such Transfer and subject to confirmation of such
calculation by Parent), and (ii) to make bona fide charitable contributions or
gifts of such securities; provided, however, that the transferee(s) of such
-------- -------
charitable contributions or gifts agree(s) in writing to hold such securities
for the period specified in Section 3(a).
4. Miscellaneous.
-------------
(a) This Agreement may be executed in one or more counterparts, each
of which shall be deemed an original, but all of which together shall constitute
one and the same document.
(b) This Agreement shall be enforceable by, and shall inure to the
benefit of and be binding upon, the parties and their respective successors and
assigns. As used in this Agreement, the term "successors and assigns" means,
where the context to permits, heirs, executors, administrators, trustees and
successor trustees, and personal and other representatives.
(c) This Agreement shall be deemed to be made in and in all respects
shall be interpreted, construed and governed by and in accordance with Delaware
law without regard to the conflict of law principles thereof. The parties
irrevocably and unconditionally consent to submit to the exclusive jurisdiction
of the courts of the State of Delaware and of the United States of America
located in Wilmington, Delaware (the "Delaware Courts") for any litigation
---------------
arising out of or relating to this Agreement and the transactions contemplated
by this Agreement (and agree not to commence any litigation relating thereto
except in such Delaware Courts), waive any objection to the laying of venue of
any such litigation in the Delaware Courts and agree not to plead or claim in
any Delaware Court that such litigation brought therein has been brought in an
inconvenient forum.
(d) If any term, provision, covenant, or restriction contained in this
Agreement is held by a court or a federal or state regulatory agency of
competent jurisdiction to be invalid, void, or unenforceable, the remainder of
the terms, provisions, covenants, and restrictions contained in this Agreement
shall remain in full force and effect, and shall in no way be affected,
impaired, or invalidated.
4
<PAGE>
(e) Counsel to and accountants for the parties to the Merger Agreement
shall be entitled to rely upon this Agreement as needed.
(f) This Agreement shall not be modified or amended, or any right
waived or any obligations excused, except by a written agreement signed by both
parties.
(g) Notwithstanding any other provision contained in this Agreement,
this Agreement and all obligations under this Agreement shall terminate upon the
termination of the Merger Agreement in accordance with its terms.
(h) From and after the Effective Time of the Merger and as long as is
necessary in order to permit Stockholder to sell Parent Common Stock held by
Stockholder pursuant to Rule 145 and, to the extent applicable, Rule 144 under
the Act, Parent will file on a timely basis all reports required to be filed by
it pursuant to the Securities Exchange Act of 1934, as amended, and the rules
and regulations thereunder, as the same shall be in effect at the time, and
shall otherwise make available adequate public information regarding Parent in
such manner as may be required to satisfy the requirements of paragraph (c) of
Rule 144 under the Act.
5
<PAGE>
IN WITNESS WHEREOF, this Agreement is executed as of the date first stated
above.
ABBOTT LABORATORIES,
an Illinois corporation
By:
-----------------------------------
Name:
Title:
STOCKHOLDER
By:
-----------------------------------
Name:
Name of Signatory
(if different from name of
Stockholder):
--------------------------------------
Title of Signatory
(if applicable):
----------------------
Number of Shares Owned:
---------------
Number of Shares Issuable upon
Exercise of Stock Options:
------------
<PAGE>
EXHIBIT B
STOCKHOLDER AGREEMENT
This STOCKHOLDER AGREEMENT, dated as of June __, 1999 (this "Agreement"),
is by and between ALZA CORPORATION, a Delaware corporation (the "Company"), and
the undersigned stockholder ("Stockholder") of ABBOTT LABORATORIES, an Illinois
corporation ("Parent"). Capitalized terms not otherwise defined in this
Agreement have the meanings ascribed to them in the Merger Agreement (as defined
below).
RECITALS
--------
A. The Company and Parent have entered into an Agreement and Plan of
Merger, dated as of June 21, 1999 (the "Merger Agreement"), pursuant to which
AC Merger Sub Inc., a Delaware corporation and a wholly owned subsidiary of
Parent ("Merger Sub"), will merge with and into the Company (the "Merger"), with
the Company surviving the Merger and becoming a wholly owned subsidiary of
Parent;
B. It is a condition to the effectiveness of the Merger that (i) legal
counsel to Parent and the Company shall have delivered their respective opinions
to the effect that the Merger will constitute a reorganization within the
meaning of Section 368(a) of the Internal Revenue Code of 1986, as amended (the
"Code") and Parent, Merger Sub and the Company each will be a party to the
reorganization within the meaning of Section 368(b) of the Code, and (ii) the
independent public accounting firms for Parent and the Company shall have
delivered their respective opinions to the effect that the Merger will qualify
for pooling-of-interests accounting treatment;
C. The execution and delivery of this Agreement by Stockholder is a
material inducement to the Company to enter into the Merger Agreement; and
D. Stockholder has been advised that Stockholder may be deemed to be an
"affiliate" of Parent, as such term is used in the Commission's Accounting
Series Releases 130 and 135, as amended, although nothing contained herein shall
be construed as an admission by Stockholder that Stockholder is in fact an
affiliate of Parent.
NOW, THEREFORE, intending to be legally bound, the parties agree as
follows:
1. Acknowledgments by Stockholder. Stockholder acknowledges and
------------------------------
understands that the representations, warranties and covenants made by
Stockholder set forth in this Agreement will be relied upon by the Company,
Parent and their respective affiliates, counsel and accounting firms, and that
substantial losses and damages may be incurred by such persons if Stockholder's
representations, warranties or covenants are breached. Stockholder has
carefully read this
<PAGE>
Agreement and the Merger Agreement and has consulted with such legal counsel and
financial advisers as Stockholder has deemed appropriate in connection with the
execution of this Agreement.
2. Covenants Related to Pooling of Interests.
-----------------------------------------
(a) During the period beginning on the date 30 days prior to the
Closing Date (as defined in the Merger Agreement) and ending on the day after
Parent has published (within the meaning of Section 201.01 of the Commission's
Codification of Financial Reporting Policies) financial results covering at
least 30 days of combined operations of the Company and Parent (the "Restricted
Period"), Stockholder will not sell, exchange, transfer, pledge, distribute or
otherwise dispose of or grant any option, establish any "short" or "put"-
equivalent position with respect to or enter into any similar transaction
(through derivatives or otherwise) intended to have or having the effect,
directly or indirectly, of reducing its risk relative to any shares of Parent
Common Stock owned by Stockholder. The parties acknowledge that sales of Parent
Common Stock issuable on exercise of stock options solely to provide for payment
of the exercise price of such stock options simultaneously with the exercise of
such stock options shall not constitute such reduction of relative risk.
(b) Notwithstanding anything to the contrary contained in Section
2(a), Stockholder will be permitted, during the Restricted Period, (i) to sell,
exchange, transfer, pledge, distribute or otherwise dispose of or grant any
option, establish any "short" or "put"-equivalent position with respect to or
enter into any similar transaction (through derivatives or otherwise) intended
to have or having the effect, directly or indirectly, of reducing its risk
relative to any shares of Parent Common Stock owned by Stockholder (a
"Transfer") equal to the lesser of (A) 10% of the Parent Common Stock owned by
Stockholder and (B) Stockholder's pro rata portion of 1% of the total number of
outstanding shares of Parent Common Stock owned by Stockholder and all other
stockholders of Parent (in each of clause (A) and clause (B) above as measured
as of the date of such Transfer and subject to confirmation of such calculation
by Parent), and (ii) to make bona fide charitable contributions or gifts of such
securities; provided, however, that the transferee(s) of such charitable
-------- -------
contributions or gifts agree(s) in writing to hold such securities for the
period specified in Section 2(a).
3. Miscellaneous.
-------------
(a) This Agreement may be executed in one or more counterparts, each
of which shall be deemed an original, but all of which together shall constitute
one and the same document.
(b) This Agreement shall be enforceable by, and shall inure to the
benefit of and be binding upon, the parties and their respective successors and
assigns. As used in this Agreement, the term "successors and assigns" means,
where the context so permits, heirs, executors, administrators, trustees and
successor trustees, and personal and other representatives.
<PAGE>
(c) This Agreement shall be deemed to be made in and in all respects
shall be interpreted, construed and governed by and in accordance with Delaware
law without regard to the conflict of law principles thereof. The parties
irrevocably and unconditionally consent to submit to the exclusive jurisdiction
of the courts of the State of Delaware and of the United States of America
located in Wilmington, Delaware (the "Delaware Courts") for any litigation
---------------
arising out of or relating to this Agreement and the transactions contemplated
by this Agreement (and agree not to commence any litigation relating thereto
except in such Delaware Courts), waive any objection to the laying of venue of
any such litigation in the Delaware Courts and agree not to plead or claim in
any Delaware Court that such litigation brought therein has been brought in an
inconvenient forum.
(d) If any term, provision, covenant, or restriction contained in this
Agreement is held by a court or a federal or state regulatory agency of
competent jurisdiction to be invalid, void, or unenforceable, the remainder of
the terms, provisions, covenants, and restrictions contained in this Agreement
shall remain in full force and effect, and shall in no way be affected,
impaired, or invalidated.
(e) Counsel to and accountants for the parties to the Merger Agreement
shall be entitled to rely upon this Agreement as needed.
(f) This Agreement shall not be modified or amended, or any right waived or
any obligation excused, except by a written agreement signed by both parties.
(g) Notwithstanding any other provision contained in this Agreement, this
Agreement and all obligations under this Agreement shall terminate upon the
termination of the Merger Agreement in accordance with its terms.
3
<PAGE>
IN WITNESS WHEREOF, this Agreement is executed as of the date first stated
above.
ALZA CORPORATION,
a Delaware corporation
By:____________________________________
Name:
Title:
Stockholder
By:____________________________________
Name:
Name of Signatory
(if different from name of
Stockholder):
_______________________________________
Title of Signatory
(if applicable):
Number of Shares Owned:________________
Number of Shares Issuable upon
Exercise of Stock Options:_____________
<PAGE>
Exhibit 99.1
ABBOTT LABORATORIES TO ACQUIRE ALZA CORPORATION
ABBOTT PARK, Ill., and PALO ALTO, Calif., June 21, 1999 -- Abbott
Laboratories (NYSE: ABT) and ALZA Corporation (NYSE: AZA) today announced that
the companies have entered into a definitive agreement for Abbott to acquire
ALZA, a research-based pharmaceutical company with a growing portfolio of
products and leading drug delivery technologies.
Under the terms of the agreement, Abbott will acquire all of ALZA's
outstanding stock in a stock-for-stock merger transaction intended to be tax-
free. ALZA shareholders will receive a fixed exchange ratio of 1.20 shares of
Abbott common stock for each share of ALZA. The total transaction value is
approximately $7.3 billion. Abbott intends to account for the transaction as a
pooling of interests. The transaction is expected to be completed by year end,
subject to approval by ALZA's stockholders, regulatory agencies and customary
closing conditions.
As required to qualify for a pooling transaction, the Board of Directors of
Abbott Laboratories rescinded its authorization to purchase shares of its common
stock under its share repurchase program.
"Our acquisition of ALZA is an excellent strategic fit and an important
step that builds our pharmaceutical business and accelerates Abbott's long-term
growth," said Miles D. White, chairman and chief executive officer of Abbott
Laboratories. "ALZA brings a number of key assets to Abbott that provide both
short- and long-term value, including: a portfolio of pharmaceutical products
that Abbott can rapidly grow and expand through its strong global sales
organization; new products in development; strong technical relationships with
pharmaceutical industry partners; and important scientific expertise in drug
delivery technologies that enhance patient care and provide a strategic
technology platform for application across all of Abbott's diverse businesses."
"I am immensely proud of the progress that ALZA's employees have made in
transforming our business from a client-based, product-development laboratory
into an integrated pharmaceutical company with strong therapeutic franchises in
urology and oncology," said Ernest Mario, Ph.D., chairman and chief executive
officer of ALZA. "Our relationship with Abbott and the exceptional fit of these
companies represents an exciting opportunity to fully realize the commercial
value of our products and technologies. The combination of Abbott's global
commercial infrastructure, broad product portfolio and strong R&D resources with
ALZA's specialized product portfolio and powerful drug delivery expertise will
significantly accelerate the growth and development of our combined core
businesses."
"ALZA's marketed products and pharmaceutical pipeline in the areas of
urology and oncology fit perfectly into Abbott's pharmaceutical franchise
areas," said Arthur Higgins, senior vice president, pharmaceutical operations at
Abbott. "Our existing leadership positions in urology and neuroscience will be
enhanced by ALZA's products, and ALZA's oncology presence will give Abbott an
additional platform for a leadership
<PAGE>
position in cancer treatment that augments our own internal cancer research and
development efforts as well as our broad line of multi-source oncology
products."
"This is an exciting event for ALZA -- an opportunity to join our world-
class technology and pharmaceutical business with the resources of a global
research-based pharmaceutical company," said Alejandro Zaffaroni, PhD., ALZA's
founder. "I believe that this relationship with Abbott further validates the
extraordinary contributions and scientific excellence of so many colleagues at
ALZA, and the technologies and products that we all helped create."
Upon closure of the transaction, there will be a restatement of 1999
earnings. Abbott expects the acquisition will result in a $.03 dilution in 2000,
and will be accretive to earnings in 2001 and thereafter. In addition, the
acquisition will result in a one-time charge of approximately $100 million in
1999.
ALZA Corporation, headquartered in Palo Alto, Calif., is a research-based
pharmaceutical products company with leading drug delivery technologies. The
company applies its delivery technologies to develop pharmaceutical products
with enhanced therapeutic value for its own portfolio and for many of the
world's leading pharmaceutical companies. ALZA's sales and marketing efforts are
currently focused in urology and oncology. The company employs approximately
2,000 people. In 1998, ALZA's sales and net earnings were $646.9 million and
$108.3 million, respectively, with diluted earnings per share of $1.07. ALZA
Corporation was advised by Chase Securities Inc. and Merrill Lynch & Co.
Abbott Laboratories is a global, diversified health care company devoted to
the discovery, development, manufacture and marketing of pharmaceutical,
diagnostic, nutritional and hospital products. The company employs 56,000 people
and markets its products in more than 130 countries. In 1998, the company's
sales and net earnings were $12.5 billion and $2.3 billion, respectively, with
diluted earnings per share of $1.51. Morgan Stanley Dean Witter & Co., Inc.
acted as financial advisor to Abbott.
<PAGE>
Exhibit 99.2
CO-PROMOTION AGREEMENT
----------------------
This Co-Promotion Agreement ("Agreement") is entered into as of the 21st
day of June, 1999 (the "Effective Date") between ALZA Corporation ("ALZA") and
Abbott Laboratories Inc. ("ABBOTT").
WHEREAS, ALZA markets Ditropan XL7, a proprietary controlled release
urinary incontinence product; and
WHEREAS, ABBOTT desires to co-promote Ditropan XL7 with ALZA in the United
States, in accordance with the terms and conditions of this Agreement.
NOW THEREFORE, in consideration of the mutual covenants contained herein,
the parties agree as follows:
1. Definitions. For purposes of this Agreement, the following definitions
-----------
shall be applicable:
1.1 "Contract Month" means a full calendar month (except that the
first Contract Month shall start on the day of the ABBOTT launch of the
Sales Call effort and end on the last day of such calendar month, and the
last Contract Month shall mean the calendar month in which this Agreement
terminates).
1.2 "Net Sales" means gross sales of the Product (as set forth on the
invoice for such Product) in the United States for use in the United States
by ALZA and any ALZA affiliate, to unrelated third parties, in arm's length
transactions, including but not limited to, pharmaceutical wholesalers,
pharmacies, hospitals, or dispensing physicians, less any of the following
charges or expenses that are incurred in connection with gross sales of the
Product during the Term:
(i) discounts, including cash discounts, customary trade allowances
or rebates actually taken or allowed, governmental rebates,
charge-backs, and group purchasing management fees for formulary
access;
(ii) credits or allowances given or made for rejection, recall or
return (including return reserves) of previously sold Product
actually taken or allowed;
(iii) any tax or governmental charge (including any tax such as a
value added or similar tax or government charge) to the extent
it appears on Product invoices (other than an income tax levied
on the sale, transportation or delivery of Product); and
(iv) freight, insurance and duties on shipments of Product.
<PAGE>
The parties agree that the only discounts, allowances or rebates permitted
to be charged against "Net Sales" hereunder shall be those that are
extended by ALZA in good faith and consistent with discounts, allowances or
rebates extended by ALZA on other ALZA products in the ordinary course of
business.
1.3 "Product" means Ditropan XL7, a proprietary controlled release
urinary incontinence product currently marketed by ALZA in the United
States.
1.4 "Representative" means a sales employee of ALZA or ABBOTT, as the
case may be, trained to make Sales Calls to the Target Audience.
1.5 "Sales Call" means a presentation to a member of the Target
Audience by a Representative during which such Representative promotes the
Product. "Sales Call" may also refer to a presentation to a member of the
Target Audience by a sales employee of Innovex, Inc. ("Innovex") or UCB
Pharma, Inc. ("UCB") in accordance with the terms of ALZA's agreements with
Innovex and UCB, respectively, during which such sales employee promotes
the Product.
1.6 "Sales Quarter" shall mean a period of three (3) consecutive
Contract Months, except that the first Sales Quarter shall mean the period
from the launch of ABBOTT Sales Calls through the end of the calendar month
and the following three (3) Contract Months.
1.7 "Target Audience" means general practitioners, urologists and
other medical personnel in a position to prescribe the Product.
1.8 "Term" means the period commencing on the Effective Date and
ending ninety (90) days following the date of launch of the ABBOTT Sales
Call effort, as the Term may be extended pursuant to Section 6 hereof.
---------
2. Co-promotion Activities
-----------------------
2.1 Appointment and Acceptance. ALZA hereby appoints ABBOTT, and
--------------------------
ABBOTT hereby accepts appointment, as a co-promoter of Product in the United
States in accordance with the terms and conditions of this Agreement. In the
event that ALZA desires to add additional Sales Calls to its marketing effort
through a co-promotion arrangement with a third party, ALZA agrees that ABBOTT
shall have a right of first negotiation to perform such Sales Calls, and the
parties agree to negotiate in good faith the terms for ABBOTT performing such
additional Sales Calls. If the parties are unable to agree on such terms, ALZA
agrees that it shall not offer more favorable terms to a third party without
first re-offering the additional Sales Calls to ABBOTT on such more favorable
terms.
2.2 Scope of Co-Promotion. Abbott Representatives shall perform
---------------------
Sales Calls on the Target Audience as follows:
(a) ABBOTT Representatives shall perform a minimum of fifteen
thousand (15,000) Sales Calls per Contract Month (except for the first
and last
-2-
<PAGE>
Contract Months in which ABBOTT Representatives shall perform an
appropriate number of Sales Calls as determined by ABBOTT). In the
event ABBOTT fails to perform such required minimum Sales Calls by a
variance of minus ten percent (10%) or less, ABBOTT shall be entitled
to make up such variance by performing all of such variance in the
subsequent Contract Month, in which case ABBOTT shall be compensated
for such variance.
(b) All Sales Calls by ABBOTT Representatives shall be performed
in the first position.
(c) ABBOTT Representatives shall deliver promotional materials
supplied by ALZA pursuant to Section 2.7 to the Target Audience.
-----------
ABBOTT shall not distribute any other Product promotional materials.
(d) ABBOTT Representatives shall perform Sales Calls in
accordance with approved labeling and all applicable laws and
regulations, including but not limited to the Food, Drug and Cosmetics
Act of 1938, as amended, and the Prescription Drug Marketing Act of
1987, as amended.
(e) ABBOTT shall launch the Sales Calls by the ABBOTT
Representatives within thirty (30) days after the Effective Date.
2.3 ALZA Sales Calls Efforts. ALZA Representatives shall continue to
------------------------
perform Sales Calls substantially in accordance with (or greater than) its
current level of performance, which, when combined with the number of Sales
Calls required of Innovex, is equal to fourteen thousand (14,000) Sales
Calls per month.
2.4 Sales Calls Tracking. Each party shall keep track of the number
--------------------
and position of Sales Calls by its Representatives in accordance with its
normal internal reporting procedures. From time to time upon the
reasonable request of a party, the other party shall provide a report with
respect to the number of Sales Calls performed by its Representatives
during the preceding time period. In addition, from time to time, upon
request by ABBOTT, ALZA shall provide a report with respect to the number
of Sales Calls performed by Innovex and UCB, respectively. Each party
shall have the right from time to time to accompany Representatives of the
other party on Sales Calls or otherwise audit Sales Calls for compliance
with this Agreement.
2.5 Communication. ABBOTT and ALZA shall meet at least once in each
-------------
Sales Quarter during the Term to review co-promotion effectiveness and to
formulate and implement Sales Calls strategies and other aspects of the co-
promotion. Each party will designate an individual responsible for
overseeing that party's day-to-day performance under this Agreement.
ALZA's initial designee is Mr. Jay Shepard and ABBOTT's initial designee is
Mr. Robert Altman. Either party may change its designate by written notice
to the other.
2.6 Training. ALZA will provide, at ALZA's expense (except for
--------
ABBOTT personnel travel and lodging expense), an initial training meeting,
within fourteen (14) days after the Effective Date, with ABBOTT personnel
to prepare ABBOTT to train its
-3-
<PAGE>
Representatives on the Product. In addition, ALZA shall provide ABBOTT with
Product training materials for all ABBOTT Representatives. All other
training expenses of ABBOTT Representatives shall be at the sole expense of
ABBOTT.
2.7 Promotional Materials; Samples. ALZA shall provide to ABBOTT,
------------------------------
without charge, currently available promotional materials specific to the
Product, in sufficient quantities for ABBOTT to perform its obligations
hereunder. ABBOTT shall use promotional materials for the Product supplied
by ALZA or approved in writing by ALZA and the approved Product labeling
and will not deviate from the text of such materials and/or labeling. In
addition, ALZA shall supply ABBOTT, without charge, Product samples for
distribution by the ABBOTT Representatives at a level of samples consistent
with that supplied by ALZA to its own Representatives. ABBOTT shall cause
its Representatives to comply with all federal, state and local laws, rules
and regulations concerning the handling, distribution and tracking of
samples, and ABBOTT shall maintain all required records to enable ALZA to
account for and track such samples.
2.8 Product Complaints. ABBOTT shall give ALZA notice of any
------------------
complaint or correspondence concerning the Product, including, but not
limited to, any adverse drug experience associated with the Product, in
accordance with the following procedure:
(i) information concerning any adverse drug experience
associated with a Product shall be reported to ALZA's Director of
Medical Safety by telefax within twenty-four (24) hours and by hard
copy in writing three (3) days after initial receipt of such
information;
(ii) all Product complaints not covered by (i) above shall be
reported in writing within twenty (20) calendar days following receipt
of such complaint. Such reports shall contain (a) the date the report
was received; (b) the name of the reporter; (c) the address and
telephone number of the reporter; and (d) an indication of the adverse
drug experience.
3. Compensation.
------------
(a) For the period from the date of launch of the ABBOTT Sales
Call effort through the end of the initial ninety (90) day Term, ALZA
shall pay ABBOTT the sum of Three Million One Hundred Fifty Thousand
Dollars ($3,150,000.00) in consideration for ABBOTT performing forty
five thousand (45,000)Sales Calls as required hereunder, so long as
Net Sales are at least Seven Million Dollars ($7,000,000.00) during
the period commencing July 1, 1999 through the end of the initial
Term. In any Contract Month during any extension of the initial Term,
the preceding figures shall be One Million Fifty Thousand Dollars
($1,050,000.00) consideration, fifteen thousand (15,000) Sales Calls
and Two Million Three Hundred Thirty Three Thousand Three Hundred
Thirty Three Dollars ($2,333,333.00) in baseline Net Sales. ALZA
shall have no obligation to pay ABBOTT for Sales Calls conducted by
ABBOTT Representatives in excess of forty five thousand (45,000) Sales
Calls over the initial Term (and in excess of fifteen thousand
(15,000) Sales Calls per each Contract Month during any
-4-
<PAGE>
extension of the initial Term). If ABBOTT performs less than forty
five thousand (45,000) Sales Calls from the date of launch through the
end of the initial Term (or less than fifteen thousand (15,000) Sales
Calls for any Contract Month during any extension of the initial Term,
then ALZA shall only pay a proportionate amount of Three Million One
Hundred Fifty Thousand Dollars ($3,150,000.00) for those Sales Calls
which ABBOTT has performed (One Million Fifty Thousand Dollars
($1,050,000.00) for any Contract Month during any extension of the
initial Term, subject to ABBOTT's right to make up a variance in the
number of Sales Calls performed in a given Contract Month as provided
in Section 2.2(a) hereof. For example, if ABBOTT performs forty
--------------
thousand (40,000) Sales Calls during the initial Term, ALZA would be
obligated to pay ABBOTT Two Million Eight Hundred Thousand Dollars
($2,800,000.00), subject to ABBOTT's right to make up the variance in
the number of Sales Calls performed as provided in Section 2.2(a)
--------------
hereof. Subject to Section 7.3 hereof, such reduction in compensation
-----------
shall be ALZA's sole and exclusive remedy with respect to ABBOTT's
non-performance of Sales Calls hereunder. At the end of the initial
Term (and at the end of each Contract Month thereafter during any
extension of the initial Term, ABBOTT shall issue an invoice to ALZA
for Sales Calls performed by ABBOTT during the applicable period, and
ALZA agrees to pay the amount of such invoice within thirty (30) days
after issuance.
(b) Within thirty (30) days after the end of each Sales Quarter,
ALZA shall provide ABBOTT with a report showing: (i) gross sales of
the Product in the U.S. for such Sales Quarter; (ii) a calculation
demonstrating the adjustments to gross sales in order to arrive at Net
Sales; and (iii) the calculation of the commission payable, including
any adjustments to the commission payable.
(c) If ABBOTT, in its reasonable judgment, determines that an
audit of ALZA's relevant books and records is necessary to verify the
information supplied by ALZA pursuant to Section 3(c), then ABBOTT's
------------
designee, under duty of confidentiality to ALZA and ABBOTT, and
provided such designee is an independent certified public accountant,
shall have the right, on fifteen (15) days advance written notice, at
ABBOTT's expense, to perform an audit of the relevant books and
records of ALZA not more than once in any twelve (12) month period to
verify the information supplied by ALZA. If an audit reveals that
there has been a variance of two percent (2%) or more in the
determination of the applicable Net Sales, then the cost for such
audit shall be paid by ALZA.
4. Terms of Sales and Market Support Responsibility. All terms of sale
------------------------------------------------
for Product, including, without limitation, policies concerning pricing, credit
terms, cash discounts and returns and allowances shall be set by ALZA. All
sales of Product shall be recorded on the books of ALZA. ABBOTT is not
authorized to negotiate pricing issues with regard to the Product or make any
representations about such Product except as included in promotional materials
provided hereunder and/or in the Product labeling.
5. Records. Each party shall keep complete and accurate records as are
-------
required to implement and administer this Agreement.
-5-
<PAGE>
6. Term. The Term shall commence on the Effective Date and terminate
----
ninety (90) days following the date of launch of the ABBOTT Sales Call effort,
unless earlier terminated pursuant to Article 7. ABBOTT may extend the Term for
---------
one or more additional thirty (30) day periods (but not to extend beyond April
30, 2000) by providing ALZA with at least fifteen (15) days advance written
notice prior to expiration of the then existing Term.
7. Termination.
-----------
7.1 Termination. This Agreement may be terminated at any time by
-----------
either party without cause upon thirty (30) days prior written notice.
7.2 Breach. Either party may terminate this Agreement for material
------
breach on thirty (30) days notice to the other party specifying the breach.
If such breach is not cured within such thirty (30) day period, then this
Agreement shall terminate at the end of such notice period.
7.3 Termination by ALZA. ALZA may terminate this Agreement on thirty
-------------------
(30) days notice to ABBOTT if ABBOTT fails to make at least thirty thousand
(30,000) Sales Calls during any three (3) consecutive Contract Months.
7.4 Effects of Termination. Upon termination of this Agreement for
----------------------
any reason, ABBOTT shall deliver to ALZA any and all of its inventory of
Product samples and other promotional material relating to the Product.
Expiration or termination of this Agreement shall not affect the remedies
of the parties otherwise available at law or equity in relation to any
rights accrued under this Agreement prior to expiration or termination.
8. Liability.
---------
8.1 Indemnification by ALZA. ALZA shall defend, indemnify and hold
-----------------------
harmless ABBOTT and its officers, directors, agents and employees
(collectively, the "Abbott Indemnitees"), from and against any and all
liability, loss, damages and expenses (including attorneys' fees) as a
result of claims, demands, costs or judgements (collectively, the "Losses")
arising out of or resulting from:
(i) any negligent act or omission or willful misconduct of ALZA
and its directors, officers or employees or Representatives with
respect to the promotion of Product, including but not limited to
product liability claims arising out of out-of-label promotions by
ALZA, its directors, officers or employees or Representatives; or
(ii) any violation of approved labeling or applicable statute or
regulation with respect to the Product, or
(iii breach of this Agreement by ALZA, or
-6-
<PAGE>
(iv) the manufacturing, marketing, sale or use of the Product,
including any Product liability claims and/or patent infringement
claims, or
(v) any claim, warranty or representation by ALZA, with respect
to the Product, or
(vi) any infringement claim related to Abbott's use of the ALZA
name or logo of the ALZA trademarks in connection with the promotion
or sale of the Product, provided ABBOTT's use is in compliance with
the terms of this Agreement.
Provided, however, that ALZA shall not be required to indemnify ABBOTT to
the extent that such Losses arise out of or result from: (1) the
negligence, recklessness or willful misconduct of the Abbott Indemnitees,
including, but not limited to, out-of-label promotion of the Product; and
or (2) any breach by ABBOTT of this Agreement. ABBOTT shall not be
considered negligent for purposes of this Section or Section 8.2 if such
claim arises with respect to the content of the promotional materials,
Product labeling or other materials provided to ABBOTT by ALZA as long as
ABBOTT has distributed or employed such promotional materials as directed
herein.
ALZA shall have the exclusive right to control the defense of any action
which is to be indemnified in whole by ALZA hereunder, including the right
to select counsel reasonably acceptable to ABBOTT to defend ABBOTT and to
settle any claim, provided that, without the written consent of ABBOTT
(which shall not be unreasonably withheld or delayed), ALZA shall not agree
to settle any claim against ABBOTT. The provision of this Section shall
survive and remain in full force and effect after termination, expiration
or cancellation of this Agreement.
8.2 Indemnification by ABBOTT. ABBOTT shall defend, indemnify and
-------------------------
hold harmless ALZA and its officers, directors, agents and employees
(collectively, the "ALZA Indemnitees"), from and against any and all
liability, loss, damages and expenses (including attorneys' fees) as a
result of claims, demands, costs or judgments (collectively, the "Losses")
arising out of or resulting from:
(i) any negligent act or omission or willful misconduct of
ABBOTT with respect to the co-promotion of the Product, or
(ii) any breach of this Agreement by ABBOTT.
Provided, however, that ABBOTT shall not be required to indemnify the ALZA
Indemnitees to the extent that any Losses arise out of or result from: (1)
the negligence, recklessness, or willful misconduct of any ALZA Indemnitee,
including but not limited to, out-of-label promotion of the Product; and/or
(2) any breach by ALZA of this Agreement.
ABBOTT shall have the exclusive right to control the defense of any action
which is to be indemnified in whole by ABBOTT hereunder, including the
right to select counsel
-7-
<PAGE>
reasonably acceptable to ALZA to defend ALZA and to settle any claim,
provided that, without the written consent of ALZA (which shall not be
unreasonably withheld or delayed), ABBOTT shall not agree to settle any
claim against ALZA. The provision of this Section shall survive and remain
in full force and effect after termination, expiration or cancellation of
this Agreement.
8.3 Indemnification Procedure. If any claims are made against an
-------------------------
indemnified party as to which the indemnification provisions set forth in
this Article 8 may apply, as soon as reasonably practicable, the
---------
indemnified party will inform the other party thereof and the indemnifying
party and/or its insurers will assume the defense of any such claims. The
indemnified party will cooperate in the disposition of any such matters.
The indemnified party shall have the right to participate at its own
expense in the defense of any such claim.
8.4 Disclaimer of Consequential Damages. IN NO EVENT SHALL EITHER
-----------------------------------
ABBOTT OR ALZA BE LIABLE TO THE OTHER FOR ANY SPECIAL, CONSEQUENTIAL OR
INCIDENTAL DAMAGES ARISING UNDER OR AS A RESULT OF THIS AGREEMENT (OR THE
TERMINATION HEREOF).
9. Relationship of the Parties. Each party is performing hereunder as an
---------------------------
independent contractor of the other party and its employees and representatives
are not eligible to participate in any benefits programs offered by the other
party to its employees, or in any pension plans, profit sharing plans, insurance
plans or any other employee benefits plans. Each party acknowledges and agrees
that it shall be solely responsible for designing and administering any
incentive program to its Representatives in respect to their activity promoting
the Product; and for paying all salaries, wages, benefits and other compensation
which its employees may be entitled to receive in connection with the
performance of this Agreement. Except as specifically set forth herein, no
employees or representatives of a party shall have any authority to bind or
obligate the other party to this Agreement for any such or in any manner
whatsoever, or to create or impose any contractual or other liability on the
other party without such other party's authorized written approval. For all
purposes and notwithstanding any provision of this Agreement to the contrary,
the parties' legal relationship under this Agreement shall be that the parties
are independent of each other and not that of partners or joint venturers.
Neither party hereto is authorized to make any statements or representations on
behalf of the other party or in any way obligate the other party, except as
expressly authorized in writing by the other party.
10. Confidential Information. Except as otherwise expressly provided
------------------------
under this Agreement, each party shall hold in confidence, and not use for any
purpose other than performing it obligations under this Agreement, all
confidential information concerning the other party, including, without
limitation, the amount of net sales of the Product. "Confidential Information"
shall not include information: (a) which is or becomes generally available to
the public other than as a result of disclosure thereof by the receiving party;
(b) which is lawfully received by the receiving party on a nonconfidential basis
from a third party that is not itself under any obligation of confidentiality or
nondisclosure to the disclosing party or any other person with respect to such
information; (c) which by written evidence can be shown by the receiving party
to have been independently developed by or for the receiving party; or (d) which
-8-
<PAGE>
the receiving party establishes by competent proof was in its possession at the
time of disclosure by the other party and was not acquired, directly or
indirectly from the other party.
11. Right of First Negotiation. ALZA hereby grants to ABBOTT and ABBOTT
--------------------------
hereby accepts a first right of negotiation from the Effective Date through
April 30, 2000 to obtain from ALZA co-promotion and/or license rights to OROS(R)
Methylphenidate in the U.S. In the event ALZA elects to co-promote with and/or
license rights to a third party with respect to OROS(R) Methylphenidate in the
U.S., then prior to entering into such negotiations with a third party, ALZA
shall prepare and submit to ABBOTT a data package which shall consist of at
least the following information: stage of development, therapeutic category,
targeted indications, mechanism of action, safety profile, and anticipated FDA
submission date. If ABBOTT notifies ALZA within thirty (30) days of its receipt
of the data package of its desire to pursue discussions to co-promote and/or
license OROS(R) Methylphenidate in the U.S., then the parties shall, in good
faith, proceed within three (3) months thereafter to negotiate the terms of a
co-promotion and/or license agreement, as the case may be. ALZA shall not grant
any third party any rights that conflict with ABBOTT's right of first
negotiation unless ABBOTT has waived its right to exercise its right of first
negotiation to co-promote and/or license with respect to OROS(R)
Methylphenidate. If the parties are not able to agree on the terms of a co-
promotion and/or license, as the case may be, after good faith negotiations,
within three (3) months of ABBOTT's notice, then ALZA shall not offer co-
promotion and/or license rights to any third party for OROS(R) Methylphenidate
on economic terms and/or structure of the overall arrangement more favorable to
such third party than those last offered to ABBOTT, without first re-offering
such rights to ABBOTT on such terms in accordance with the procedures set forth
in this Article 11, provided that in such case the period for ABBOTT to exercise
----------
its rights and negotiate a written agreement shall be thirty (30) days.
12. Miscellaneous.
-------------
12.1 Compliance with Law. In performing the co-promotion activities
-------------------
contemplated by this Agreement, each party shall comply with all applicable
federal and state laws and regulations (including without limitation the
Prescription Drug Marketing Act and laws relating to "fraud and abuse" in
Medicare or Medicaid) and shall not be required to perform any service in
respect to a Product if in doing so it might violate any such law or
regulation.
12.2 Amendment. This Agreement may not be amended except in writing
---------
signed by both parties.
12.3 Governing Law. This Agreement shall be governed and construed
-------------
in accordance with the laws of the state of New York as applied to
residents of that state entering into agreements wholly to be performed in
that state.
12.4 Notices. Notices required under this Agreement shall be in
-------
writing and sent by registered or certified mail, postage prepaid, or by
telex or facsimile and confirmed by registered or certified mail and
addressed as follows:
-9-
<PAGE>
If to ALZA: ALZA Corporation
950 Page Mill Road
P.O. Box 10950
Palo Alto, CA 94303-0802
Attn: Senior Vice President and General Counsel
Fax: (650) 496-8048
If to ABBOTT: Abbott Laboratories Inc.
100 Abbott Park Road
Bldg. AP6D, Dept. 364
Abbott Park, IL 60064-6049
Attn: Senior Vice President, Secretary
and General Counsel
Fax: (847) 938-1206
All notices shall be deemed to be effective five (5) days after the date of
mailing or upon receipt if sent by telefax or facsimile (but only if
followed by certified or registered confirmation). Either party may change
the address at which notice is to be received by written notice pursuant to
this Section 12.4.
------------
12.5 Publicity. ABBOTT and ALZA agree not to disclose any terms or
---------
conditions of this Agreement to any third party or to make any public
statement about this Agreement without the prior consent of the other party
(which consent shall not be unreasonably withheld or delayed) except as is
required by applicable law, rule or regulation.
12.6 Severability. If any provision of this Agreement is held by a
------------
court of competent jurisdiction to be invalid or unenforceable, it shall be
modified, if possible, to the minimum extent necessary to make it valid and
enforceable or, if such modification is not possible, it shall be stricken
and the remaining provisions shall remain in full force and effect, unless
the deletion of such provision or provisions would result in such a
material change as to cause completion of the transactions contemplated
herein to be impossible and provided that the performance required by this
Agreement with such clause deleted remains substantially consistent with
the intent of the parties.
12.7 Headings. The headings set forth at the beginning of the
--------
various sections of this Agreement are for reference and convenience and
shall not affect the meanings of the provisions of this Agreement.
12.8 Assignment. This Agreement may not be assigned or otherwise
----------
transferred by either party without the consent of the other party. Any
purported assignment in violation of the proceeding sentences shall be
void. Any permitted assignee shall assume all obligations of its assignor
under this Agreement (provided that such assigning party shall remain
primarily liable hereunder in the case of any assignment to an affiliate).
Notwithstanding the foregoing, this Agreement shall be binding upon and
-10-
<PAGE>
inure to the benefit of any successor by merger to either of the parties,
whether by purchase of a controlling interest of such party's stock, assets
or otherwise.
12.9 Survival. The provisions of Sections 2.8, 3 (only as to
---------------------------
amounts accrued to the termination date), 7.4, 8, 10, 11, 12.3, 12.4, 12.5,
--------------------------------------------------------------------------
12.8 and this Section 12.9 shall survive the expiration or termination of
---- ------------
of this Agreement.
12.10 Entire Agreement. This Agreement sets forth the entire
----------------
understanding between the parties hereto as to the subject matter hereof
and supersedes all other documents, agreements, verbal consents,
arrangements and understandings by or between the parties with respect to
the subject matter hereof.
12.12 Counterparts. The Agreement may be executed simultaneously in
------------
any number of counterparts and may be executed by facsimile. All
counterparts collectively constitute one and the same Agreement.
ABBOTT LABORATORIES INC. ALZA CORPORATION
By: /s/ Miles D. White By: /s/ Ernest Mario
_____________________ _______________________
Title: Chairman & CEO Title: Chairman & CEO
_____________________ _______________________
-11-
<PAGE>
EXHIBIT 99.3
CO-PROMOTION AGREEMENT
----------------------
This Co-Promotion Agreement ("Agreement") is entered into as of the 21st
day of June, 1999 between ALZA Corporation ("ALZA") and Abbott Laboratories
Inc. ("ABBOTT").
WHEREAS, ALZA markets Ditropan XL(R), a proprietary controlled release
urinary incontinence product; and
WHEREAS, ABBOTT desires to co-promote Ditropan XL(R) with ALZA in the
United States, in accordance with the terms and conditions of this Agreement.
NOW THEREFORE, in consideration of the mutual covenants contained herein,
the parties agree as follows:
1. Definitions. For purposes of this Agreement, the following definitions
-----------
shall be applicable:
1.1 "Contract Month" means a full calendar month (except that the
first Contract Month shall start on the Effective Date and end on the last
day of such calendar month).
1.2 "Effective Date" shall mean that date which is thirty (30) days
after the date of termination of the Agreement and Plan of Merger between
ALZA, ABBOTT and AC MERGER SUB INC.
1.3 "Net Sales" means gross sales of the Product (as set forth on the
invoice for such Product) in the United States for use in the United States
in a given Sales Quarter by ALZA and any ALZA affiliate, to unrelated third
parties, in arm's length transactions, including but not limited to,
pharmaceutical wholesalers, pharmacies, hospitals, or dispensing
physicians, less any of the following charges or expenses that are incurred
in connection with gross sales of the Product during the Term:
(i) discounts, including cash discounts, customary trade allowances
or rebates actually taken or allowed, governmental rebates,
charge-backs, and group purchasing management fees for formulary
access;
(ii) credits or allowances given or made for rejection, recall or
return (including return reserves) of previously sold Product
actually taken or allowed;
(iii) any tax or governmental charge (including any tax such as a
value added or similar tax or government charge) to the extent
it appears on Product invoices (other than an income tax levied
on the sale, transportation or delivery of Product); and
<PAGE>
(iv) freight, insurance and duties on shipments of Product.
The parties agree that the only discounts, allowances or rebates permitted
to be charged against "Net Sales" hereunder shall be those that are
extended by ALZA in good faith and consistent with discounts, allowances or
rebates extended by ALZA on other ALZA products in the ordinary course of
business.
1.4 "Product" means Ditropan XL(R), a proprietary controlled release
urinary incontinence product currently marketed by ALZA in the United
States.
1.5 "Representative" means a sales employee of ALZA or ABBOTT, as the
case may be, trained to make Sales Calls to the Target Audience.
1.6 "Sales Call" means a presentation to a member of the Target
Audience by a Representative during which such Representative promotes the
Product. "Sales Call" may also refer to a presentation to a member of the
Target Audience by a sales employee of Innovex, Inc. ("Innovex") or UCB
Pharma, Inc. ("UCB") in accordance with the terms of ALZA's agreements with
Innovex and UCB, respectively, during which such sales employee promotes
the Product.
1.7 "Sales Quarter" shall mean a period of three (3) consecutive
Contract Months, except that the first Sales Quarter shall mean the period
from the launch of ABBOTT Sales Calls through the end of the calendar month
and the following three (3) Contract Months.
1.8 "Target Audience" means general practitioners, urologists and
other medical personnel in a position to prescribe the Product.
1.9 "Term" means the period commencing on the Effective Date and
ending on June 30, 2004.
2. Co-promotion Activities
-----------------------
2.1 Appointment and Acceptance. ALZA hereby appoints ABBOTT, and
--------------------------
ABBOTT hereby accepts appointment, as a co-promoter of Product in the United
States in accordance with the terms and conditions of this Agreement. In the
event that ALZA desires to add additional Sales Calls to its marketing effort
through a co-promotion arrangement with a third party, ALZA agrees that ABBOTT
shall have a right of first negotiation to perform such Sales Calls, and the
parties agree to negotiate in good faith the terms for ABBOTT performing such
additional Sales Calls. If the parties are unable to agree on such terms, ALZA
agrees that it shall not offer more favorable terms to a third party without
first re-offering the additional Sales Calls to ABBOTT on such more favorable
terms.
2.2 Scope of Co-Promotion. Abbott Representatives shall perform
---------------------
Sales Calls on the Target Audience as follows:
-2-
<PAGE>
(a) ABBOTT Representatives shall perform a minimum of forty five
thousand (45,000) Sales Calls per Sales Quarter (except for the first
Sales Quarter in which ABBOTT Representatives shall perform an
appropriate number of Sales Calls as determined by ABBOTT for the
first Contract Month and forty five thousand (45,000) Sales Calls for
the following three (3) Contract Months). In the event ABBOTT fails
to perform such required minimum Sales Calls in a given Sales Quarter
by a variance of minus ten percent (10%) or less, ABBOTT shall be
entitled to make up such variance by performing all of such variance
in the subsequent Sales Quarter, in which case ABBOTT shall be
compensated for such variance in accordance with the procedure set
forth in Section 3(a).
------------
(b) All Sales Calls by ABBOTT Representatives shall be performed
in the first position.
(c) ABBOTT Representatives shall deliver promotional materials
supplied by ALZA pursuant to Section 2.7 to the Target Audience.
-----------
ABBOTT shall not distribute any other Product promotional materials.
(d) ABBOTT Representatives shall perform Sales Calls in
accordance with approved labeling and all applicable laws and
regulations, including but not limited to the Food, Drug and Cosmetics
Act of 1938, as amended, and the Prescription Drug Marketing Act of
1987, as amended.
2.3 ALZA Sales Calls Efforts. ALZA Representatives shall continue to
------------------------
perform Sales Calls substantially in accordance with (or greater than) its
current level of performance, which, when combined with the number of Sales
Calls required of Innovex, is equal to fourteen thousand (14,000) Sales
Calls per month.
2.4 Sales Calls Tracking. Each party shall keep track of the number
--------------------
and position of Sales Calls by its Representatives in accordance with its
normal internal reporting procedures. From time to time upon the
reasonable request of a party, the other party shall provide a report with
respect to the number of Sales Calls performed by its Representatives
during the preceding time period. In addition, from time to time, upon
request by ABBOTT, ALZA shall provide a report with respect to the number
of Sales Calls performance by Innovex and UCB, respectively. Each party
shall have the right from time to time to accompany Representatives of the
other party on Sales Calls or otherwise audit Sales Calls for compliance
with this Agreement.
2.5 Communication. ABBOTT and ALZA shall meet at least once in each
-------------
Sales Quarter during the Term to review co-promotion effectiveness and to
formulate and implement Sales Calls strategies and other aspects of the co-
promotion. Each party will designate an individual responsible for
overseeing that party=s day-to-day performance under this Agreement.
ALZA=s initial designee is Mr. Jay Shepard and ABBOTT=s initial designee is
Mr. Robert Altman. Either party may change its designate by written notice
to the other.
-3-
<PAGE>
2.6 Training. ALZA shall provide ABBOTT with Product training
--------
materials for all ABBOTT Representatives, at ALZA's expense. All other
training expenses of ABBOTT Representatives shall be at the sole expense of
ABBOTT.
2.7 Promotional Materials; Samples. ALZA shall provide to ABBOTT,
------------------------------
without charge, currently available promotional materials specific to the
Product, in sufficient quantities for ABBOTT to perform its obligations
hereunder. ABBOTT shall use promotional materials for the Product supplied
by ALZA or approved in writing by ALZA and the approved Product labeling
and will not deviate from the text of such materials and/or labeling. In
addition, ALZA shall supply ABBOTT, without charge, Product samples for
distribution by the ABBOTT Representatives at a level of samples consistent
with that supplied by ALZA to its own Representatives. ABBOTT shall cause
its Representatives to comply with all federal, state and local laws, rules
and regulations concerning the handling, distribution and tracking of
samples, and ABBOTT shall maintain all required records to enable ALZA to
account for and track such samples.
2.8 Product Complaints. ABBOTT shall give ALZA notice of any
------------------
complaint or correspondence concerning the Product, including, but not
limited to, any adverse drug experience associated with the Product, in
accordance with the following procedure:
(i) information concerning any adverse drug experience associated
with a Product shall be reported to ALZA=s Director of Medical Safety
by telefax within twenty-four (24) hours and by hard copy in writing
three (3) days after initial receipt of such information;
(ii) all Product complaints not covered by (i) above shall be
reported in writing within twenty (20) calendar days following receipt
of such complaint. Such reports shall contain (a) the date the report
was received; (b) the name of the reporter; (c) the address and
telephone number of the reporter; and (d) an indication of the adverse
drug experience.
3. Compensation.
------------
(a) For the period commencing on the Effective Date through the
end of the Term, ALZA shall pay ABBOTT a commission equal to fifteen
percent (15%) of Net Sales for each Sales Quarter in which ABBOTT
makes at least forty five thousand (45,000) Sales Calls within forty-
five (45) days after the end of each Sales Quarter. If the number of
Sales Calls made by ABBOTT Representatives in a Sales Quarter are less
than forty five thousand (45,000), then the commission percentage
shall be reduced proportionately by multiplying fifteen percent (15%)
times the quotient derived from the number of Sales Calls actually
performed by ABBOTT Representatives divided by forty five thousand
(45,000). For example, if in a given Sales Quarter ABBOTT performed
only forty thousand (40,000) Sales Calls, ABBOTT's compensation would
be 13.33% of Net Sales for such Sales Quarter (i.e., 15% times
[40,000/45,000]). This product is subject to
-4-
<PAGE>
adjustment upward to fifteen percent (15%) if the variance is made up
in the following Sales Quarter in accordance with Section 2.2(a), in
--------------
which case ALZA shall compensate ABBOTT for the difference between
fifteen percent (15%) of Net Sales less the amount paid to ABBOTT for
the preceding Sales Quarter. ALZA shall make such additional payment
to ABBOTT with the commission payment due ABBOTT for the subsequent
Sales Quarter.
(b) Within thirty (30) days after the end of each Sales Quarter,
ALZA shall provide ABBOTT with a report showing: (i) gross sales of
the Product in the U.S. for such Sales Quarter; (ii) a calculation
demonstrating the adjustments to gross sales in order to arrive at Net
Sales; and (iii) the calculation of the commission payable, including
any adjustments to the commission payable.
(c) If ABBOTT, in its reasonable judgment, determines that an
audit of ALZA's relevant books and records is necessary to verify the
information supplied by ALZA pursuant to Section 3(c), then ABBOTT's
------------
designee, under duty of confidentiality to ALZA and ABBOTT, and
provided such designee is an independent certified public accountant,
shall have the right, on fifteen (15) days advance written notice, at
ABBOTT's expense, to perform an audit of the relevant books and
records of ALZA not more than once in any twelve (12) month period to
verify the information supplied by ALZA. If an audit reveals that
there has been a variance of two percent (2%) or more in the
determination of the applicable Net Sales, then the cost for such
audit shall be paid by ALZA.
4. Terms of Sales and Market Support Responsibility. All terms of sale
------------------------------------------------
for Product, including, without limitation, policies concerning pricing, credit
terms, cash discounts and returns and allowances shall be set by ALZA. All
sales of Product shall be recorded on the books of ALZA. ABBOTT is not
authorized to negotiate pricing issues with regard to the Product or make any
representations about such Product except as included in promotional materials
provided hereunder and/or in the Product labeling.
5. Records. Each party shall keep complete and accurate records as are
-------
required to implement and administer this Agreement.
6. Term. The Term shall commence on the Effective Date and terminate on
----
June 30, 2004, unless earlier terminated pursuant to Article 7. The parties may
---------
extend this Agreement for additional time periods as mutually agreed in writing.
7. Termination.
-----------
7.1 Termination. This Agreement may be terminated at any time by
-----------
ABBOTT without cause upon six (6) month's prior written notice.
7.2 Breach. Either party may terminate this Agreement for material
------
breach on thirty (30) days notice to the other party specifying the breach.
If such breach is not
-5-
<PAGE>
cured within such thirty (30) day period, then this Agreement shall
terminate at the end of such notice period.
7.3 Termination by ALZA. ALZA may terminate this Agreement on thirty
-------------------
(30) days notice to ABBOTT if ABBOTT fails to make at least thirty thousand
(30,000) Sales Calls during any three (3) consecutive Contract Months.
7.4 Effects of Termination. Upon termination of this Agreement for
----------------------
any reason, ABBOTT shall deliver to ALZA any and all of its inventory of
Product samples and other promotional material relating to the Product.
Expiration or termination of this Agreement shall not affect the remedies
of the parties otherwise available at law or equity in relation to any
rights accrued under this Agreement prior to expiration or termination.
8. Liability.
---------
8.1 Indemnification by ALZA. ALZA shall defend, indemnify and hold
-----------------------
harmless ABBOTT and its officers, directors, agents and employees
(collectively, the "Abbott Indemnitees"), from and against any and all
liability, loss, damages and expenses (including attorneys' fees) as a
result of claims, demands, costs or judgements (collectively, the "Losses")
arising out of or resulting from:
(i) any negligent act or omission or willful misconduct of ALZA
and its directors, officers or employees or Representatives with
respect to the promotion of Product, including but not limited to
product liability claims arising out of out-of-label promotions by
ALZA, its directors, officers or employees or Representatives; or
(ii) any violation of approved labeling or applicable statute or
regulation with respect to the Product, or
(iii) breach of this Agreement by ALZA, or
(iv) the manufacturing, marketing, sale or use of the Product,
including any Product liability claims and/or patent infringement
claims, or
(v) any claim, warranty or representation by ALZA, with respect
to the Product, or
(vi) any infringement claim related to Abbott's use of the ALZA
name or logo of the ALZA trademarks in connection with the promotion
or sale of the Product, provided ABBOTT's use is in compliance with
the terms of this Agreement.
Provided, however, that ALZA shall not be required to indemnify ABBOTT to
the extent that such Losses arise out of or result from: (1) the
negligence, recklessness or willful
-6-
<PAGE>
misconduct of the Abbott Indemnitees, including, but not limited to, out-
of-label promotion of the Product; and or (2) any breach by ABBOTT of this
Agreement. ABBOTT shall not be considered negligent for purposes of this
Section or Section 8.2 if such claim arises with respect to the content of
the promotional materials, Product labeling or other materials provided to
ABBOTT by ALZA as long as ABBOTT has distributed or employed such
promotional materials as directed herein.
ALZA shall have the exclusive right to control the defense of any action
which is to be indemnified in whole by ALZA hereunder, including the right
to select counsel reasonably acceptable to ABBOTT to defend ABBOTT and to
settle any claim, provided that, without the written consent of ABBOTT
(which shall not be unreasonably withheld or delayed), ALZA shall not agree
to settle any claim against ABBOTT. The provision of this Section shall
survive and remain in full force and effect after termination, expiration
or cancellation of this Agreement.
8.2 Indemnification by ABBOTT. ABBOTT shall defend, indemnify and
-------------------------
hold harmless ALZA and its officers, directors, agents and employees
(collectively, the "ALZA Indemnitees"), from and against any and all
liability, loss, damages and expenses (including attorneys' fees) as a
result of claims, demands, costs or judgments (collectively, the "Losses")
arising out of or resulting from:
(i) any negligent act or omission or willful misconduct of
ABBOTT with respect to the co-promotion of the Product, or
(ii) any breach of this Agreement by ABBOTT.
Provided, however, that ABBOTT shall not be required to indemnify the ALZA
Indemnitees to the extent that any Losses arise out of or result from: (1)
the negligence, recklessness, or willful misconduct of any ALZA Indemnitee,
including but not limited to, out-of-label promotion of the Product; and/or
(2) any breach by ALZA of this Agreement.
ABBOTT shall have the exclusive right to control the defense of any action
which is to be indemnified in whole by ABBOTT hereunder, including the
right to select counsel reasonably acceptable to ALZA to defend ALZA and to
settle any claim, provided that, without the written consent of ALZA (which
shall not be unreasonably withheld or delayed), ABBOTT shall not agree to
settle any claim against ALZA. The provision of this Section shall survive
and remain in full force and effect after termination, expiration or
cancellation of this Agreement
8.3 Indemnification Procedure. If any claims are made against an
-------------------------
indemnified party as to which the indemnification provisions set forth in
this Article 8 may apply, as soon as reasonably practicable, the
indemnified party will inform the other party thereof and the indemnifying
party and/or its insurers will assume the defense of any such claims. The
-7-
<PAGE>
indemnified party will cooperate in the disposition of any such matters.
The indemnified party shall have the right to participate at its own
expense in the defense of any such claim.
8.4 Disclaimer of Consequential Damages. IN NO EVENT SHALL EITHER
-----------------------------------
ABBOTT OR ALZA BE LIABLE TO THE OTHER FOR ANY SPECIAL, CONSEQUENTIAL OR
INCIDENTAL DAMAGES ARISING UNDER OR AS A RESULT OF THIS AGREEMENT (OR THE
TERMINATION HEREOF).
9. Relationship of the Parties. Each party is performing hereunder as an
---------------------------
independent contractor of the other party and its employees and representatives
are not eligible to participate in any benefits programs offered by the other
party to its employees, or in any pension plans, profit sharing plans, insurance
plans or any other employee benefits plans. Each party acknowledges and agrees
that it shall be solely responsible for designing and administering any
incentive program to its Representatives in respect to their activity promoting
the Product; and for paying all salaries, wages, benefits and other compensation
which its employees may be entitled to receive in connection with the
performance of this Agreement. Except as specifically set forth herein, no
employees or representatives of a party shall have any authority to bind or
obligate the other party to this Agreement for any such or in any manner
whatsoever, or to create or impose any contractual or other liability on the
other party without such other party's authorized written approval. For all
purposes and notwithstanding any provision of this Agreement to the contrary,
the parties= legal relationship under this Agreement shall be that the parties
are independent of each other and not that of partners or joint venturers.
Neither party hereto is authorized to make any statements or representations on
behalf of the other party or in any way obligate the other party, except as
expressly authorized in writing by the other party.
10. Confidential Information. Except as otherwise expressly provided
------------------------
under this Agreement, each party shall hold in confidence, and not use for any
purpose other than performing it obligations under this Agreement, all
confidential information concerning the other party, including, without
limitation, the amount of net sales of the Product. "Confidential Information"
shall not include information: (a) which is or becomes generally available to
the public other than as a result of disclosure thereof by the receiving party;
(b) which is lawfully received by the receiving party on a nonconfidential basis
from a third party that is not itself under any obligation of confidentiality or
nondisclosure to the disclosing party or any other person with respect to such
information; (c) which by written evidence can be shown by the receiving party
to have been independently developed by or for the receiving party; or (d) which
the receiving party establishes by competent proof was in its possession at the
time of disclosure by the other party and was not acquired, directly or
indirectly from the other party.
11. Right of First Negotiation. ALZA hereby grants to ABBOTT and ABBOTT
--------------------------
hereby accepts a first right of negotiation to obtain from ALZA co-promotion
and/or license rights to OROS(R) Methylphenidate in the U.S. In the event ALZA
elects to co-promote with and/or license rights to a third party with respect to
OROS(R) Methylphenidate in the U.S., then prior to entering into such
negotiations with a third party, ALZA shall prepare and submit to ABBOTT a data
package which shall consist of at least the following information: stage of
development, therapeutic category, targeted indications, mechanism of action,
safety profile, and
-8-
<PAGE>
anticipated FDA submission date. If ABBOTT notifies ALZA within thirty (30)
days of its receipt of the data package of its desire to pursue discussions to
co-promote and/or license OROS 7 Methylphenidate in the U.S., then the parties
shall, in good faith, proceed within three (3) months thereafter to negotiate
the terms of a co-promotion and/or license agreement, as the case may be. ALZA
shall not grant any third party any rights that conflict with ABBOTT's right of
first negotiation unless ABBOTT has waived its right to exercise its right of
first negotiation to co-promote and/or license with respect to OROS(R)
Methylphenidate. If the parties are not able to agree on the terms of a co-
promotion and/or license, as the case may be, after good faith negotiations,
within three (3) months of ABBOTT's notice, then ALZA shall not offer co-
promotion and/or license rights to any third party for OROS(R) Methylphenidate
on economic terms and/or structure of the overall arrangement more favorable to
such third party than those last offered to ABBOTT, without first re-offering
such rights to ABBOTT on such terms in accordance with the procedures set forth
in this Article 11, provided that in such case the period for ABBOTT to exercise
----------
its rights and negotiate a written agreement shall be thirty (30) days.
12. Miscellaneous.
-------------
12.1 Compliance with Law. In performing the co-promotion activities
-------------------
contemplated by this Agreement, each party shall comply with all applicable
federal and state laws and regulations (including without limitation the
Prescription Drug Marketing Act and laws relating to Afraud and abuse@ in
Medicare or Medicaid) and shall not be required to perform any service in
respect to a Product if in doing so it might violate any such law or
regulation.
12.2 Amendment. This Agreement may not be amended except in writing
---------
signed by both parties.
12.3 Governing Law. This Agreement shall be governed and construed
-------------
in accordance with the laws of the state of New York as applied to
residents of that state entering into agreements wholly to be performed in
that state.
12.4 Notices. Notices required under this Agreement shall be in
-------
writing and sent by registered or certified mail, postage prepaid, or by
telex or facsimile and confirmed by registered or certified mail and
addressed as follows:
If to ALZA: ALZA Corporation
950 Page Mill Road
P.O. Box 10950
Palo Alto, CA 94303-0802
Attn: Senior Vice President and General Counsel
Fax: (650) 496-8048
-9-
<PAGE>
If to ABBOTT: Abbott Laboratories Inc.
100 Abbott Park Road
Bldg. AP6D, Dept. 364
Abbott Park, IL 60064-6049
Attn: Senior Vice President, Secretary
and General Counsel
Fax: (847) 938-1206
All notices shall be deemed to be effective five (5) days after the date of
mailing or upon receipt if sent by telefax or facsimile (but only if
followed by certified or registered confirmation). Either party may change
the address at which notice is to be received by written notice pursuant to
this Section 12.4.
------------
12.5 Publicity. ABBOTT and ALZA agree not to disclose any terms or
---------
conditions of this Agreement to any third party or to make any public
statement about this Agreement without the prior consent of the other party
(which consent shall not be unreasonably withheld or delayed) except as is
required by applicable law, rule or regulation.
12.6 Severability. If any provision of this Agreement is held by a
------------
court of competent jurisdiction to be invalid or unenforceable, it shall be
modified, if possible, to the minimum extent necessary to make it valid and
enforceable or, if such modification is not possible, it shall be stricken
and the remaining provisions shall remain in full force and effect, unless
the deletion of such provision or provisions would result in such a
material change as to cause completion of the transactions contemplated
herein to be impossible and provided that the performance required by this
Agreement with such clause deleted remains substantially consistent with
the intent of the parties.
12.7 Headings. The headings set forth at the beginning of the
--------
various sections of this Agreement are for reference and convenience and
shall not affect the meanings of the provisions of this Agreement.
12.8 Assignment. This Agreement may not be assigned or otherwise
----------
transferred by either party without the consent of the other party. Any
purported assignment in violation of the proceeding sentences shall be
void. Any permitted assignee shall assume all obligations of its assignor
under this Agreement (provided that such assigning party shall remain
primarily liable hereunder in the case of any assignment to an affiliate).
Notwithstanding the foregoing, this Agreement shall be binding upon and
inure to the benefit of any successor by merger to either of the parties,
whether by purchase of a controlling interest of such party's stock, assets
or otherwise.
12.9 Survival. The provisions of Sections 2.8, 3 (but only as to
-------- -------------------------------
amounts accrued to the termination date), 7.4, 8, 10, 12.3, 12.4, 12.5,
-----------------------------------------------------------------------
12.8 and this Section 12.9 shall survive the expiration or termination of
---- ------------
this Agreement.
-10-
<PAGE>
12.10 Entire Agreement. This Agreement sets forth the entire
----------------
understanding between the parties hereto as to the subject matter hereof
and supersedes all other documents, agreements, verbal consents,
arrangements and understandings by or between the parties with respect to
the subject matter hereof.
12.12 Counterparts. The Agreement may be executed simultaneously in
------------
any number of counterparts and may be executed by facsimile. All
counterparts collectively constitute one and the same Agreement.
ABBOTT LABORATORIES INC. ALZA CORPORATION
By: /s/ Miles D. White By: /s/ Ernest Mario
_____________________ _______________________
Title: Chairman & CEO Title: Chairman & CEO
_____________________ _______________________
-11-
